Anti-steap1 antigen-binding molecules and uses thereof

MYPI2025000406A0Undetermined Publication Date: 2024-01-22GENENTECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025000406
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-07-22
Filing Date
2023-07-21
Publication Date
2024-01-22

AI Technical Summary

Technical Problem

Current cancer therapies face challenges in targeting shared antigens across different cancer subtypes and those that develop resistance due to mutations, limiting their effectiveness in treating heterogeneous cancers.

Method used

Development of multispecific antigen-binding molecules that bind to STEAP1 and T cell receptors, comprising specific heavy and light chain variable regions, which are designed to recognize and target STEAP1-expressing cancer cells while activating T cell responses.

Benefits of technology

These molecules demonstrate potent killing of STEAP1-expressing cancer cells, including those with acquired resistance, by enhancing T cell activation and targeting multiple cancer subtypes effectively.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025000406_DRAWING_001
    Figure PI2025000406_DRAWING_001
  • Figure PI2025000406_DRAWING_002
    Figure PI2025000406_DRAWING_002
  • Figure PI2025000406_DRAWING_003
    Figure PI2025000406_DRAWING_003
Patent Text Reader

Abstract

The present invention provides monospecific and multispecific antigen-binding molecules and compositions thereof. The invention also features methods of treating a disease or disorder, such as cancer, methods of inhibiting tumor growth, kits for use with the one or more methods. [No Figure Suitable]
Need to check novelty before this filing date? Find Prior Art

Description

[0001] ANTI-STEAP1 ANTIGEN-BINDING MOLECULES AND USES THEREOF

[0002] SEQUENCE LISTING

[0003] The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on July 18, 2023, is named “50474-301 WO2_Sequence_Listing” and is 170,087 bytes in size.

[0004] TECHNICAL FIELD

[0005] The present invention relates to antigen-binding molecules that bind to STEAP1 , including monospecific and multispecific antibodies, compositions thereof, and methods for treating diseases such as cancer.

[0006] BACKGROUND

[0007] Cancer is a heterogeneous disease which evolves at the genetic, phenotypic, and pathological levels. Current therapies include chemotherapy, radiation therapy, surgery, hormone therapy, targeted therapy, immunotherapy, and stem cell transplant. Targeted therapy and immunotherapy have shown promise in mediating potent killing of tumor cells. However, the presence of intratumoral heterogeneity, cancer subtypes, and mutations leading to acquired resistance present challenges in target selection. There remains a need for developing therapeutic agents that recognize one or more targets shared among the different cancer subtypes and those that acquired resistance driving by mutations.

[0008] SUMMARY

[0009] At least one aspect of the invention described herein relates to a multispecific antigen-binding molecule comprising: (A) a first antigen-binding domain that binds to STEAP1 and comprises an anti- STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3 of a VH sequence selected from SEQ ID NOs: 7, 17-25, 30-34, 38 and 68; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3 of a VL sequence selected from SEQ ID NOs: 8, 26-29, 39 and 69; and (B) a second antigen-binding domain that binds to a T cell receptor.

[0010] At least another aspect of the invention described herein relates to a multispecific antigen- binding molecule comprising: (A) a first antigen-binding domain that binds to STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3; and (B) a second antigen-binding domain that binds to a T cell receptor; wherein:

[0011] CDR-H1 comprises Xaa1Xaa2YMA (SEQ ID NO: 35); wherein Xaa1is Asp (D) or Asn (N); and Xaa2is His (H), Tyr (Y), or Phe (F);

[0012] CDR-H2 comprises YIXaa3YDGXaa4Xaa5TXaa6YGDSVKG (SEQ ID NO: 36); wherein Xaa3is Asp (D) or Ser (S); Xaa4is Gly (G), Asp (D), or Leu (L); Xaa5is Ser (S), Asp (D), or Asn (N); and Xaa6is Ser (S) or Tyr (Y); CDR-H3 comprises RSGXaa7YHVGYAMXaa8Xaa9(SEQ ID NO: 37); wherein Xaa7is Phe (F) or Tyr (Y); Xaa8is Asn (N) or Asp (D); and Xaa9is Ala (A) or Gly (G);

[0013] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6.

[0014] In some embodiments, the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 10,

[0015] I , or 9.

[0016] In some embodiments, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 2,

[0017] I I , 12, or 13.

[0018] In some embodiments, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 16, 3, 14, or 15.

[0019] In some embodiments, the first antigen-binding domain comprises: CDR-H1 comprising the amino acid sequence of SEQ ID NO: 10; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; CDR-H3 comprising the amino acid sequence of SEQ ID NO: 16; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

[0020] In some embodiments, the first antigen-binding domain comprises: CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

[0021] In some embodiments, the first antigen-binding domain comprises: CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 1 1 ; CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

[0022] In some embodiments, the first antigen-binding domain comprises: CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12; CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

[0023] In some embodiments, the first antigen-binding domain comprises: CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12; CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

[0024] In some embodiments, the first antigen-binding domain comprises: CDR-H1 comprising the amino acid sequence of SEQ ID NO: 10; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; CDR-H3 comprising the amino acid sequence of SEQ ID NO: 15; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

[0025] In some embodiments, the multispecific antigen-binding molecule is a humanized antibody.

[0026] In some embodiments, the first antigen-binding domain and the second antigen-binding domain each independently comprises an IgG framework region, optionally an IgG 1 or lgG4 framework region.

[0027] In some embodiments, the first antigen-binding domain comprises an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 7, 17-25, 30-34, 38, or 68.

[0028] In some embodiments, the first antigen-binding domain comprises an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 8, 26-29, 39, or 69.

[0029] In some embodiments, the first antigen-binding domain comprises an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 68, and an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 69.

[0030] In some embodiments, the first antigen-binding domain comprises an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 34, and an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 27.

[0031] In some embodiments, the first antigen-binding domain comprises an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 30, and an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 27.

[0032] In some embodiments, the first antigen-binding domain comprises an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 31 , and an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 27.

[0033] In some embodiments, the first antigen-binding domain comprises an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 32, and an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 27.

[0034] In some embodiments, the first antigen-binding domain comprises an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 33, and an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 27.

[0035] In some embodiments, the T cell receptor is cluster of differentiation 3 (CD3).

[0036] In some embodiments, the second antigen-binding domain that binds to CD3 comprises an anti-CD3 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3, and an anti- CD3 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3, wherein the CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3 comprise the sequences of SEQ ID NOs: 48-53, respectively.

[0037] In some embodiments, the second antigen-binding domain that binds to CD3 comprises an anti-CD3 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 54, and a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 55.

[0038] In some embodiments, the second antigen-binding domain that binds to CD3 comprises an anti-CD3 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3, and an anti- CD3 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3, wherein the CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3 comprise the sequences of SEQ ID NO: 40-45, respectively.

[0039] In some embodiments, the second antigen-binding domain that binds to CD3 comprises an anti-CD3 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 46, and an anti-CD3 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 47.

[0040] In some embodiments, the multispecific antigen binding molecule comprises one or more heavy chain constant domains, wherein the one or more heavy chain constant domains are selected from a first CH1 (CH11) domain, a first CH2 (CH21) domain, a first CH3 (CH31) domain, a second CH1 (CH12) domain, a second CH2 (CH22) domain, and a second CH3 (CH32) domain.

[0041] In some embodiments, at least one of the one or more heavy chain constant domains is paired with another heavy chain constant domain.

[0042] In some embodiments, the CH31and CH32domains each comprise a protuberance or cavity, and wherein the protuberance or cavity in the CH31domain is positionable in the cavity or protuberance, respectively, in the CH32domain.

[0043] In some embodiments, the CH31and CH32domains meet at an interface between said protuberance and cavity.

[0044] In some embodiments, the CH21and CH22domains each comprise a protuberance or cavity, and wherein the protuberance or cavity in the CH21domain is positionable in the cavity or protuberance, respectively, in the CH22domain.

[0045] In some embodiments, the CH21and CH22domains meet at an interface between said protuberance and cavity.

[0046] In some embodiments, the first antigen-binding domain comprises an anti-STEAP1 heavy chain constant region sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 83 and an anti-STEAP1 light chain constant region sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 82; and the second antigen-binding domain comprises an anti-CD heavy chain constant region sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 85 and an anti-CD light chain constant region sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 84.

[0047] In some embodiments, the antigen-binding molecule comprises an anti-STEAP1 heavy chain constant region sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 85 and an anti-STEAP1 light chain constant region sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 84; and the second antigen-binding domain comprises an anti-CD3 heavy chain constant region sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 83 and an anti-CD3 light chain constant region sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 82.

[0048] In some embodiments, the multispecific antigen-binding molecule comprises an anti-STEAP1 heavy chain comprising SEQ ID NO: 73, an anti-STEAP1 light chain comprising SEQ ID NO: 72, an anti-CD3 heavy chain comprising SEQ ID NO: 79, and an anti-CD3 light chain comprising SEQ ID NO: 78.

[0049] In some embodiments, the multispecific antigen-binding molecule comprises an anti-STEAP1 heavy chain comprising SEQ ID NO: 73, an anti-STEAP1 light chain comprising SEQ ID NO: 72, an anti-CD3 heavy chain comprising SEQ ID NO: 81 , and an anti-CD3 light chain comprising SEQ ID NO: 80.

[0050] In some embodiments, the multispecific antigen-binding molecule comprises an anti-STEAP1 heavy chain comprising SEQ ID NO: 71 , an anti-STEAP1 light chain comprising SEQ ID NO: 70, an anti-CD3 heavy chain comprising SEQ ID NO: 79, and an anti-CD3 light chain comprising SEQ ID NO: 78.

[0051] In some embodiments, the multispecific antigen-binding molecule comprises an anti-STEAP1 heavy chain comprising SEQ ID NO: 71 , an anti-STEAP1 light chain comprising SEQ ID NO: 70, an anti-CD3 heavy chain comprising SEQ ID NO: 81 , and an anti-CD3 light chain comprising SEQ ID NO: 80.

[0052] In some embodiments, the antigen-binding molecule is a single-chain Fv (scFv), trispecific (Fab3), bispecific (Fab2), diabody ((VL-VH)2 or (VH-VL)2), triabody (trivalent), tetrabody (tetravalent), minibody ((scFV-CH)2), bispecific single-chain Fv (Bis-scFv), lgGdeltaCH2, scFv-Fc, or (scFv)2-Fc.

[0053] In some embodiments, the multispecific antigen-binding molecule is a multispecific antibody, preferably a bispecific or trispecific antibody.

[0054] In some embodiments, the multispecific antigen-binding molecule further comprises a third antigen-binding domain that binds to a tumor-associated antigen. In some embodiments, the tumor- associated antigen is a receptor expressed on a prostate cancer cell or Ewing sarcoma. In some embodiments, the tumor-associated antigen is prostate-specific membrane antigen (PSMA), STEAP2, prostate stem cell antigen (PSCA), epithelial cell adhesion molecule (EpCAM), prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), or HBA-71 .

[0055] In some embodiments, the multispecific antigen-binding molecule binds to human STEAP1 , cynomolgus monkey STEAP1 , or a combination thereof, preferably wherein the multispecific antigen- binding molecule binds to the human STEAP1 of SEQ ID NO: 65. In some embodiments, the first antigen-binding domain binds to at least one, at least two, at least three, at least four, or at least five residue selected from Seri 01 , His102, Gln103, Trp195, Gln198, Gln202, and Lys281 of STEAP1 , wherein the residue positions 101 , 102, 103, 195, 198, 202, and 281 correspond to positions 101 , 102, 103, 195, 198, 202, and 281 set forth in SEQ ID NO: 65. In some embodiments, the first antigen-binding domain binds to Ser101 , His102, Gln103, Trp195, G In 198, Gln202, and Lys281 of STEAP1 . In some embodiments, the heavy chain variable region of the first antigen-binding domain forms a hydrogen bond with at least one, at least two, at least three, at least four, or at least five residue selected from Ser101 , His102, Gln103, Trp195, Gln198, Gln202, and Lys281 of STEAP1 . In some embodiments, at least one, at least two, at least three, at least four, or at least five residue selected from Leu56, Ser73, Asn74, G ly 101 , Tyr103, and Tyr107 of the heavy chain variable region of the first antigen-binding domain forms a hydrogen bond with at least one, at least two, at least three, at least four, or at least five residue selected from Seri 01 , His102, Gin 103, Trp195, Gln198, Gln202, and Lys281 of STEAP1 , wherein the residue positions of the heavy chain variable region of the first antigen-binding domain correspond to positions 56, 73, 74, 101 , 103, and 107 set forth in SEQ ID NO: 18.

[0056] In some embodiments, the first antigen-binding domain binds to at least one, at least two, or at least three residue selected from Gln201 , Gln202, Asn203 and Lys204 of STEAP1 , wherein the residue positions 201 , 202, 203 and 204 correspond to positions 201 , 202, 203 and 204 set forth in SEQ ID NO: 65. In some embodiments, the first antigen-binding domain binds to Gln201 , Gln202, Asn203 and Lys204 of STEAP1 . In some embodiments, the light chain variable region of the first antigen-binding domain forms a hydrogen bond with at least one residue selected from Gln201 and Gln202 of STEAP1 . In some embodiments, at least one residue selected from Tyr53 and Tyr54 of the light chain variable region of the first antigen-binding domain forms a hydrogen bond with at least one residue selected from Gln201 and Gln202, wherein the residue positions of the light chain variable region of the first antigen-binding domain correspond to positions 53 and 54 set forth in SEQ ID NO: 18. In some embodiments, a residue of the light chain variable region of the first antigen-binding domain forms Van der Waals interactions with at least one residue selected from Asn203 and Lys204 of STEAP1 .

[0057] In some embodiments, the multispecific antigen-binding molecule has a Cmax of about 11 , 11.5, 12, 12.6, 13, 13.5, 15, 18, 20, 23.4, 25, 27.9, 29.1 , or 30 μg / mL.

[0058] In some embodiments, the multispecific antigen-binding molecule has a Cmax of about 11 μg / mL to about 30 μg / mL.

[0059] In some embodiments, the multispecific antigen-binding molecule has a Cmax of about 20 μg / mL to about 28 μg / mL.

[0060] In some embodiments, the multispecific antigen-binding molecule has a Cmax of about 24 μg / mL.

[0061] In some embodiments, the multispecific antigen-binding molecule has an EC50of about 0.6, 0.56, 0.5, 0.45, 0.4, 0.35, 0.3, 0.25, 0.2, 0.15, 0.1 , 0.09, 0.05, or lower. In some embodiments, the multispecific antigen-binding molecule has an EC50of about 0.05 to about 0.8.

[0062] In some embodiments, the EC50is determined in a cell killing assay at 72 hours with human CD8+ T cells and STEAP1 -expressing LNCaP-X1 .2 cells, and the EC50is about 0.05 to about 0.4.

[0063] In some embodiments, the EC50is about 0.08 or about 0.3.

[0064] In some embodiments, the EC50is determined in a cell killing assay at 72 hours with human CD8+ T cells and STEAP1 -expressing LNCaPXI .2KO3-13 cells, and the EC50is about 0.1 to about 0.8.

[0065] In some embodiments, the EC50is about 0.1 or about 0.7.

[0066] In some embodiments, the multispecific antigen-binding molecule binds to STEAP1 monovalently.

[0067] At least another aspect of the invention described herein relates to an antigen-binding molecule that binds to STEAP1 , comprising an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3 of a VH sequence selected from SEQ ID NOs: 7, 17-25, 30-34, 38, and 68; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3 of a VL sequence selected from SEQ ID NOs: 8, 26-29, 39, and 69.

[0068] At least another aspect of the invention described herein relates to an antigen-binding molecule that binds to STEAP1 , comprising: an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3; wherein

[0069] CDR-H1 comprises Xaa1Xaa2YMA (SEQ ID NO: 35); wherein Xaa1is Asp (D) or Asn (N); and Xaa2is His (H), Tyr (Y), or Phe (F);

[0070] CDR-H2 comprises YIXaa3YDGXaa4Xaa5TXaa6YGDSVKG (SEQ ID NO: 36); wherein Xaa3is Asp (D) or Ser (S); Xaa4is Gly (G), Asp (D), or Leu (L); Xaa5is Ser (S), Asp (D), or Asn (N); and Xaa6is Ser (S) or Tyr (Y);

[0071] CDR-H3 comprises RSGXaa7YHVGYAMXaa8Xaa9(SEQ ID NO: 37); wherein Xaa7is Phe (F) or Tyr (Y); Xaa8is Asn (N) or Asp (D); and Xaa9is Ala (A) or Gly (G);

[0072] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6.

[0073] In some embodiments, the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 10,

[0074] I , or 9. In some embodiments, the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 2,

[0075] I I , 12, or 13. In some embodiments, the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 16, 3, 14, or 15.

[0076] In some embodiments, the antigen-binding molecule comprises: CDR-H1 comprising the amino acid sequence of SEQ ID NO: 10; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; CDR-H3 comprising the amino acid sequence of SEQ ID NO: 16; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6. In some embodiments, the antigen-binding molecule comprises: CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2; CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

[0077] In some embodiments, the antigen-binding molecule comprises: CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 11 ; CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

[0078] In some embodiments, the antigen-binding molecule comprises: CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12; CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

[0079] In some embodiments, the antigen-binding molecule comprises: CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12; CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

[0080] In some embodiments, the antigen-binding molecule comprises: CDR-H1 comprising the amino acid sequence of SEQ ID NO: 10; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13; CDR-H3 comprising the amino acid sequence of SEQ ID NO: 15; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

[0081] In some embodiments, the antigen-binding molecule is a humanized antibody.

[0082] In some embodiments, the antigen-binding molecule comprises an IgG framework region, optionally an IgG 1 framework region.

[0083] In some embodiments, the antigen-binding molecule comprises an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 7, 17-25, 30-34, 38, or 68.

[0084] In some embodiments, the antigen-binding molecule comprises an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 8, 26-29, 39, or 69.

[0085] In some embodiments, the antigen-binding molecule comprises an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 68, and an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 69. In some embodiments, the antigen-binding molecule comprises an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 34, and an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 27.

[0086] In some embodiments, the antigen-binding molecule comprises an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 30, and an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 27.

[0087] In some embodiments, the antigen-binding molecule comprises an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 31 , and an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 27.

[0088] In some embodiments, the antigen-binding molecule comprises an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 32, and an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 27.

[0089] In some embodiments, the antigen-binding molecule comprises an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 33, and an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 27.

[0090] In some embodiments, the antigen-binding molecule comprises an anti-STEAP1 heavy chain constant region sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 83 and an anti-STEAP1 light chain constant region sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 82.

[0091] In some embodiments, the antigen-binding molecule comprises an anti-STEAP1 heavy chain constant region sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 85 and an anti-STEAP1 light chain constant region sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 84.

[0092] In some embodiments, the antigen-binding molecule comprises an anti-STEAP1 heavy chain comprising SEQ ID NO: 73 and an anti-STEAP1 light chain comprising SEQ ID NO: 72. In some embodiments, the antigen-binding molecule comprises an anti-STEAP1 heavy chain comprising SEQ ID NO: 71 and an anti-STEAP1 light chain comprising SEQ ID NO: 70.

[0093] In some embodiments, the antigen-binding molecule is a full-length antibody or a fragment thereof.

[0094] In some embodiments, the antigen-binding molecule is a Fab, Fab’, F(ab’)2, Fv, Fd, single- chain Fv (scFv), trispecific (Fab3), bispecific (Fab2), diabody ((VL-VH)2 or (VH-VL)2), triabody (trivalent), tetrabody (tetravalent), minibody ((scFV-CH)2), bispecific single-chain Fv (Bis-scFv), lgGdeltaCH2, scFv-Fc, or (scFv)2-Fc. In some embodiments, the antigen-binding molecule is a multispecific antibody, preferably wherein the antigen-binding molecule is a bispecific antibody or a trispecific antibody.

[0095] In some embodiments, the antigen-binding molecule further comprises an antigen-binding domain that binds to a T cell receptor. In some embodiments, the T cell receptor is cluster of differentiation 3 (CD3).

[0096] In some embodiments, the antigen-binding domain that binds to CD3 comprises an anti-CD3 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3, and an anti-CD3 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3, wherein CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3 comprise the amino acid sequences of SEQ ID NOs: 48-53, respectively.

[0097] In some embodiments, the antigen-binding domain that binds to CD3 comprises an anti-CD3 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 54, and an anti-CD3 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 55.

[0098] In some embodiments, the antigen-binding domain that binds to CD3 comprises an anti-CD3 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3, and an anti-CD3 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3, wherein CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3 comprise the amino acid sequences of SEQ ID NO: 40-45, respectively.

[0099] In some embodiments, the antigen-binding domain that binds to CD3 comprises an anti-CD3 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 46, and an anti-CD3 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 47.

[0100] In some embodiments, the antigen-binding molecule further comprises an additional antigen- binding domain that binds to a tumor-associated antigen. In some embodiments, the tumor- associated antigen is a receptor expressed on a prostate cancer cell or Ewing sarcoma. In some embodiments, the tumor-associated antigen is prostate-specific membrane antigen (PSMA), STEAP2, prostate stem cell antigen (PSCA), epithelial cell adhesion molecule (EpCAM), prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), or HBA-71 .

[0101] In some embodiments, the antigen-binding molecule binds to human STEAP1 , cynomolgus monkey STEAP1 , or a combination thereof, preferably wherein the antigen-binding molecule binds to the human STEAP1 of SEQ ID NO: 65.

[0102] In some embodiments, the antigen-binding molecule binds to at least one, at least two, at least three, at least four, or at least five residue selected from Seri 01 , His102, Gln103, Trp195, Gln198, Gln202, and Lys281 of STEAP1 , wherein the residue positions 101 , 102, 103, 195, 198, 202, and 281 correspond to positions 101 , 102, 103, 195, 198, 202, and 281 set forth in SEQ ID NO: 65. In some embodiments, the antigen-binding molecule binds to Seri 01 , His102, Gln103, Trp195, G In 198, Gln202, and Lys281 of STEAP1 . In some embodiments, the heavy chain variable region of the antigen-binding molecule forms a hydrogen bond with at least one, at least two, at least three, at least four, or at least five residues selected from Ser101 , His102, Gln103, Trp195, Gln198, Gln202, and Lys281 of STEAP1 . In some embodiments, at least one, at least two, at least three, at least four, or at least five residues selected from Leu56, Ser73, Asn74, Gly 101 , Tyr103, and Tyr107 of the heavy chain variable region of the antigen-binding molecule forms a hydrogen bond with at least one, at least two, at least three, at least four, or at least five residues selected from Seri 01 , His102, Gin 103, Trp195, Gln198, Gln202, and Lys281 of STEAP1 , wherein the residue positions of the heavy chain variable region of the antigen-binding molecule correspond to positions 56, 73, 74, 101 , 103, and 107 set forth in SEQ ID NO: 18.

[0103] In some embodiments, the antigen-binding molecule binds to at least one, at least two, at or at least three residue selected from Gln201 , Gln202, Asn203 and Lys204 of STEAP1 , wherein the residue positions 201 , 202, 203 and 204 correspond to positions 201 , 202, 203 and 204 set forth in SEQ ID NO: 65. In some embodiments, the antigen-binding molecule binds to Gln201 , Gln202, Asn203 and Lys204 of STEAP1 . In some embodiments, the light chain variable region of the antigen- binding molecule forms a hydrogen bond with at least one residue selected from Gln201 and Gln202 of STEAP1 . In some embodiments, at least one residue selected from Tyr53 and Tyr54 of the light chain variable region of the antigen-binding molecule forms a hydrogen bond with at least one residue selected from Gln201 and Gln202, wherein the residue positions of the light chain variable region of the antigen-binding molecule correspond to positions 53 and 54 set forth in SEQ ID NO: 18. In some embodiments, a residue of the light chain variable region of the antigen-binding molecule forms Van der Waals interactions with at least one residue selected from Asn203 and Lys204 of STEAP1 .

[0104] In some embodiments, the antigen-binding molecule binds to STEAP1 monovalently.

[0105] At least another aspect of the invention described herein relates to an antibody comprising a first antigen-binding domain that binds to human STEAP1 at one or more residues selected from Ser101 , His102, Gln103, Trp195, Gln198, Gln202, and Lys281 , wherein the residue positions 101 , 102, 103, 195, 198, 202, and 281 correspond to positions 101 , 102, 103, 195, 198, 202, and 281 set forth in SEQ ID NO: 65.

[0106] In some embodiments, the first antigen-binding domain binds to at least one, at least two, at least three, at least four, or at least five residue selected from Seri 01 , His102, Gln103, Trp195, Gln198, Gln202, and Lys281 of SEQ ID NO: 65. In some embodiments, the first antigen-binding domain binds to Ser101 , His102, Gln103, Trp195, Gin 198, Gln202, and Lys281 of SEQ ID NO: 65. In some embodiments, the heavy chain variable region of the first antigen-binding domain forms a hydrogen bond with at least one, at least two, at least three, at least four, or at least five residues selected from Seri 01 , His102, G In 103, Trp195, G In 198, Gln202, and Lys281 of STEAP1 . In some embodiments, at least one, at least two, at least three, at least four, or at least five residues selected from Leu56, Ser73, Asn74, G ly 101 , Tyr103, and Tyr107 of the heavy chain variable region of the first antigen-binding domain forms a hydrogen bond with at least one, at least two, at least three, at least four, or at least five residues selected from Seri 01 , His102, G In 103, Trp195, G In 198, Gln202, and Lys281 of STEAP1 , wherein the residue positions of the heavy chain variable region of the first antigen-binding domain correspond to positions 56, 73, 74, 101 , 103, and 107 set forth in SEQ ID NO: 18.

[0107] In some embodiments, the first antigen-binding domain comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3 of a VH sequence selected from SEQ ID NO: 7, 17-25, 30-34, 38, and 68; and three CDRs of an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3 of a VL sequence selected from SEQ ID NO: 8, 26-29, 39, and 69.

[0108] In some embodiments, the first antigen-binding domain comprises an anti-STEAP1 heavy chain variable region comprising a VH sequence comprising at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 7, 17-25, 30-34, 38, or 68.

[0109] In some embodiments, the first antigen-binding domain comprises an anti-STEAP1 light chain variable region comprising a VL sequence comprising at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 8, 26-29, 39, or 69.

[0110] In some embodiments, the antibody further comprises a second antigen-binding domain that binds to a T cell receptor. In some embodiments, the T cell receptor is cluster of differentiation 3 (CD3).

[0111] In some embodiments, the second antigen-binding domain that binds to CD3 comprises an anti-CD3 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3, and an anti- CD3 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3, wherein the CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3 comprise the amino acid sequences of SEQ ID NO: 48-53, respectively.

[0112] In some embodiments, the second antigen-binding domain that binds to CD3 comprises an anti-CD3 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 54 and an anti-CD3 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 55.

[0113] In some embodiments, the second antigen-binding domain that binds to CD3 comprises an anti-CD3 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3, and an anti- CD3 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3, wherein the CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3 comprise the amino acid sequences of SEQ ID NO: 40-45, respectively.

[0114] In some embodiments, the second antigen-binding domain that binds to CD3 comprises an anti-CD3 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 46 and an anti-CD3 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 47.

[0115] In some embodiments, the multispecific antigen-binding molecule further comprises a third antigen-binding domain that binds to a tumor-associated antigen. In some embodiments, the tumor- associated antigen is a receptor expressed on a prostate cancer cell. In some embodiments, the tumor-associated antigen is prostate-specific membrane antigen (PSMA), STEAP2, prostate stem cell antigen (PSCA), epithelial cell adhesion molecule (EpCAM), prostate-specific antigen (PSA), or prostatic acid phosphatase (PAP).

[0116] At least another aspect of the invention described herein relates to one or more isolated nucleic acids individually or together encoding the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein.

[0117] At least another aspect of the invention described herein relates to one or more vectors individually or together comprising the isolated nucleic acid(s) described herein.

[0118] At least another aspect of the invention described herein relates to one or more host cells individually or together comprising the isolated nucleic acid(s) described herein or the vector(s) described herein. In some embodiments, the host cell is a mammalian cell. In some embodiments, the mammalian cell is a Chinese hamster ovary (CHO) cell. In some embodiments, the host cell is an insect cell. In some embodiments, the host cell is a prokaryotic cell.

[0119] At least another aspect of the invention described herein relates to a method of producing the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein, comprising culturing the host cell(s) described herein in a culture medium. In some embodiments, the method further comprises harvesting the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein from the host cell(s) or the culture medium.

[0120] At least another aspect of the invention described herein relates to a pharmaceutical composition comprising the multispecific antigen-binding molecule described herein, the antigen- binding molecule described herein, or the antibody described herein. In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier, excipient, or diluent.

[0121] In some embodiments, the pharmaceutical composition is for use as a medicament. In some embodiments, the pharmaceutical composition is for use in treating or delaying progression of a STEAP1 expressing cancer. In some embodiments, the pharmaceutical composition is for use in treating or delaying progression of prostate cancer or Ewing sarcoma.

[0122] At least another aspect of the invention described herein relates to use of the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein for use in treating or delaying progression of a STEAP1 -expressing cancer in a subject in need thereof.

[0123] At least another aspect of the invention described herein relates to use of the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein for use in inhibiting or reducing the proliferation of a STEAP1 expressing cancer cell.

[0124] In some embodiments, the STEAP1 -expressing cancer is a solid tumor.

[0125] In some embodiments, the STEAP1 -expressing cancer is prostate cancer or Ewing sarcoma. In some embodiments, the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein is to be used in combination with an additional therapeutic agent or an additional therapeutic regimen.

[0126] In some embodiments, the additional therapeutic agent comprises a chemotherapeutic agent, an immunotherapeutic agent, a targeted therapy, radiation therapy, or a combination thereof.

[0127] In some embodiments, the additional therapeutic agent comprises a first-line, second-line, or third-line therapy.

[0128] In some embodiments, the additional therapeutic regimen comprises surgery.

[0129] In some embodiments, the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein and the additional therapeutic agent are to be administered simultaneously.

[0130] In some embodiments, the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein and the additional therapeutic agent are to be administered sequentially.

[0131] In some embodiments, the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein is to be administered first prior to administering the additional therapeutic agent.

[0132] In some embodiments, the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein is to be administered after administering the additional therapeutic agent.

[0133] In some embodiments, the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein is to be administered systemically.

[0134] In some embodiments, the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein is to be administered locally.

[0135] In some embodiments, the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein is to be administered by parenteral administration.

[0136] In some embodiments, the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein is to be administered intravenously or subcutaneously.

[0137] In some embodiments, the subject is a human.

[0138] At least another aspect of the invention described herein relates to use of the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein in the manufacture of a medicament for treating or delaying progression of a STEAP1 expressing cancer, optionally for treating or delaying progression of prostate cancer or Ewing sarcoma. At least another aspect of the invention described herein relates to use of the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein in the manufacture of a medicament for inhibiting or reducing the proliferation of a STEAP1 expressing cancer cell, optionally a prostate cancer cell or Ewing sarcoma cell.

[0139] At least another aspect of the invention described herein relates to a method for treating or delaying progression of a STEAP1 -expressing cancer in a subject in need thereof, comprising administering to the subject an effective amount of the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein.

[0140] In some embodiments, the STEAP1 expressing cancer is a solid tumor. In some embodiments, the STEAP1 expressing cancer is prostate cancer or Ewing sarcoma.

[0141] In some embodiments, the method further comprises administering to the subject an additional therapeutic agent or an additional therapeutic regimen. In some embodiments, the additional therapeutic agent comprises a chemotherapeutic agent, an immunotherapeutic agent, a targeted therapy, radiation therapy, or a combination thereof. In some embodiments, the additional therapeutic agent comprises a first-line, second-line, or third-line therapy. In some embodiments, the additional therapeutic regimen comprises surgery.

[0142] In some embodiments, the additional therapeutic agent are administered simultaneously with the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein.

[0143] In some embodiments, the additional therapeutic agent are administered sequentially with the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein.

[0144] In some embodiments, the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein is administered first prior to administering the additional therapeutic agent.

[0145] In some embodiments, the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein is administered after administering the additional therapeutic agent.

[0146] In some embodiments, the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein is administered systemically. In some embodiments, the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein is administered locally. In some embodiments, the multispecific antigen-binding molecule described herein, the antigen- binding molecule described herein, or the antibody described herein is administered by parenteral administration. In some embodiments, the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein is administered intravenously or subcutaneously.

[0147] In some embodiments, the subject is a human. At least another aspect of the invention described herein relates to a method of inhibiting or reducing the proliferation of a STEAP1 expressing cell, comprising contacting the cell with , the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, or the antibody described herein for a time sufficient to inhibit proliferation of the cell.

[0148] In some embodiments, the cell is a prostate cancer cell or Ewing sarcoma cell. In some embodiments the method is an in vivo method. In some embodiments the method is an in vitro or an ex vivo method.

[0149] At least another aspect of the invention described herein relates to a kit comprising the multispecific antigen-binding molecule described herein, the antigen-binding molecule described herein, the antibody described herein, the isolated nucleic acid(s) described herein, the vector(s) described herein, the host cell(s) described herein, or the pharmaceutical composition described herein, optionally comprising a set of instructions.

[0150] BRIEF DESCRIPTION OF THE DRAWINGS

[0151] FIG. 1 A illustrates screening of select rat monoclonal antibodies for specific binding to STEAP1 -expressing cells. The rat monoclonal antibodies are STEAP1 -44, STEAP1 -45, STEAP1 -81 , STEAP1 -75, STEAP1 -103, STEAP1 -10, STEAP1 -23, STEAP1 -67, STEAP1 -34, STEAP1 -19, and STEAP1 -92.

[0152] FIG. 1 B illustrates screening of select rat monoclonal antibodies for specific binding to STEAP1 -expressing cells. The rat monoclonal antibodies are STEAP1 -48, STEAP1 -15, STEAP1 -28, STEAP1 -95, STEAP1 -54, STEAP1 -69, STEAP1 -2, STEAP1 -59, STEAP1 -49, and STEAP1 -62. Ab120 is the control antibody.

[0153] FIG. 1 C shows binding of antibody STEAP1 -44 in a titration assay. Arrows indicate the minimal concentration in which binding of STEAP1 -44 to 293-hSTEAP1 , PC3-hSTEAP1 , LNCaP X1 .2, and 22Rv1 cells was observed, which was 0.39 nM, 6.25 nM, 3.125 nM, and 12.5 nM, respectively.

[0154] FIG. 2 illustrates variable region sequences of antibody STEAP1 -44 and STEAP1 -44 clonal variants obtained by deep sequencing aligned to closest rat germline segment sequences (top sequences). For the clonal variants obtained by deep sequencing (“NGS”) only heavy chains are available. These were combined with the STEAP1 -44 light chain to produce full-length antibodies and thus share light chains. Presumed somatic mutations are shown in black background. CDR boundaries according to the Kabat and Chothia systems shown above the alignments, with Kabat CDRs boundaries underlined. Residue numbering is according to the Kabat system. Dots represent sequence gaps introduced by aligning software. Germline segment names are shown in the alignments. The SEQ ID NOs for the Kabat CDRs and the VH and VL sequences are shown in Table 1 . The SEQ ID NOs for the Chothia CDRs are shown in Table 2.

[0155] FIG. 3 illustrates scoring of somatic mutations in the STEAP1 -44 clonotype group in the deep sequencing dataset. Sequence read counts with each of the amino acid mutations are shown for each position. Black boxes indicate germline segment wild-type residue. Residues highlighted in grey show the most prevalent somatic mutations in CDR regions.

[0156] FIG. 4A shows testing of STEAP1 -44 clonal variants binding to STEAP1 on surface of cells.

[0157] FIG. 4B shows testing of STEAP1 -44 clonal variants binding to soluble recombinant STEAP1 .

[0158] FIG. 5A shows light chain variable region sequences of STEAP1 -44 humanization variants aligned to humanization frameworks. Differences in variants with humanization variants are shown in black background. CDR boundaries according to the Kabat and Chothia systems shown above the alignments, with Kabat CDRs boundaries underlined. Residue numbering is according to the Kabat system. Dots represent sequence gaps introduced by aligning software. The SEQ ID NOs for the Kabat CDRs and the VL sequences are illustrated in Table 1 . The SEQ ID NOs for the Chothia CDRs are illustrated in Table 2.

[0159] FIG. 5B shows heavy chain variable region sequences of STEAP1 -44 humanization variants aligned to humanization frameworks. Differences in variants with humanization frameworks are shown in black background. CDR boundaries according to the Kabat and Chothia systems shown above the alignments, with Kabat CDRs boundaries underlined. Residue numbering is according to the Kabat system. Dots represent sequence gaps introduced by aligning software. The SEQ ID NOs for the Kabat CDRs and the VH sequences are illustrated in Table 1 . The SEQ ID NOs for the Chothia CDRs are illustrated in Table 2.

[0160] FIG. 6A shows median fluorescence units (MFI) for antibody humanization variants tested at two different concentrations. Variants are ranked from strongest to weakest binding from left to right, in the same order in both concentrations tested.

[0161] FIG. 6B shows humanized variant huAb44.v6 with the somatic mutations of 5 NGS-based variants were tested for binding to LNCaP-X1 .2 cells expressing STEAP1 . huAb44.v6 is the parental humanized clone, chAb44 is a human lgG1 with the rat variable domains of Ab44 and huAb44.v6.01 to 05 are the sequence variants of huAb44.v6 with somatic mutations identified by repertoire NGS.

[0162] FIG. 6C shows sequence of humanized antibody variant huAb44.v6.05 aligned to humanized antibody huAb44.v6. Differences in huAb44.v6.05 relative huAb44.v6 are shown in black background. CDR boundaries according to the Kabat and Chothia systems shown above the alignments, with Kabat CDRs boundaries underlined. Residue numbering is according to the Kabat system. The SEQ ID NOs for the Kabat CDRs and VH and VL region sequences are illustrated in Table 1 . The SEQ ID NOs for the Chothia CDRs are illustrated in Table 2.

[0163] FIG. 7A shows bispecific anti-STEAP1 / anti-CD3 antibodies tested in cell killing assays with human CD8+ T cells and STEAP1 -expressing LNCaP-X1 .2 cells. The anti-CD3 arm of the TDB molecules is indicated as MD1 .

[0164] FIG. 7B shows bispecific anti-STEAP1 / anti-CD3 antibodies tested in cell killing assays with human CD8+ T cells and STEAP1 -expressing LNCaP-X1 .2 cells. The anti-CD3 arm of the TDB molecules is indicated as either MD1 or 40G5c. FIG. 8A shows STEAP1 levels in gene editing-modified LNCaPXI .2 sublines (LNCaP-X1 .2- KO-3-13, LNCaP-X1 .KO-2-11 ) measured by fluorescence activated cell sorting (FACS) analysis or Western blot. LNCaP-X1 .2-KO-2-8 lacks STEAP1 expression.

[0165] FIG. 8B shows huAb44v6.05 TDBs were tested in cell killing assays with human CD8+ T cells and indicated cell lines.

[0166] FIG. 8C shows target-dependent T cell activation (24 h) for huAb44.v6.05 / 40G5c.

[0167] FIG. 8D shows target-dependent cytokine secretion (24 h) for huAb44.v6.05 / 40G5c.

[0168] FIG. 9 illustrates STEAP1 -TDBs suppressing growth of established LNCaP-X1 .2, LNCaP- XI .2-KO-3-13, and LNCaP-X1 .KO-2-11 tumors in NSG mice supplemented with human PBMCs. Animals received a single IV dose at day 0 of indicated STEAP1 -TDB. Doses varied from 0.1 mg / kg to 0.5 mg / kg. Individual tumor volumes were plotted for every treatment group. Dotted lines indicate the fitted tumor volume for the control group (vehicle), solid lines indicate individual tumors.

[0169] FIG. 10A illustrates concentration-time profiles of anti-STEAP1 antibodies following a single intravenous dose of 1 mg / kg in female SCID mouse.

[0170] FIG. 10B shows concentration-time profiles of anti-STEAP1 / CD3 TDBs and anti-gD following a single intravenous dose of 1 mg / kg in female SCID mouse.

[0171] FIG. 10C shows concentration-time profiles of huAb44.v6.05 / 40G5c and huAb44.v6.05 / MD1 TDBs following intravenous administration in cynomolgus monkeys.

[0172] FIG. 11 A shows cryo-EM reconstruction of STEAP1 in complex with Ab44 at a resolution of ~3 A. An isosurface rendering of the STEAP1 homotrimer (arrows 1 , 2, and 3 indicate protomers) in complex with three Ab44 Fabs (arrow 4 indicates heavy chains, arrow 5 indicates light chains, arrow 6 indicates constant regions) is shown. STEAP1 extracellular loops ECL1 , ECL2 and ECL3 are indicated by arrows 7, 8 and 9, respectively.

[0173] FIG. 11 B shows ribbon rendering of the structure. A side view (along the plane of the membrane, equivalent to panel A) and a top view are shown. For clarity, heme from only one subunit is shown (indicated by arrow 10). Numbering of the remaining arrows is the same as in FIG. 11 A.

[0174] FIG. 12A shows interactions between Ab44 Fab and STEAP1 subunit A (two orthogonal side views rotated by 90 degrees are shown). STEAP1 residues located within 4 A of Ab44 Fab are shown in spheres. Numbering of the arrows is the same as in FIG. 11 B. STEAP1 subunits B and C have been omitted for clarity.

[0175] FIG. 12B shows interactions between Ab44 Fab and STEAP1 neighboring subunit B. Views are identical to panel A. STEAP1 subunits A and C have been omitted for clarity. Numbering of the arrows is the same as in FIG. 11 B.

[0176] FIG. 13A shows surface representation of the STEAP1 :Fab44 complex. The surfaces buried by complex formation are indicated by arrow 1 (Fab A to STEAP1 subunit A) and arrow 2 (Fab A to STEAP1 subunit B); surfaces buried representing homotypic interactions are indicated by arrow 3 (Fab A to Fab B) or arrow 4 (Fab A to Fab C). STEAP1 monomers are indicated by letters A, B, and C. Light chains are indicated by arrow 5 and heavy chains are indicated by arrows 6, 7, and 8. FIG. 13B shows open-book representation of the same surfaces with surface area measurements for each buried surface indicated.

[0177] FIG. 14 shows organization of Ab44 and Vandortuzumab upon binding to STEAP1 . Multiple polar homotypic Fab interactions (shown in spheres) are observed along the three-fold axis of the STEAP1 :Ab44 structure and are mostly driven by LC-LC contacts (left panel, viewed from the extracellular side). In contrast, limited interactions are observed between Vandortuzumab Fabs (right panel). Light chains are indicated by arrow 1 and heavy chains are indicated by arrows 2, 3, and 4. For clarity, STEAP1 homotrimer is not shown (except for the residues located within 4 A of Fab A, represented in spheres).

[0178] FIG. 15 shows sequence alignment of human, Macaca fascicularis and Pongo abelii. Expected transmembrane helices are highlighted in yellow and extracellular loops 1 , 2 and 3 are highlighted in green, red and orange boxes, respectively.

[0179] FIG. 16 shows sequence alignment of variable regions of humanized antibody variant huAb44.v6, huAb44.v6.01 , huAb44.v6.02, huAb44.v6.03, huAb44.v6.04, and huAb44.v6.05. CDR sequences according to Kabat definition are underlined. The SEQ ID NOs for the Kabat CDRs and the VH and VL sequences are illustrated in Table 1 . The SEQ ID NOs for the Chothia CDRs are illustrated in Table 2.

[0180] FIG. 17 shows sequence alignment of STEAP1 -specific variable regions of bispecific antibodies. CDR sequences according to Kabat definition are underlined. The SEQ ID NOs for the Kabat CDRs and the VH and VL sequences are illustrated in Table 1 . The SEQ ID NOs for the Chothia CDRs are illustrated in Table 2.

[0181] FIG. 18 shows sequence alignment of CD3-specific variable regions of bispecific antibodies. CDR sequences according to Kabat definition are underlined. The SEQ ID NOs for the Kabat CDRs and the VH and VL sequences are illustrated in Table 1 . The SEQ ID NOs for the Chothia CDRs are illustrated in Table 2.

[0182] FIG. 19 shows sequence alignment of constant regions of STEAP1 -specific chains.

[0183] FIG. 20 shows sequence alignment of constant regions of CD3-specific chains.

[0184] FIG. 21 shows sequence alignment of variable regions of rabbit anti-human STEAP1 antibodies. CDR boundaries according to the Kabat and Chothia systems shown above the alignments, with Kabat CDRs boundaries underlined. Residue numbering is according to the Kabat system. Dots represent sequence gaps introduced by aligning software. The SEQ ID NOs for the Kabat CDRs and the VH and VL sequences are shown in Table 1 . The SEQ ID NOs for the Chothia CDRs are shown in Table 2.

[0185] FIG. 22 shows a comparison of binding of huAb44v6.05 and vandortuzumab to LNCaP-X1 .2 cells expressing STEAP1 as assessed by FACS. MFI for antibody variants was tested at the indicated concentrations. The EC50 for vandortuzumab was 3.5 nM, and the EC50 for huAb44.v6.05 was 1 .9 nM.

[0186] FIG. 23A shows bispecific anti-STEAP1 / anti-CD3 antibodies tested in cell killing assays with human CD8+ T cells and STEAP1 -expressing LNCaP-X1.2 cells. Vandortuzumab- and huAb44v6.05- containing TDBs were compared. The anti-CD3 arm of the TDB molecules was either MD1 or 40G5c, as indicated.

[0187] FIG. 23B shows bispecific anti-STEAP1 / anti-CD3 antibodies tested in cell killing assays with human CD8+ T cells and STEAP1 -expressing LNCaPXI .2KO3-13 cells. Vandortuzumab- and huAb44v6.05-containing TDBs were compared. The anti-CD3 arm of the TDB molecules was either MD1 or 40G5c, as indicated.

[0188] FIGS. 24A-24D are a series of graphs showing a comparison of huAb44.v6.05 / 40G5c and vandortuzumab / 40G5c TDBs in a T-cell activation assay. Fig. 24A shows results of CD4 T cell activation using LNCaP-X12 cells. Fig. 24B shows results of CD8 T cell activation using LNCaP-X12 cells. Fig. 24C shows results of CD4 T cell activation using LNCaP-X1 .2-KO-3-13 cells. Fig. 24D shows results of CD8 T cell activation using LNCaP-X1 .2-KO-3-13 cells. For each of these experiments, the ratio of PBMCs to target was 10:1 , and the incubation time was 24 h.

[0189] FIGS. 25A-25J are a series of graphs showing a comparison of huAb44.v6.05 / 40G5c and vandortuzumab / 40G5c in a cytokine secretion assay at 24 h. Figs. 25A-25E show results with LNCaP-X1 .2 cells, and Figs. 25F-25J show results with LNCaP-X1 .2-KO-3-13 cells. Figs. 25A and 25F show interferon (IFN) gamma secretion. Figs. 25B and 25G show tumor necrosis factor (TNF) alpha secretion. FIGS. 25C and 25H show IL-2 secretion. Figs. 25D and 25I show IL-6 secretion. Figs. 25E and 25J show granzyme B secretion.

[0190] DETAILED DESCRIPTION

[0191] I. DEFINITIONS

[0192] The term “about” as used herein refers to the usual error range for the respective value readily known to the skilled person in this technical field. Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se.

[0193] “Affinity” refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1 :1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can generally be represented by the equilibrium dissociation constant (KD). Affinity can be measured by common methods known in the art, including those described herein. Specific illustrative and exemplary embodiments for measuring binding affinity are described in the following.

[0194] As used herein, the term “binds to” refers to measurable and reproducible interactions such as binding between a target and an antigen-binding molecule (e.g., an antibody), which is determinative of the presence of the target in the presence of a heterogeneous population of molecules including biological molecules. For example, an antigen-binding molecule that specifically binds to a target (which can be an epitope) is an antigen-binding molecule that binds this target with greater affinity, avidity, more readily, and / or with greater duration than it binds to other targets. In one embodiment, the extent of binding of an antigen-binding molecule to an unrelated target is less than about 10% of the binding of the antigen-binding molecule to the target as measured, e.g., by surface plasmon resonance (SPR), radioimmunoassay (RIA), or Kinetic Exclusion Assay (KinExA®). In certain embodiments, an antigen-binding molecule that specifically binds to a target has an equilibrium dissociation constant (KD) of ≤ 1 pM, ≤ 100 nM, ≤ 10 nM, ≤ 1 nM, or ≤ 0.1 nM. In certain embodiments, an antigen-binding molecule specifically binds to an epitope on a protein that is conserved among the protein from different species. In another embodiment, specific binding can include, but does not require exclusive binding.

[0195] As used herein, the term “antigen-binding molecule” refers to a molecule that specifically binds to a target epitope, antigen, ligand, or receptor. Antigen-binding molecules include, but are not limited to, antibodies (e.g., monoclonal, polyclonal, recombinant, humanized, and chimeric antibodies), antibody fragments or portions thereof (e.g., Fab fragments, Fab’2, scFv antibodies, SMIP, domain antibodies, diabodies, minibodies, scFv-Fc, affibodies, nanobodies, and VH and / or VL domains of antibodies), receptors, ligands, aptamers, and other molecules having an identified binding partner. An “affinity matured” antibody refers to an antibody with one or more alterations in one or more complementarity determining regions (CDRs) or hypervariable regions (HVRs), compared to a parent antibody which does not possess such alterations, such alterations resulting in an improvement in the affinity of the antibody for antigen.

[0196] The term “antigen-binding domain” refers to a part of a compound or a molecule that specifically binds to a target epitope, antigen, ligand, or receptor. Molecules featuring antigen-binding domains include, but are not limited to, antibodies (e.g., monoclonal, polyclonal, recombinant, humanized, and chimeric antibodies), antibody fragments or portions thereof (e.g., Fab fragments, Fab’2, scFv antibodies, SMIP, domain antibodies, diabodies, minibodies, scFv-Fc, affibodies, nanobodies, and VH and / or VL domains of antibodies), receptors, ligands, aptamers, and other molecules having an identified binding partner.

[0197] The term “antibody” herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific or trispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.

[0198] An “antibody fragment” refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of antibody fragments include but are not limited to Fv, Fab, Fab’, Fab’-SH, F(ab’)2; diabodies; linear antibodies; single-chain antibody molecules (e.g., scFv, and scFab); single domain antibodies (dAbs); and multispecific antibodies formed from antibody fragments. For a review of certain antibody fragments, see Holliger and Hudson, Nat. Biotech. 23:1126-1136 (2005).

[0199] A “single-chain variable fragment” or “scFv” is a fusion protein of the variable domains of the heavy (VH) and light chains (VL) of an antibody, connected by a linker. In particular, the linker is typically a short polypeptide of 10 to 25 amino acids and is usually rich in glycine for flexibility, as well as serine or threonine for solubility, and can either connect the N-terminus of the VH with the C- terminus of the VL, or vice versa. This protein retains the specificity of the original antibody, despite removal of the constant regions and the introduction of the linker. For a review of scFv fragments, see, e.g., Pluckthun, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., (Springer-Verlag, New York), pp. 269-315 (1994); see also WO 93 / 16185; and U.S. Patent Nos. 5,571 ,894 and 5,587,458.

[0200] A “single chain Fab fragment” or “scFab” is a polypeptide consisting of an antibody heavy chain variable domain (VH), an antibody heavy chain constant domain 1 (CH1 ), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL) and a linker, wherein said antibody domains and said linker have one of the following orders in N-terminal to C-terminal direction: a) VH-CH1 -linker-VL-CL, b) VL-CL-linker-VH-CH1 , c) VH-CL-linker-VL-CH1 or d) VL-CH1 - linker-VH-CL. In particular, said linker is a polypeptide of at least 30 amino acids, preferably between 32 and 50 amino acids. Said single chain Fab fragments are stabilized via the natural disulfide bond between the CL domain and the CH1 domain. In addition, these single chain Fab fragments might be further stabilized by generation of interchain disulfide bonds via insertion of cysteine residues (e.g., position 44 in the variable heavy chain and position 100 in the variable light chain according to Kabat numbering).

[0201] The term “cross-Fab fragment” or “xFab fragment” or “crossover Fab fragment” refers to a Fab fragment, wherein either the variable regions or the constant regions of the heavy and light chain are exchanged. A cross-Fab fragment comprises a polypeptide chain composed of the light chain variable region (VL) and the heavy chain constant region 1 (CH1 ), and a polypeptide chain composed of the heavy chain variable region (VH) and the light chain constant region (CL). Asymmetrical Fab arms can also be engineered by introducing charged or non-charged amino acid mutations into domain interfaces to direct correct Fab pairing. See e.g., WO 2016 / 172485.

[0202] The term “antigen” denotes a proteinaceous or non-proteinaceous molecule to which an antigen-binding molecule (e.g., an antibody) binds. The antigen can include protein, protein fragment, or a hapten.

[0203] The term “epitope” denotes the site on an antigen, either proteinaceous or non-proteinaceous, to which an anti-STEAP1 antigen-binding molecule (e.g., an anti-STEAP1 antibody) binds. Epitopes can be formed both from contiguous amino acid stretches (linear epitope) or comprise non-contiguous amino acids (conformational epitope), e.g., coming in spatial proximity due to the folding of the antigen, i.e., by the tertiary folding of a proteinaceous antigen. Linear epitopes are typically still bound by an anti-STEAP1 antigen-binding molecule after exposure of the proteinaceous antigen to denaturing agents, whereas conformational epitopes are typically destroyed upon treatment with denaturing agents. An epitope comprises at least 3, at least 4, at least 5, at least 6, at least 7, or 8-10 amino acids in a unique spatial conformation.

[0204] Screening for antigen-binding molecules (e.g., antibodies) binding to a particular epitope (i.e., those binding to the same epitope) can be done using methods routine in the art such as, e.g., without limitation, alanine scanning, peptide blots (see Meth. Mol. Biol. 248 (2004) 443-463), peptide cleavage analysis, epitope excision, epitope extraction, chemical modification of antigens (see Prot. Sci. 9 (2000) 487-496), and cross-blocking (see “Antibodies,” Harlow and Lane (Cold Spring Harbor Press, Cold Spring Harbor, NY).

[0205] Antigen Structure-based Antibody Profiling (ASAP), also known as Modification-Assisted Profiling (MAP), allows binning of a multitude of monoclonal antibodies specifically binding to STEAP1 based on the binding profile of each of the antibodies from the multitude to chemically or enzymatically modified antigen surfaces (see, e.g., US 2004 / 0101920). The antibodies in each bin bind to the same epitope which may be a unique epitope either distinctly different from or partially overlapping with epitope represented by another bin.

[0206] Additionally, competitive binding can be used to easily determine whether an antigen-binding molecule (e.g., an antibody) binds to the same epitope of STEAP1 as, or competes for binding with, a reference anti-STEAP1 antibody. For example, an “antigen-binding molecule that binds to the same epitope” as a reference anti-STEAP1 antibody refers to an antigen-binding molecule that blocks binding of the reference anti-STEAP1 antibody to its antigen in a competition assay by 50% or more, and conversely, the reference antibody blocks binding of the antigen-binding molecule to its antigen in a competition assay by 50% or more. Also for example, to determine if an antigen-binding molecule binds to the same epitope as a reference anti-STEAP1 antibody, the reference antibody is allowed to bind to STEAP1 under saturating conditions. After removal of the excess of the reference anti- STEAP1 antibody, the ability of an anti-STEAP1 antigen-binding molecule in question to bind to STEAP1 is assessed. If the anti-STEAP1 antigen-binding molecule is able to bind to STEAP1 after saturation binding of the reference anti-STEAP1 antibody, it can be concluded that the anti-STEAP1 antigen-binding molecule in question binds to a different epitope than the reference anti-STEAP1 antibody. But, if the anti-STEAP1 antigen-binding molecule in question is not able to bind to STEAP1 after saturation binding of the reference anti-STEAP1 antibody, then the anti-STEAP1 antigen-binding molecule in question may bind to the same epitope as the epitope bound by the reference anti- STEAP1 antibody. To confirm whether the antigen-binding molecule in question binds to the same epitope or is just hampered from binding by steric reasons routine experimentation can be used (e.g., peptide mutation and binding analyses using ELISA, RIA, surface plasmon resonance, flow cytometry or any other quantitative or qualitative antibody-binding assay available in the art). This assay may be carried out in two set-ups, i.e., with both of the molecules being the saturating antibody. If, in both set-ups, only the first (saturating) antibody is capable of binding to STEAP1 , then it can be concluded that the anti-STEAP1 antigen-binding molecule in question and the reference anti-STEAP1 antibody compete for binding to STEAP1 .

[0207] The term “STEAP1 ” refers to any STEAP1 from any vertebrate source, including mammals such as primates (e.g., humans or non-human primates) and rodents (e.g., mice and rats). The term encompasses “full-length” STEAP1 and naturally occurring variants of STEAP1 , including, for example, splice variants or allelic variants. STEAP1 is a member of the six-transmembrane epithelial antigen of the prostate (STEAP) protein family. The STEAP protein family comprises five members, STEAP1 , STEAP2, STEAP3, STEAP4, and STEAP5. STEAP1 , STEAP2, and STEAP4 have been observed to be over-expressed in different cancer cells while minimally expressed in normal tissues. STEAP1 includes, e.g., human STEAP1 (UniProtKB Reference Number: Q9UHE8-1 ; SEQ ID NO:

[0208] 65), cynomolgus monkey STEAP1 (UniProtKB Reference Number: A0A2K5X1 J3; SEQ ID NO: 66), and orangutan STEAP1 (UniProtKB Reference Number: H2PMZ0; SEQ ID NO: 67).

[0209] Below is an exemplary amino acid sequence for human STEAP1 : MESRKDITNQEELWKMKPRRNLEEDDYLHKDTGETSMLKRPVLLHLHQTAHADEFDCPSELQHTQE LFPQWHLPIKIAAIIASLTFLYTLLREVIHPLATSHQQYFYKIPILVINKVLPMVSITLLALVYLPGVIAAIVQL HNGTKYKKFPHWLDKWMLTRKQFGLLSFFFAVLHAIYSLSYPMRRSYRYKLLNWAYQQVQQNKEDA WIEHDVWRMEIYVSLGIVGLAILALLAVTSIPSVSDSLTWREFHYIQSKLGIVSLLLGTIHALIFAWNKWI DIKQFVWYTPPTFMIAVFLPIVVLIFKSILFLPCLRKKILKIRHGWEDVTKINKTEICSQL (SEQ ID NO:

[0210] 65).

[0211] Below is an exemplary amino acid sequence for cynomolgus monkey (Macaca fascicularis) STEAP1 : MESRKDITNEEELWKMKPRRNLEEDDYLHKDTGETSMLKRPVLLHLHQTAHADEFDCPSELQHTQE LFPQWHLPIKIAAIIASLTFLYTLLREVIHPLATSHQQYFYKIPILVINKVLPMVSITLLALVYLPGVIAAIVQL HNGTKYKKFPHWLDKWMLTRKQFGLLSFFFAVLHAIYSLSYPMRRSYRYKLLNWAYQQVQQNKEDA WIEHDVWRMEIYVSLGIVGLAILALLAVTSIPSVSDSLTWREFHYIQSKLGIVSLLLATIHALIFAWNKWID IKQFVWYTPPTFMIAVFLPVVVLIFKSILFLPCLRKKILKIRHGWEDVTKINKMEISSQL (SEQ ID NO:

[0212] 66).

[0213] Below is an exemplary amino acid sequence for orangutan (Pongo abelii) STEAP1 : MESRKDITNQEELWKMKPRRNLEEDDYLHKDTGETSMLKRPVLLHLHQTAHADEFDCPSELQQTRE LFPQWHLPIKIAAIIASLTFLYTLLREVIHPLATSHQQYFYKIPILVINKVLPMVSITLLALVYLPGVIAAIVQL HNGTKYKKFPHWLDKWMLTRKQFGLLSFFFAVLHAIYSLSYPMRRSYRYKLLNWAYQQVQQNKEDA WIEHDVWRMEIYVSLGIVGLAILALLAVTSIPSVSDSLTWREFHYIQSKLGIVSLLLGTIHALIFAWNKWI DIKQFVWYTPPTFMIAVILPIVVLIFKSILFLPCLRKKILKIRHGWEDVTKINKTEISSQL (SEQ ID NO:

[0214] 67).

[0215] The term “anti-STEAP1 antigen-binding molecule” or “antigen-binding molecule that binds STEAP1 ” refer to any molecule that is capable of binding to STEAP1 with sufficient affinity such that the molecule is useful as a diagnostic and / or therapeutic agent in targeting STEAP1 . In one embodiment, the extent of binding of an anti-STEAP1 antigen-binding molecule to an unrelated, non- STEAP1 protein is less than about 10% of the binding of the antigen-binding molecule to STEAP1 as measured, e.g., by surface plasmon resonance (SPR), radioimmunoassay (RIA), or Kinetic Exclusion Assay (KinExA®). In certain aspects, an anti-STEAP1 antigen-binding molecule has a dissociation constant (KD) of ≤ 1 pM, ≤ 100 nM, ≤ 10 nM, ≤ 1 nM, ≤ 0.1 nM, ≤ 0.01 nM, or ≤ 0.001 nM (e.g., 10-8M or less, e.g., from 10-8M to 10-13M, e.g., from 10-9M to 10-13M). An antigen-binding molecule is said to “specifically bind” to STEAP1 when the antigen-binding molecule has a KDof 1 pM or less. In certain aspects, an anti-STEAP1 antigen-binding molecule binds to an epitope of STEAP1 that is conserved among STEAP from different species.

[0216] The term “anti-STEAP1 antibody” or “an antibody that binds to STEAP1 ” refers to an antibody that is capable of binding to STEAP1 with sufficient affinity such that the molecule is useful as a diagnostic and / or therapeutic agent in targeting STEAP1 . In one embodiment, the extent of binding of an anti-STEAP1 antibody to an unrelated, non-STEAP1 protein is less than about 10% of the binding of the antibody to STEAP1 as measured, e.g., by surface plasmon resonance (SPR), radioimmunoassay (RIA), or Kinetic Exclusion Assay (KinExA®). In certain aspects, an anti-STEAP1 antibody has a dissociation constant (KD) of ≤ 1 μM, ≤ 100 nM, ≤ 10 nM, ≤ 1 nM, ≤ 0.1 nM, ≤ 0.01 nM, or ≤ 0.001 nM (e.g., 10-8M or less, e.g., from 10-8M to 10-13M, e.g., from 10-9M to 10-13M). An antibody is said to “specifically bind” to STEAP1 when the antibody has a KDof 1 pM or less. In certain aspects, an anti-STEAP1 antibody binds to an epitope of STEAP1 that is conserved among STEAP from different species.

[0217] The term “cluster of differentiation 3” or “CD3,” as used herein, refers to any native CD3 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise indicated, including, for example, CD3ε, CD3γ, CD3α, and CD3β chains. The term encompasses “full-length,” unprocessed CD3 (e.g., unprocessed or unmodified CD3ε or CD3γ), as well as any form of CD3 that results from processing in the cell. The term also encompasses naturally occurring variants of CD3, including, for example, splice variants or allelic variants. CD3 includes, for example, human CD3ε protein (NCBI RefSeq No. NP_000724), which is 207 amino acids in length, and human CD3γ protein (NCBI RefSeq No. NP_000064), which is 182 amino acids in length.

[0218] The terms “anti-CD3 antibody” and “an antibody that binds to CD3” refer to an antibody that is capable of binding CD3 with sufficient affinity such that the antibody is useful as a diagnostic and / or therapeutic agent in targeting CD3. In one embodiment, the extent of binding of an anti-CD3 antibody to an unrelated, non-CD3 protein is less than about 10% of the binding of the antibody to CD3 as measured, e.g., by surface plasmon resonance (SPR), radioimmunoassay (RIA), or Kinetic Exclusion Assay (KinExA®). In certain embodiments, an antibody that binds to CD3 has a dissociation constant (KD) of ≤ 1 pM, ≤ 100 nM, ≤ 10 nM, ≤ 1 nM, ≤ 0.1 nM, ≤ 0.01 nM, or ≤ 0.001 nM (e.g., 10-8M or less, e.g., from 10-8M to 10-13M, e.g., from 10-9M to 10-13M). In certain embodiments, an anti-CD3 antibody binds to an epitope of CD3 that is conserved among CD3 from different species. In some embodiments, the anti-CD3 antibody is described in International Patent Application Publication No. WO 2015 / 095392, which is incorporated by reference herein in its entirety. In some embodiments, the anti-CD3 antibody is described in U.S. Patent No. 10,174,124, which is incorporated by reference herein in its entirety. In other embodiments, the anti-CD3 antibody is described in International Patent Application No. PCT / US2020 / 064635, which is incorporated by reference herein in its entirety.

[0219] In some embodiments, the anti-CD3 antibody is 40G5c. In some embodiments, the anti-CD3 antibody is 38E4V1 .MD1 . The SEQ ID NOs for the CDRs and the VH and VL sequences of 40G5c and 38E4V1 .MD1 are listed in Tables 1 and 2.

[0220] In some aspects, two antibodies are deemed to bind to the same or an overlapping epitope if a 1 -, 5-, 10-, 20- or 100-fold excess of one antibody inhibits binding of the other by at least 50%, at least 75%, at least 90% or even 99% or more as measured in a competitive binding assay (see, e.g., Junghans et al., Cancer Res. 50 (1990) 1495-1502). In some aspects, two antibodies are deemed to bind to the same epitope if essentially all amino acid mutations in the antigen that reduce or eliminate binding of one antibody also reduce or eliminate binding of the other. Two antibodies are deemed to have “overlapping epitopes” if only a subset of the amino acid mutations that reduce or eliminate binding of one antibody reduce or eliminate binding of the other.

[0221] The term “chimeric” antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.

[0222] The “class” of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgGi, lgG2, IgGs, lgG4, IgAi, and lgA2. In certain aspects, the antibody is of the IgG 1 isotype. In certain aspects, the antibody is of the IgG 1 isotype with the P329G, L234A and L235A mutation to reduce Fc-region effector function. In other aspects, the antibody is of the lgG2 isotype. In certain aspects, the antibody is of the lgG4 isotype with the S228P mutation in the hinge region to improve stability of lgG4 antibody. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called a, 8, E, y, and p, respectively. The light chain of an antibody may be assigned to one of two types, called kappa (K) and lambda (A), based on the amino acid sequence of its constant domain.

[0223] The term “hypervariable region” or “HVR” as used herein refers to each of the regions of an antibody variable domain which are hypervariable in sequence and which determine antigen binding specificity, for example, “complementarity determining regions” (“CDRs”).

[0224] Generally, antibodies comprise six CDRs: three in the VH (CDR-H1 , CDR-H2, CDR-H3), and three in the VL (CDR-L1 , CDR-L2, CDR-L3). Exemplary CDRs herein include:

[0225] (a) hypervariable loops occurring at amino acid residues 26-32 (L1 ), 50-52 (L2), 91 -96 (L3), 26-32 (H1 ), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901 -917 (1987));

[0226] (b) CDRs occurring at amino acid residues 24-34 (L1 ), 50-56 (L2), 89-97 (L3), 31 -35b (H1 ), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991 )); and

[0227] (c) antigen contacts occurring at amino acid residues 27c-36 (L1 ), 46-55 (L2), 89-96 (L3), 30- 35b (H1 ), 47-58 (H2), and 93-101 (H3) (MacCallum et al. J. Mol. Biol. 262: 732-745 (1996)).

[0228] Unless otherwise indicated, the CDRs are determined according to Kabat et al., supra. One of skill in the art will understand that the CDR designations can also be determined according to Chothia, supra, McCallum, supra, or any other scientifically accepted nomenclature system.

[0229] The term “variable region” or “variable domain” refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen. The variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three complementary determining regions (CDRs) or hypervariable regions (HVRs). (See, e.g., Kindt et al. Kuby Immunology, 6thed., W.H. Freeman and Co., page 91 (2007).) A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al., J. Immunol. 150:880- 887 (1993); Clarkson et al., Nature 352:624-628 (1991 ).

[0230] A “constant region derived from human origin” or “human constant region” denotes a constant heavy chain region of a human antibody of the subclass IgG 1 , lgG2, lgG3, or lgG4 and / or a constant light chain kappa or lambda region. Such constant regions are well known in the state of the art and e.g., described by Kabat, E.A., et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991 ) (see also e.g., Johnson and Wu, Nucleic Acids Res. 28 (2000) 214-218; Kabat et al., Proc. Natl. Acad. Sci. USA 72 (1975) 2785-2788). Unless otherwise specified herein, numbering of amino acid residues in the constant region is according to the EU numbering system, also called the EU index of Kabat, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991 ), NIH Publication 91 -3242.

[0231] The terms “Fc region” or “Fc domain” are herein used interchangeably to refer to a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In one embodiment, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. The term encompasses truncated Fc regions, such as those having a C-terminal truncation (e.g., a AGK truncation, e.g., as described in Hu et al., Biotechnol. Prog. 2017, 33: 786-794 and Jiang et al., J. Pharm. Sci. 2016, 105: 2066-2072. Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991 . A “subunit” of an Fc domain as used herein refers to one of the two polypeptides forming the dimeric Fc domain, i.e., a polypeptide comprising C-terminal constant regions of an immunoglobulin heavy chain, capable of stable self- association. In one embodiment, a subunit of an IgG Fc domain comprises an IgG CH2 and an IgG CH3 constant domain.

[0232] “Framework” or “FR” refers to variable domain residues other than complementary determining regions (CDRs) or hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains: FR1 , FR2, FR3, and FR4. Accordingly, the CDR and FR sequences generally appear in the following sequence in VH (or VL): FR1 -CDR-H1 (CDR-L1 )-FR2- CDR-H2(CDR-L2)-FR3- CDR-H3(CDR-L3)-FR4.

[0233] The terms “full-length antibody,” “intact antibody,” and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.

[0234] A “human antibody” is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non-human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues. Human antibodies can be produced using various techniques known in the art, including phage-display libraries. Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991 ); Marks et al., J. Mol. Biol., 222:581 (1991 ). Also available for the preparation of human monoclonal antibodies are methods described in Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985); Boerner et al., J. Immunol., 147(1 ):86-95 (1991 ). See also van Dijk and van de Winkel, Curr. Opin. Pharmacol., 5: 368-74 (2001 ). Human antibodies can be prepared by administering the antigen to a transgenic animal that has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled, e.g., immunized xenomice (see, e.g., U.S. Pat. Nos. 6,075,181 and 6,150,584 regarding XENOMOUSE™ technology). See also, for example, Li et al., Proc. Natl. Acad. Sci. USA, 103:3557-3562 (2006), regarding human antibodies generated via a human B-cell hybridoma technology.

[0235] A “human consensus framework” is a framework which represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, the subgroup of sequences is a subgroup as in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91 -3242, Bethesda MD (1991 ), vols. 1 -3. In one embodiment, for the VL, the subgroup is subgroup kappa I as in Kabat et al., supra. In one embodiment, for the VH, the subgroup is subgroup III as in Kabat et al., supra.

[0236] A “humanized” antibody refers to a chimeric antibody comprising amino acid residues from non-human CDRs or HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDRs or HVRs correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. A “humanized form” of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization.

[0237] The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and / or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein.

[0238] As used herein, the term “monospecific” refers to an antigen-binding molecule that binds to a single antigen, e.g., STEAP1 . As used herein, the term “multispecific” refers to an antigen-binding molecule that binds to multiple different antigens, e.g., STEAP1 and CD3. For example, “multispecific antibodies” are monoclonal antibodies that have binding specificities for at least two different sites, i.e., different epitopes on different antigens or different epitopes on the same antigen.

[0239] “Native antibodies” refer to naturally occurring immunoglobulin molecules with varying structures. For example, native IgG antibodies are heterotetrameric glycoproteins of about 150,000 Daltons, composed of two identical light chains and two identical heavy chains that are disulfide- bonded. From N- to C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CH1 , CH2, and CH3). Similarly, from N- to C-terminus, each light chain has a variable region (VL), also called a variable light domain or a light chain variable domain, followed by a constant light (CL) domain. The light chain of an antibody may be assigned to one of two types, called kappa (K) and lambda (A), based on the amino acid sequence of its constant domain.

[0240] “Percent (%) amino acid sequence identity” with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity for the purposes of the alignment. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, Clustal W, Megalign (DNASTAR) software or the FASTA program package. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. Alternatively, the percent identity values can be generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087 and is described in WO 2001 / 007611 .

[0241] Unless otherwise indicated, for purposes herein, percent amino acid sequence identity values are generated using the ggsearch program of the FASTA package version 36.3.8c or later with a BLOSUM50 comparison matrix. The FASTA program package was authored by Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85:2444-2448 (1988); Pearson Meth. Enzymol. 266:227- 258 (1996); and Pearson et al., Genomics 46:24-36 (1997) and is publicly available from www.fasta.bioch.virginia.edu / fasta_www2 / fasta_down.shtml or www.ebi.ac.uk / Tools / sss / fasta. Alternatively, a public server accessible at fasta.bioch.virginia.edu / fasta_www2 / index.cgi can be used to compare the sequences, using the ggsearch (global protein protein) program and default options (BLOSUM50; open: -10; ext: -2; Ktup = 2) to ensure a global, rather than local, alignment is performed. Percent amino acid identity is given in the output alignment header.

[0242] An “isolated” antibody is one which has been separated from a component of its natural environment. In some aspects, an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC) methods. For a review of methods for assessment of antibody purity, see, e.g., Flatman et al., J. Chromatogr. B 848:79-87 (2007).

[0243] The term “nucleic acid molecule” or “polynucleotide” includes any compound and / or substance that comprises a polymer of nucleotides. Each nucleotide is composed of a base, specifically a purine or pyrimidine base (i.e., cytosine (C), guanine (G), adenine (A), thymine (T) or uracil (U)), a sugar (i.e., deoxyribose or ribose), and a phosphate group. Often, the nucleic acid molecule is described by the sequence of bases, whereby said bases represent the primary structure (linear structure) of a nucleic acid molecule. The sequence of bases is typically represented from 5’ to 3’. Herein, the term nucleic acid molecule encompasses deoxyribonucleic acid (DNA) including e.g., complementary DNA (cDNA) and genomic DNA, ribonucleic acid (RNA), in particular messenger RNA (mRNA), synthetic forms of DNA or RNA, and mixed polymers comprising two or more of these molecules. The nucleic acid molecule may be linear or circular. In addition, the term nucleic acid molecule includes both, sense and antisense strands, as well as single stranded and double stranded forms. Moreover, the herein described nucleic acid molecule can contain naturally occurring or non- naturally occurring nucleotides. Examples of non-naturally occurring nucleotides include modified nucleotide bases with derivatized sugars or phosphate backbone linkages or chemically modified residues. Nucleic acid molecules also encompass DNA and RNA molecules which are suitable as a vector for direct expression of an antibody of the invention in vitro and / or in vivo, e.g., in a host or patient. Such DNA (e.g., cDNA) or RNA (e.g., mRNA) vectors, can be unmodified or modified. For example, mRNA can be chemically modified to enhance the stability of the RNA vector and / or expression of the encoded molecule so that mRNA can be injected into a subject to generate the antibody in vivo (see e.g., Stadler et al., Nat. Med. 23(7) :815-817, 2017 or EP 2 101 823 B1 ).

[0244] An “isolated” nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that ordinarily contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.

[0245] “Isolated nucleic acid encoding an anti-STEAP1 antibody” refers to one or more nucleic acid molecules encoding anti-STEAP1 antibody heavy and light chains (or fragments thereof), including such nucleic acid molecule(s) in a single vector or separate vectors, and such nucleic acid molecule(s) present at one or more locations in a host cell.

[0246] “Isolated nucleic acid encoding an anti-CD3 antibody” refers to one or more nucleic acid molecules encoding anti-CD3 antibody heavy and light chains (or fragments thereof), including such nucleic acid molecule(s) in a single vector or separate vectors, and such nucleic acid molecule(s) present at one or more locations in a host cell.

[0247] The term “vector,” as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as “expression vectors.”

[0248] The terms “host cell,” “host cell line,” and “host cell culture” are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.

[0249] The term “pharmaceutical formulation” refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.

[0250] A “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject. A pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.

[0251] As used herein, “administering” is meant a method of giving a dosage of a compound (e.g., an antigen-binding molecule of the invention or a nucleic acid encoding an antigen-binding molecule of the invention) or a composition (e.g., a pharmaceutical composition, e.g., a pharmaceutical composition including an antigen-binding molecule of the invention) to a subject. The compositions utilized in the methods described herein can be administered, for example, intramuscularly, intravenously, intradermally, percutaneously, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostatically, intrapleurally, intratracheally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, peritoneally, subcutaneously, subconjunctivally, intravesicularlly, mucosally, intrapericardially, intraumbilically, intraocularly, orally, topically, locally, by inhalation, by injection, by infusion, by continuous infusion, by localized perfusion bathing target cells directly, by catheter, by lavage, in cremes, or in lipid compositions. The method of administration can vary depending on various factors (e.g., the compound or composition being administered and the severity of the condition, disease, or disorder being treated). As used herein, “treatment” (and grammatical variations thereof such as “treat” or “treating”) refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In some embodiments, antibodies of the invention are used to delay development of a disease or to slow the progression of a disease.

[0252] As used herein, “delaying progression” of a disorder or disease means to defer, hinder, slow, retard, stabilize, and / or postpone development of the disease or disorder (e.g., a cell proliferative disorder, e.g., cancer). This delay can be of varying lengths of time, depending on the history of the disease and / or individual being treated. As is evident to one skilled in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the individual does not develop the disease. For example, a late stage cancer, such as development of metastasis, may be delayed.

[0253] By “reduce” or “inhibit” is meant the ability to cause an overall decrease, for example, of 20% or greater, of 50% or greater, or of 75%, 85%, 90%, 95%, or greater. In certain embodiments, reduce or inhibit can refer to the effector function of an antigen-binding molecule that is mediated by the Fc region, such effector functions specifically including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP).

[0254] The terms “cancer” and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Included in this definition are benign and malignant cancers. By “early stage cancer” or “early stage tumor” is meant a cancer that is not invasive or metastatic or is classified as a Stage 0, 1 , or 2 cancer. Examples of cancer include, but are not limited to, solid tumors such as brain cancer, breast cancer, colorectal cancer, endometrial cancer, kidney cancer, liver cancer, lung cancer, melanoma, pancreatic cancer, prostate cancer, stomach cancer, or thyroid cancer; and hematologic malignancies such as Burkitt’s lymphoma (BL), multiple myeloma, diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), acute myeloid leukemia (AML), chronic lymphoid leukemia (CLL), marginal zone lymphoma (MZL), small lymphocytic leukemia (SLL), lymphoplasmacytic lymphoma (LL), or Waldenstrom macroglobulinemia (WM).

[0255] The term “tumor,” as used herein, refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues. The terms “cancer,” “cancerous,” “cell proliferative disorder,” “proliferative disorder,” and “tumor” are not mutually exclusive as referred to herein.

[0256] The term “STEAP1 -expressing cancer” refers to a cancer those cancer cells are characterized with an over-expression of STEAP1 compared to the expression level of STEAP1 in equivalent non-cancerous cells. Examples of STEAP1 -expressing cancer include, but are not limited to, breast cancer, bladder cancer, cervical cancer, colorectal cancer, Ewing sarcoma, lung cancer, ovarian cancer, and prostate cancer.

[0257] Prostate cancer is one of the most common cancer in men. Prostate cancer types can include adenocarcinomas of the prostate, sarcoma of the prostate, transitional cell carcinoma of the prostate, small cell carcinomas of the prostate, neuroendocrine tumors of the prostate, and castrate- resistant prostate cancer (CRPC). Prostate cancer can also be classified based on molecular signature. For example, prostate cancers can be classified into those with rearrangements in ETS family transcription factors (e.g., ERG, ETV1 , ETV4, and FLU ) and those negative for ETS factors. ETS positive prostate cancer can also include alterations in PI3K and p53 signaling. ETS negative prostate cancers can show recurrent mutations in SPOP, FOXA1 , and IDH1 ; deletions of CHD1 ; and overexpression of SPINK1 . In some instances, the prostate cancer is a metastatic prostate cancer (e.g., metastatic castrate-resistant prostate cancer). In other instances, the prostate cancer is a relapsed or refractory prostate cancer.

[0258] Ewing sarcoma (also referred to as Ewing’s sarcoma or Ewing’s tumor) is a cancer of the bones and soft tissue (e.g., cartilage or nerves). There are several types of Ewing sarcoma, such as Ewing sarcoma of bone, extraosseous Ewing sarcoma, peripheral primitive neuroectodermal tumor (pPNET), and Askin tumor. There is no known cause of Ewing sarcoma. Symptoms include pain and swelling at the site of the tumor.

[0259] The term “tumor antigen,” as used herein, may be understood as those antigens that are presented on tumor cells. These antigens can be presented on the cell surface with an extracellular part, which is often combined with a transmembrane and cytoplasmic part of the molecule. These antigens can sometimes be presented only by tumor cells and never by the normal ones. Tumor antigens can be exclusively expressed on tumor cells or might represent a tumor specific mutation compared to normal cells. In this case, they are called tumor-specific antigens. More common are tumor antigens that are presented by tumor cells and normal cells, and they are called tumor- associated antigens. These tumor-associated antigens can be overexpressed compared to normal cells or are accessible for antibody binding in tumor cells due to the less compact structure of the tumor tissue compared to normal tissue. Exemplary tumor antigens include, but are not limited to, prostate-specific membrane antigen (PSMA), prostate stem cell antigen (PSCA), epithelial cell adhesion molecule (EpCAM), prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), STEAP2, and HBA-71 . In some cases, the TAAs for prostate cancer include prostate-specific membrane antigen (PSMA), prostate stem cell antigen (PSCA), epithelial cell adhesion molecule (EpCAM), prostate-specific antigen (PSA), and prostatic acid phosphatase (PAP). In some cases, the TAA for Ewing sarcoma include HBA-71 , an antigen localized at the cell-surface glycocalyx of tumor cells.

[0260] The term “T cell receptor” or TCR refers to a receptor expressed on a T cell. Exemplary T cell receptors include, but are not limited to, CD3.

[0261] An “effective amount” of a compound, for example, a bispecific antigen-binding molecule of the invention or a composition (e.g., pharmaceutical composition) thereof, is at least the minimum amount required to achieve the desired therapeutic or prophylactic result, such as a measurable improvement or prevention of a particular disorder (e.g., a cell proliferative disorder, e.g., cancer). An effective amount herein may vary according to factors such as the disease state, age, sex, and weight of the patient, and the ability of the antibody to elicit a desired response in the individual. An effective amount is also one in which any toxic or detrimental effects of the treatment are outweighed by the therapeutically beneficial effects. For prophylactic use, beneficial or desired results include results such as eliminating or reducing the risk, lessening the severity, or delaying the onset of the disease, including biochemical, histological and / or behavioral symptoms of the disease, its complications and intermediate pathological phenotypes presenting during development of the disease. For therapeutic use, beneficial or desired results include clinical results such as decreasing one or more symptoms resulting from the disease, increasing the quality of life of those suffering from the disease, decreasing the dose of other medications required to treat the disease, enhancing effect of another medication such as via targeting, delaying the progression of the disease, and / or prolonging survival. In the case of cancer or tumor, an effective amount of the drug may have the effect in reducing the number of cancer cells; reducing the tumor size; inhibiting (i.e., slow to some extent or desirably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and desirably stop) tumor metastasis; inhibiting to some extent tumor growth; and / or relieving to some extent one or more of the symptoms associated with the disorder. An effective amount can be administered in one or more administrations. For purposes of this invention, an effective amount of drug, compound, or pharmaceutical composition is an amount sufficient to accomplish prophylactic or therapeutic treatment either directly or indirectly. As is understood in the clinical context, an effective amount of a drug, compound, or pharmaceutical composition may or may not be achieved in conjunction with another drug, compound, or pharmaceutical composition. Thus, an “effective amount” may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable result may be or is achieved.

[0262] As used herein, “first-line therapy” comprises a primary treatment for a subject with a cancer. In some instances, the cancer is a primary cancer. In other instances, the cancer is a metastatic or recurrent cancer. In some cases, the first-line therapy comprises chemotherapy. In other cases, the first-line treatment comprises radiation therapy. A skilled artisan would readily understand that different first-line treatments may be applicable to different type of cancers.

[0263] In some cases, the additional therapeutic agent comprises a second-line therapy, a third-line therapy, a fourth-line therapy, or a fifth-line therapy. As used herein, a second-line therapy encompasses treatments that are utilized after the primary or first-line treatment stops. A third-line therapy, a fourth-line therapy, or a fifth-line therapy encompass subsequent treatments. As indicated by the naming convention, a third-line therapy encompass a treatment course upon which a primary and second-line therapy have stopped.

[0264] As used herein, the terms “individual,” “patient,” or “subject” are used interchangeably, and each refers to a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain aspects, the individual, patient, or subject is a human.

[0265] II. COMPOSITIONS

[0266] In one aspect, the invention is based, in part, on antigen-binding molecules (e.g., mono- specific and / or multispecific antigen-binding molecules). In certain embodiments, the antigen-binding molecules bind to STEAP1 . In certain embodiments, the antigen-binding molecules are multispecific antigen-binding molecules that bind to STEAP1 and to one or more additional antigens of interest. In certain embodiments, the multispecific antigen-binding molecules bind to STEAP1 monovalently. Antigen-binding molecules of the invention are useful, e.g., for treating or delaying the progression of a cancer (e.g., STEAP1 -expressing cancer).

[0267] Exemplary antigen-binding molecules that bind to STEAP1

[0268] Antigen-binding molecules that bind to STEAP1

[0269] In some embodiments, the invention provides isolated antigen-binding molecules that bind to STEAP1 . In some embodiments, an antigen-binding molecule of the present invention comprises at least one, at least two, at least three, at least four, at least five, or all six CDRs as illustrated in Table 1 (Kabat) or Table 2 (Chothia). In some instances, the antigen-binding molecule comprises a VH and / or a VL as illustrated in Table 1 .

[0270] Table 1

[0271]

[0272] Table 2

[0273] In some embodiments, the antigen-binding molecule that binds to STEAP1 comprises of an anti-STEAP1 heavy chain variable region (VH) comprising, consisting essentially of, or consisting of CDR-H1 , CDR-H2, and / or CDR-H3 of a VH sequence selected from SEQ ID NO: 7, 17-25, 30-34, and 38; and / or an anti-STEAP1 light chain variable region (VL) comprising, consisting essentially of, or consisting of CDR-L1 , CDR-L2, and / or CDR-L3 of a VL sequence selected from SEQ ID NO: 8, 26- 29, 39, and 69. In some instances, at least one, at least two, at least three, at least four, at least five, or all six CDRs are selected from the CDR(s) of the VH sequence selected from SEQ ID NOs: 7, 17- 25, 30-34, 38, and 68 and the VL sequence selected from SEQ ID NO: 8, 26-29, 39, and 69. In some cases, the six CDRs are defined according to the Kabat numbering (see Table 1 ). In other cases, the six CDRs are defined according to the Chothia numbering (see Table 2). In additional cases, the six CDRs are defined according to the EU numbering.

[0274] In some embodiments, the antigen-binding molecule that binds to STEAP1 comprises an anti- STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and / or CDR-H3; and / or an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and / or CDR-L3; wherein: CDR-H1 comprises Xaa1Xaa2YMA (SEQ ID NO: 35); wherein

[0275] Xaa1is Asp (D) or Asn (N); and

[0276] Xaa2is His (H), Tyr (Y), or Phe (F);

[0277] CDR-H2 comprises YIXaa3YDGXaa4Xaa5TXaa6YGDSVKG (SEQ ID NO: 36); wherein

[0278] Xaa3is Asp (D) or Ser (S);

[0279] Xaa4is Gly (G), Asp (D), or Leu (L);

[0280] Xaa5is Ser (S), Asp (D), or Asn (N); and

[0281] Xaa6is Ser (S) or Tyr (Y);

[0282] CDR-H3 comprises RSGXaa7YHVGYAMXaa8Xaa9(SEQ ID NO: 37); wherein

[0283] Xaa7is Phe (F) or Tyr (Y);

[0284] Xaa8is Asn (N) or Asp (D); and

[0285] Xaa9is Ala (A) or Gly (G);

[0286] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0287] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6.

[0288] In some cases, the anti-STEAP1 antigen-binding molecule comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3.

[0289] In some embodiments, the antigen-binding molecule that binds to STEAP1 comprises an anti- STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and / or CDR-H3; and / or an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and / or CDR-L3; wherein:

[0290] CDR-H1 comprises the amino acid sequence of SEQ ID NO: 10, 1 , or 9;

[0291] CDR-H2 comprises YIXaa3YDGXaa4Xaa5TXaa6YGDSVKG (SEQ ID NO: 36); wherein

[0292] Xaa3is Asp (D) or Ser (S);

[0293] Xaa4is Gly (G), Asp (D), or Leu (L);

[0294] Xaa5is Ser (S), Asp (D), or Asn (N); and

[0295] Xaa6is Ser (S) or Tyr (Y);

[0296] CDR-H3 comprises RSGXaa7YHVGYAMXaa8Xaa9(SEQ ID NO: 37); wherein

[0297] Xaa7is Phe (F) or Tyr (Y);

[0298] Xaa8is Asn (N) or Asp (D); and

[0299] Xaa9is Ala (A) or Gly (G);

[0300] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0301] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or

[0302] CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6.

[0303] In some cases, the anti-STEAP1 antigen-binding molecule comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3.

[0304] In some embodiments, the antigen-binding molecule that binds to STEAP1 comprises an anti- STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and / or CDR-H3; and / or an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and / or CDR-L3; wherein

[0305] CDR-H1 comprises the amino acid sequence of SEQ ID NO: 10, 1 , or 9;

[0306] CDR-H2 comprises the amino acid sequence of SEQ ID NO: 2, 1 1 , 12, or 13;

[0307] CDR-H3 comprises RSGXaa7YHVGYAMXaa8Xaa9(SEQ ID NO: 37); wherein

[0308] Xaa7is Phe (F) or Tyr (Y);

[0309] Xaa8is Asn (N) or Asp (D); and

[0310] Xaa9is Ala (A) or Gly (G);

[0311] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0312] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or

[0313] CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6.

[0314] In some cases, the anti-STEAP1 antigen-binding molecule comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3. In some embodiments, the antigen-binding molecule that binds to STEAP1 comprises an anti- STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and / or CDR-H3; and / or an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and / or CDR-L3; wherein

[0315] CDR-H1 comprises Xaa1Xaa2YMA (SEQ ID NO: 35); wherein

[0316] Xaa1is Asp (D) or Asn (N); and

[0317] Xaa2is His (H), Tyr (Y), or Phe (F);

[0318] CDR-H2 comprises the amino acid sequence of SEQ ID NO: 2, 11 , 12, or 13; CDR-H3 comprises RSGXaa7YHVGYAMXaa8Xaa9(SEQ ID NO: 37); wherein

[0319] Xaa7is Phe (F) or Tyr (Y);

[0320] Xaa8is Asn (N) or Asp (D); and

[0321] Xaa9is Ala (A) or Gly (G);

[0322] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0323] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or

[0324] CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6.

[0325] In some cases, the anti-STEAP1 antigen-binding molecule comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3.

[0326] In some embodiments, the antigen-binding molecule that binds to STEAP1 comprises an anti- STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and / or CDR-H3; and / or an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and / or CDR-L3; wherein

[0327] CDR-H1 comprises Xaa1Xaa2YMA (SEQ ID NO: 35); wherein

[0328] Xaa1is Asp (D) or Asn (N); and

[0329] Xaa2is His (H), Tyr (Y), or Phe (F);

[0330] CDR-H2 comprises the amino acid sequence of SEQ ID NO: 2, 11 , 12, or 13; CDR-H3 comprises the amino acid sequence of SEQ ID NO: 16, 3, 14, or 15; CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0331] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6.

[0332] In some cases, the anti-STEAP1 antigen-binding molecule comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3.

[0333] In some embodiments, the antigen-binding molecule that binds to STEAP1 comprises an anti- STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and / or CDR-H3; and / or an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and / or CDR-L3; wherein

[0334] CDR-H1 comprises Xaa1Xaa2YMA (SEQ ID NO: 35); wherein

[0335] Xaa1is Asp (D) or Asn (N); and

[0336] Xaa2is His (H), Tyr (Y), or Phe (F);

[0337] CDR-H2 comprises YIXaa3YDGXaa4Xaa5TXaa6YGDSVKG (SEQ ID NO: 36); wherein

[0338] Xaa3is Asp (D) or Ser (S);

[0339] Xaa4is Gly (G), Asp (D), or Leu (L);

[0340] Xaa5is Ser (S), Asp (D), or Asn (N); and

[0341] Xaa6is Ser (S) or Tyr (Y);

[0342] CDR-H3 comprises the amino acid sequence of SEQ ID NO: 16, 3, 14, or 15;

[0343] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0344] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6.

[0345] In some cases, the anti-STEAP1 antigen-binding molecule comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3.

[0346] In some embodiments, the antigen-binding molecule that binds to STEAP1 comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and / or CDR-H3; and / or an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and / or CDR-L3; wherein

[0347] CDR-H1 comprises the amino acid sequence of SEQ ID NO: 10, 1 , or 9;

[0348] CDR-H2 comprises YIXaa3YDGXaa4Xaa5TXaa6YGDSVKG (SEQ ID NO: 36); wherein

[0349] Xaa3is Asp (D) or Ser (S);

[0350] Xaa4is Gly (G), Asp (D), or Leu (L);

[0351] Xaa5is Ser (S), Asp (D), or Asn (N); and

[0352] Xaa6is Ser (S) or Tyr (Y);

[0353] CDR-H3 comprises the amino acid sequence of SEQ ID NO: 16, 3, 14, or 15;

[0354] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0355] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6.

[0356] In some cases, the anti-STEAP1 antigen-binding molecule comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3.

[0357] In some embodiments, the antigen-binding molecule that binds to STEAP1 comprises an anti- STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and / or CDR-H3; and / or an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and / or CDR-L3; in which CDR-H1 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 10, 1 , or 9; CDR-H2 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 2, 1 1 , 12, or 13; CDR-H3 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 16, 3, 14, or 15; CDR-L1 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 6. In some cases, the anti-STEAP1 antigen- binding molecule comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3.

[0358] In some instances, the antigen-binding molecule comprises CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 1 ; CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 2; CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 3; CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6.

[0359] In some instances, the antigen-binding molecule comprises CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 9; CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 11 ; CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 3; CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6.

[0360] In some instances, the antigen-binding molecule comprises CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 9; CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 12; CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 3; CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6.

[0361] In some instances, the antigen-binding molecule comprises CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 9; CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 12; CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 14; CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6.

[0362] In some instances, the antigen-binding molecule comprises CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 10; CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 13; CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 15; CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6.

[0363] In some instances, the antigen-binding molecule comprises CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 10; CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 2; CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 16; CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6.

[0364] In some embodiments, the antigen-binding molecule that binds to STEAP1 comprises an anti- STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and / or CDR-H3; and / or an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and / or CDR-L3; wherein CDR-H1 comprises GFTFSXaa10Xaa11(SEQ ID NO: 63); wherein

[0365] Xaa10is Asn (N) or Asp (D); and

[0366] Xaa11is Tyr (Y), Phe (F), or His (H);

[0367] CDR-H2 comprises Xaa12YDGXaa13Xaa14(SEQ ID NO: 64); wherein

[0368] Xaa12is Asp (D) or Ser (S);

[0369] Xaa13is Gly (G), Asp (D), or Leu (L); and

[0370] Xaa14is Ser (S), Asp (D), or Asn (N);

[0371] CDR-H3 comprises RSGXaa7YHVGYAMXaa8Xaa9(SEQ ID NO: 37); wherein

[0372] Xaa7is Phe (F) or Tyr (Y);

[0373] Xaa8is Asn (N) or Asp (D); and

[0374] Xaa9is Ala (A) or Gly (G);

[0375] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0376] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or

[0377] CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6.

[0378] In some cases, the anti-STEAP1 antigen-binding molecule comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3.

[0379] In some embodiments, the antigen-binding molecule that binds to STEAP1 comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and / or CDR-H3; and / or an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and / or CDR-L3; wherein

[0380] CDR-H1 comprises the amino acid sequence of SEQ ID NO: 56, 58, or 59;

[0381] CDR-H2 comprises Xaa12YDGXaa13Xaa14(SEQ ID NO: 64); wherein

[0382] Xaa12is Asp (D) or Ser (S);

[0383] Xaa13is Gly (G), Asp (D), or Leu (L); and

[0384] Xaa14is Ser (S), Asp (D), or Asn (N);

[0385] CDR-H3 comprises RSGXaa7YHVGYAMXaa8Xaa9(SEQ ID NO: 37); wherein

[0386] Xaa7is Phe (F) or Tyr (Y);

[0387] Xaa8is Asn (N) or Asp (D); and

[0388] Xaa9is Ala (A) or Gly (G);

[0389] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0390] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6.

[0391] In some cases, the anti-STEAP1 antigen-binding molecule comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3.

[0392] In some embodiments, the antigen-binding molecule that binds to STEAP1 comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and / or CDR-H3; and / or an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and / or CDR-L3; wherein

[0393] CDR-H1 comprises the amino acid sequence of SEQ ID NO: 56, 58, or 59;

[0394] CDR-H2 comprises the amino acid sequence of SEQ ID NO: 57, 60, 61 , or 62;

[0395] CDR-H3 comprises RSGXaa7YHVGYAMXaa8Xaa9(SEQ ID NO: 37); wherein

[0396] Xaa7is Phe (F) or Tyr (Y);

[0397] Xaa8is Asn (N) or Asp (D); and

[0398] Xaa9is Ala (A) or Gly (G);

[0399] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0400] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6.

[0401] In some cases, the anti-STEAP1 antigen-binding molecule comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3.

[0402] In some embodiments, the antigen-binding molecule that binds to STEAP1 comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and / or CDR-H3; and / or an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and / or CDR-L3; wherein

[0403] CDR-H1 comprises GFTFSXaa10Xaa11(SEQ ID NO: 63); wherein

[0404] Xaa10is Asn (N) or Asp (D); and

[0405] Xaa11is Tyr (Y), Phe (F), or His (H);

[0406] CDR-H2 comprises the amino acid sequence of SEQ ID NO: 57, 60, 61 , or 62;

[0407] CDR-H3 comprises RSGXaa7YHVGYAMXaa8Xaa9(SEQ ID NO: 37); wherein

[0408] Xaa7is Phe (F) or Tyr (Y);

[0409] Xaa8is Asn (N) or Asp (D); and

[0410] Xaa9is Ala (A) or Gly (G);

[0411] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0412] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6.

[0413] In some cases, the anti-STEAP1 antigen-binding molecule comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3.

[0414] In some embodiments, the antigen-binding molecule that binds to STEAP1 comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and / or CDR-H3; and / or an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and / or CDR-L3; wherein

[0415] CDR-H1 comprises GFTFSXaa10Xaa11(SEQ ID NO: 63); wherein

[0416] Xaa10is Asn (N) or Asp (D); and

[0417] Xaa11is Tyr (Y), Phe (F), or His (H);

[0418] CDR-H2 comprises the amino acid sequence of SEQ ID NO: 57, 60, 61 , or 62;

[0419] CDR-H3 comprises the amino acid sequence of SEQ ID NO: 16, 3, 14, or 15;

[0420] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0421] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6.

[0422] In some cases, the anti-STEAP1 antigen-binding molecule comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3.

[0423] In some embodiments, the antigen-binding molecule that binds to STEAP1 comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and / or CDR-H3; and / or an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and / or CDR-L3; wherein CDR-H1 comprises GFTFSXaa10Xaa11(SEQ ID NO: 63); wherein

[0424] Xaa10is Asn (N) or Asp (D); and

[0425] Xaa11is Tyr (Y), Phe (F), or His (H);

[0426] CDR-H2 comprises Xaa12YDGXaa13Xaa14(SEQ ID NO: 64); wherein

[0427] Xaa12is Asp (D) or Ser (S);

[0428] Xaa13is Gly (G), Asp (D), or Leu (L); and

[0429] Xaa14is Ser (S), Asp (D), or Asn (N);

[0430] CDR-H3 comprises the amino acid sequence of SEQ ID NO: 16, 3, 14, or 15;

[0431] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0432] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6.

[0433] In some cases, the anti-STEAP1 antigen-binding molecule comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3.

[0434] In some embodiments, the antigen-binding molecule that binds to STEAP1 comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and / or CDR-H3; and / or an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and / or CDR-L3; wherein

[0435] CDR-H1 comprises the amino acid sequence of SEQ ID NO: 56, 58, or 59;

[0436] CDR-H2 comprises Xaa12YDGXaa13Xaa14(SEQ ID NO: 64); wherein

[0437] Xaa12is Asp (D) or Ser (S);

[0438] Xaa13is Gly (G), Asp (D), or Leu (L); and

[0439] Xaa14is Ser (S), Asp (D), or Asn (N);

[0440] CDR-H3 comprises the amino acid sequence of SEQ ID NO: 16, 3, 14, or 15;

[0441] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0442] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6.

[0443] In some cases, the anti-STEAP1 antigen-binding molecule comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3.

[0444] In some embodiments, the antigen-binding molecule that binds to STEAP1 comprises a heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and / or CDR-H3; and / or an anti- STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and / or CDR-L3; in which CDR- H1 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 56, 58, or 59; CDR-H2 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 57, 60, 61 , or 62; CDR-H3 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 16, 3, 14, or 15; CDR-L1 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 6. In some cases, the anti-STEAP1 antigen- binding molecule comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3.

[0445] In some instances, the antigen-binding molecule comprises CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 56; CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 57; CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 3; CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6.

[0446] In some instances, the antigen-binding molecule comprises CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 58; CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 60; CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 3; CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6.

[0447] In some instances, the antigen-binding molecule comprises CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 58; CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 61 ; CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 3; CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6.

[0448] In some instances, the antigen-binding molecule comprises CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 58; CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 61 ; CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 14; CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6.

[0449] In some instances, the antigen-binding molecule comprises CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 59; CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 62; CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 15; CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6.

[0450] In some instances, the antigen-binding molecule comprises CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 59; CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 57; CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 16; CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6.

[0451] The antigen-binding molecules of the present invention can be humanized antibodies. In some instances, an antigen-binding molecule of the present invention comprises a constant region derived from an IgG framework region. In some cases, the IgG framework region is an IgGi, lgG2, or lgG4 framework region. In some cases, the IgG framework region is an IgG 1 framework region.

[0452] In some embodiments, the antigen-binding molecule comprises a heavy chain variable region comprising one or more (e.g., 1 , 2, 3, or all 4) of a framework region (FR)-H1 sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 110; an FR-H2 having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 118; an FR-H3 having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 112; and / or an FR-H4 having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 113. In some embodiments, the antigen-binding molecule comprises a heavy chain variable region comprising an FR-H2 having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 118. In some embodiments, the antigen-binding molecule comprises a heavy chain variable region comprising an FR-H2 having the amino acid sequence of SEQ ID NO: 118. In other embodiments, the antigen-binding molecule comprises a heavy chain variable region comprising an FR-H2 having the amino acid sequence of SEQ ID NO: 120.

[0453] In some embodiments, the antigen-binding molecule comprises a heavy chain variable region comprising one or more (e.g., 1 , 2, 3, or all 4) of an FR-H1 sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 110; an FR-H2 having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 111 ; an FR-H3 having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 112; and / or an FR-H4 having at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1 13.

[0454] In some embodiments, the antigen-binding molecule comprises a light chain variable region comprising one or more (e.g., 1 , 2, 3, or all 4) of an FR-L1 having at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1 14; an FR-L2 having at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1 19; an FR-L3 co having at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1 16; and / or an FR-L4 having at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1 17. In some embodiments, the antigen-binding molecule comprises a heavy chain variable region comprising an FR-L2 having at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1 19. In some embodiments, the antigen-binding molecule comprises a heavy chain variable region comprising an FR-L2 having the amino acid sequence of SEQ ID NO: 1 19. In other embodiments, the antigen-binding molecule comprises a heavy chain variable region comprising an FR-L2 having the amino acid sequence of SEQ ID NO: 121 .

[0455] In some embodiments, the antigen-binding molecule comprises a light chain variable region comprising one or more (e.g., 1 , 2, 3, or all 4) of an FR-L1 having at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1 14; an FR-L2 having at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1 15; an FR-L3 co having at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1 16; and / or an FR-L4 having at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1 17.

[0456] For example, in some instances, the antigen-binding molecule comprises an FR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 1 10; an FR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 1 1 1 ; an FR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 1 12; an FR-H4 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 1 13; an FR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 1 14; an FR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 1 15; an FR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 1 16; and an FR-L4 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 1 17.

[0457] In some embodiments, the antigen-binding molecule comprises a heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 7, 17-25, 30-34, 38, or 68. In some instances, the heavy chain variable region comprises a VH sequence having at least 90% sequence identity to SEQ ID NO: 7, 17-25, 30-34, 38, or 68. In some instances, the heavy chain variable region comprises a VH sequence having at least 95% sequence identity to SEQ ID NO: 7, 17-25, 30-34, 38, or 68. In some instances, the heavy chain variable region comprises a VH sequence having at least 98% sequence identity to SEQ ID NO: 7, 17-25, 30-34, 38, or 68. In some instances, the heavy chain variable region comprises a VH sequence having at least 99% sequence identity to SEQ ID NO: 7, 17-25, 30-34, 38, or 68. In some instances, the heavy chain variable region comprises a VH sequence having 100% sequence identity to SEQ ID NO: 7, 17-25, 30-34, 38, or 68. In certain aspects, a VH sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to SEQ ID NO: 7, 17-25, 30-34, 38, or 68, but an anti-STEAP1 antibody comprising that sequence retains the ability to bind to STEAP1 . In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 7, 17-25, 30-34, 38, or 68. In certain aspects, substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs).

[0458] In some embodiments, the antigen-binding molecule comprises a light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 8, 26-29, 39, or 69. In some instances, the light chain variable region comprises a VL sequence having at least 90% sequence identity to SEQ ID NO: 8, 26-29, 39, or 69. In some instances, the light chain variable region comprises a VL sequence having at least 95% sequence identity to SEQ ID NO: 8, 26-29, 39, or 69. In some instances, the light chain variable region comprises a VL sequence having at least 98% sequence identity to SEQ ID NO: 8, 26-29, 39, or 69. In some instances, the light chain variable region comprises a VL sequence having at least 99% sequence identity to SEQ ID NO: 8, 26-29, 39, or 69. In some instances, the light chain variable region comprises a VL sequence having 100% sequence identity to SEQ ID NO: 8, 26- 29, 39, or 69. In certain aspects, a VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to SEQ ID NO: 8, 26-29, 39, or 69, but an anti-STEAP1 antibody comprising that sequence retains the ability to bind to STEAP1 . In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 8, 26-29, 39, or 69. In certain aspects, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs).

[0459] In some embodiments, the antigen-binding molecule of any of the preceding embodiments features a VH and a VL region, in which the VH region comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 9, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 11 , or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 3. In some instances, the VH region comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 58, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 60, or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 3. In some embodiments, the VH region comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 30 (e.g., at least 95% sequence identity to SEQ ID NO: 30, at least 96% sequence identity to SEQ ID NO: 30, at least 97% sequence identity to SEQ ID NO: 30, at least 98% sequence identity to SEQ ID NO: 30, at least 99% sequence identity to SEQ ID NO: 30, or 100% sequence identity to SEQ ID NO: 30). In some embodiments, the VL region comprises one, two, or all three of the following CDRs: (a) CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4, (b) CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5, or (c) CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6. In some embodiments, the VL region comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 27 (e.g., at least 95% sequence identity to SEQ ID NO: 27, at least 96% sequence identity to SEQ ID NO: 27, at least 97% sequence identity to SEQ ID NO: 27, at least 98% sequence identity to SEQ ID NO: 27, at least 99% sequence identity to SEQ ID NO: 27, or 100% sequence identity to SEQ ID NO: 27).

[0460] In some embodiments, the antigen-binding molecule of any of the preceding embodiments features a VH and a VL region, in which the VH region comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 9, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 12, or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 3. In some instances, the VH region comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 58, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 61 , or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 3. In some embodiments, the VH region comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 31 (e.g., at least 95% sequence identity to SEQ ID NO: 31 , at least 96% sequence identity to SEQ ID NO: 31 , at least 97% sequence identity to SEQ ID NO: 31 , at least 98% sequence identity to SEQ ID NO: 31 , at least 99% sequence identity to SEQ ID NO: 31 , or 100% sequence identity to SEQ ID NO: 31 ). In some embodiments, the VL region comprises one, two, or all three of the following CDRs: (a) CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4, (b) CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5, or (c) CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6. In some embodiments, the VL region comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 27 (e.g., at least 95% sequence identity to SEQ ID NO: 27, at least 96% sequence identity to SEQ ID NO: 27, at least 97% sequence identity to SEQ ID NO: 27, at least 98% sequence identity to SEQ ID NO: 27, at least 99% sequence identity to SEQ ID NO: 27, or 100% sequence identity to SEQ ID NO: 27). In some embodiments, the antigen-binding molecule of any of the preceding embodiments features a VH and a VL region, in which the VH region comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 9, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 12, or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 14. In some instances, the VH region comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 58, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 61 , or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 14. In some embodiments, the VH region comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 32 (e.g., at least 95% sequence identity to SEQ ID NO: 32, at least 96% sequence identity to SEQ ID NO: 32, at least 97% sequence identity to SEQ ID NO: 32, at least 98% sequence identity to SEQ ID NO: 32, at least 99% sequence identity to SEQ ID NO: 32, or 100% sequence identity to SEQ ID NO: 32). In some embodiments, the VL region comprises one, two, or all three of the following CDRs: (a) CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4, (b) CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5, or (c) CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6. In some embodiments, the VL region comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 27 (e.g., at least 95% sequence identity to SEQ ID NO: 27, at least 96% sequence identity to SEQ ID NO: 27, at least 97% sequence identity to SEQ ID NO: 27, at least 98% sequence identity to SEQ ID NO: 27, at least 99% sequence identity to SEQ ID NO: 27, or 100% sequence identity to SEQ ID NO: 27).

[0461] In some embodiments, the antigen-binding molecule of any of the preceding embodiments features a VH and a VL region, in which the VH region comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 10, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 13, or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 15. In some instances, the VH region comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 59, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 62, or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 15. In some embodiments, the VH region comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 33 (e.g., at least 95% sequence identity to SEQ ID NO: 33, at least 96% sequence identity to SEQ ID NO: 33, at least 97% sequence identity to SEQ ID NO: 33, at least 98% sequence identity to SEQ ID NO: 33, at least 99% sequence identity to SEQ ID NO: 33, or 100% sequence identity to SEQ ID NO: 33). In some embodiments, the VL region comprises one, two, or all three of the following CDRs: (a) CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4, (b) CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5, or (c) CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6. In some embodiments, the VL region comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 27 (e.g., at least 95% sequence identity to SEQ ID NO: 27, at least 96% sequence identity to SEQ ID NO: 27, at least 97% sequence identity to SEQ ID NO: 27, at least 98% sequence identity to SEQ ID NO: 27, at least 99% sequence identity to SEQ ID NO: 27, or 100% sequence identity to SEQ ID NO: 27).

[0462] In some embodiments, the antigen-binding molecule of any of the preceding embodiments features a VH and a VL region, in which the VH region comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 10, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 2, or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 16. In some instances, the VH region comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 59, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 57, or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 16. In some embodiments, the VH region comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 34 (e.g., at least 95% sequence identity to SEQ ID NO: 34, at least 96% sequence identity to SEQ ID NO: 34, at least 97% sequence identity to SEQ ID NO: 34, at least 98% sequence identity to SEQ ID NO: 34, at least 99% sequence identity to SEQ ID NO: 34, or 100% sequence identity to SEQ ID NO: 34). In some embodiments, the VL region comprises one, two, or all three of the following CDRs: (a) CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4, (b) CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5, or (c) CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6. In some embodiments, the VL region comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 27 (e.g., at least 95% sequence identity to SEQ ID NO: 27, at least 96% sequence identity to SEQ ID NO: 27, at least 97% sequence identity to SEQ ID NO: 27, at least 98% sequence identity to SEQ ID NO: 27, at least 99% sequence identity to SEQ ID NO: 27, or 100% sequence identity to SEQ ID NO: 27).

[0463] In some embodiments, the VH region comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 68 (e.g., at least 95% sequence identity to SEQ ID NO: 68, at least

[0464] 96% sequence identity to SEQ ID NO: 68, at least 97% sequence identity to SEQ ID NO: 68, at least

[0465] 98% sequence identity to SEQ ID NO: 68, at least 99% sequence identity to SEQ ID NO: 68, or 100% sequence identity to SEQ ID NO: 68). In some embodiments, the VL region comprises one, two, or all three of the following CDRs: (a) CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4, (b) CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5, or (c) CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6. In some embodiments, the VL region comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 69 (e.g., at least 95% sequence identity to SEQ ID NO: 69, at least 96% sequence identity to SEQ ID NO: 69, at least 97% sequence identity to SEQ ID NO: 69, at least 98% sequence identity to SEQ ID NO: 69, at least 99% sequence identity to SEQ ID NO: 69, or 100% sequence identity to SEQ ID NO: 69).

[0466] In some embodiments, the antigen-binding molecule of any of the preceding embodiments features a VH and a VL region, in which the VH region comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 35, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 36, or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 37. In some instances, the VH region comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 63, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 64, or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 37. In some embodiments, the VH region comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 38 (e.g., at least 95% sequence identity to SEQ ID NO: 38, at least 96% sequence identity to SEQ ID NO: 38, at least 97% sequence identity to SEQ ID NO: 38, at least 98% sequence identity to SEQ ID NO: 38, at least 99% sequence identity to SEQ ID NO: 38, or 100% sequence identity to SEQ ID NO: 38). In some embodiments, the VL region comprises one, two, or all three of the following CDRs: (a) CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4, (b) CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5, or (c) CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6. In some embodiments, the VL region comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 39 (e.g., at least 95% sequence identity to SEQ ID NO: 39, at least 96% sequence identity to SEQ ID NO: 39, at least 97% sequence identity to SEQ ID NO: 39, at least 98% sequence identity to SEQ ID NO: 39, at least 99% sequence identity to SEQ ID NO: 39, or 100% sequence identity to SEQ ID NO: 39).

[0467] In some embodiments, the antigen-binding molecule binds to an epitope on STEAP1 comprising one or more amino acid residues selected from Seri 01 , His102, G In 103, and Lys281 of STEAP1 . In some embodiments, the epitope comprises amino acid residues Seri 01 of ECL1 of

[0468] STEAP1 . In some embodiments, the epitope comprises amino acid residues His102 of ECL1 of

[0469] STEAP1 . In some embodiments, the epitope comprises amino acid residues Gin 103 of ECL1 of

[0470] STEAP1 . In some embodiments, the epitope comprises amino acid residues Lys281 of ECL3 of

[0471] STEAP1 . In some embodiments, the epitope comprises Seri 01 , His102, Gl n 103 of ECL1 of STEAP1 , and Lys281 of ECL3 of STEAP1 . In some embodiments, the epitope further comprises one or more additional amino acid residues selected from Trp195, Gln198, Gln201 , Gln202, Asn203 and Lys204 of ECL2 of STEAP1 . In some embodiments, the epitope does not comprise amino acid residue G In 104 of STEAP1 . In some embodiments, the epitope does not comprise amino acid residue Tyr107 of STEAP1 . In some embodiments, the epitope does not comprise amino acid residue Asn194 of STEAP1 . In some embodiments, the epitope does not comprise amino acid residue Glu205 of STEAP1 . In some embodiments, the epitope does not comprise amino acid residues Ala207 of STEAP1 .

[0472] In some embodiments, the antigen-binding molecule binds human STEAP1 with a KDof about 100 nM or lower, as measured by Kinetic Exclusion Assay (KinExA®). In some embodiments, the antigen-binding molecule binds human STEAP1 with a KDof between about 10 pM to about 100 nM. In some embodiments, the antigen-binding molecule binds human STEAP1 with a KDof between about 100 pM to about 50 nM. In some embodiments, the antigen-binding molecule binds human STEAP1 with a KDof between about 1 nM to about 30 nM. In some embodiments, the antigen- binding molecule binds cynomolgus STEAP1 with a KDof about 100 nM or lower, as measured by Kinetic Exclusion Assay (KinExA®). In some embodiments, the antigen-binding molecule binds cynomolgus STEAP1 with a KDof between about 10 pM to about 100 nM. In some embodiments, the antigen-binding molecule binds cynomolgus STEAP1 with a KDof between about 100 pM to about 50 nM. In some embodiments, the antigen-binding molecule binds cynomolgus STEAP1 with a KDof between about 1 nM to about 30 nM.

[0473] Multispecific antigen-binding molecules

[0474] In some embodiments, the invention provides isolated multispecific antigen-binding molecules that comprises a first antigen-binding domain that binds to STEAP1 as described above. In some instances, the multispecific antigen-binding molecule binds to STEAP1 monovalently. In some instances, the multispecific antigen-binding molecule further comprises a second binding domain that binds to a T cell receptor. In additional instances, the multispecific antigen-binding molecule comprises a third binding domain that binds to an additional antigen (e.g., a tumor-associated antigen).

[0475] In some embodiments, a multispecific antigen-binding molecule of the invention is a bispecific antigen-binding molecule (e.g., a bispecific antibody) comprising a first antigen-binding domain that binds to STEAP1 and a second antigen-binding domain that binds to a T cell receptor. Exemplary T cell receptors include cluster of differentiation 3 (CD3). In some instances, the second antigen- binding domain comprises an antibody or fragment thereof that binds to CD3. Exemplary antigen- binding domains that bind to CD3 include, but are not limited to 40G5c and 38E4v1 .MD1 . Additional antigen-binding domains that bind to CD3 (e.g., UCHT 1 ,v9, 38E4v11 , 30E4c, SP34v52, etc.) are described in U.S. Patent No. 10,174,124, WO2015 / 095392, WO2016 / 205520, and International Patent Application No. PCT / US2020 / 064635, each of which is incorporated herein by reference in its entirety. In some embodiments, the second antigen-binding domain binds to an epitope on CD3 comprising amino acid residue Glu6 of CD3. In some embodiments, the epitope further comprises one or more additional amino acid residues selected from Gl n 1 , Asp2, and Met7 of CD3. In some embodiments, the epitope comprises amino acid residues Gln1 , Asp2, and Glu6 of CD3. In some embodiments, the epitope comprises amino acid residues Gin 1 , Asp2, Glu6, and Met7 of CD3. In some embodiments, the epitope does not comprise amino acid residue Glu5 of CD3. In some embodiments, the epitope does not comprise amino acid residues Gly3 and Glu5 of CD3. In some embodiments, the epitope consists of amino acid residues Gl n 1 , Asp2, Glu6, and Met7 of CD3. In some embodiments, the second antigen-binding domain is capable of binding to a human CD3 polypeptide or a cyno CD3 polypeptide. In some embodiments, the human CD3 polypeptide or the cyno CD3 polypeptide is a human CD3e polypeptide or a cyno CD3e polypeptide, respectively. In some embodiments, the human CD3 polypeptide or the cyno CD3 polypeptide is a human CD3γ polypeptide or a cyno CD3γ polypeptide, respectively. In some embodiments, the second antigen- binding domain binds the human CD3e polypeptide with a KDof about 100 nM or lower. In some embodiments, the second antigen-binding domain binds the human CD3e polypeptide with a KDof between about 10 pM to about 100 nM. In some embodiments, the second antigen-binding domain binds the human CD3e polypeptide with a KDof between about 100 pM to about 50 nM. In some embodiments, the second antigen-binding domain binds the human CD3e polypeptide with a KDof between about 1 nM to about 10 nM.

[0476] In some embodiments, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3 of 38E4v1 .MD1 . In some cases, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or all six CDRs, in which CDR-H1 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 40, CDR- H2 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 41 , CDR-H3 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO:

[0477] 42, CDR-L1 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO:

[0478] 43, CDR-L2 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO:

[0479] 44, or CDR-L3 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 45. In some cases, the second antigen-binding domain comprises a VH sequence comprising at least 80% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO: 46. In some cases, the second antigen-binding domain comprises a VL sequence comprising at least 80% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO: 47. In certain aspects, a VH or VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to SEQ ID NO: 46 or 47, but a multispecific antibody comprising that sequence retains the ability to bind to CD3. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 46 or 47. In certain aspects, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs). In some embodiments, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3 of 40G5c. In some cases, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or all six CDRs, in which CDR-H1 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 48, CDR-H2 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 49, CDR- H3 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 50, CDR-L1 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 51 , CDR-L2 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 52, or CDR-L3 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 53. In some cases, the second antigen-binding domain comprises a VH sequence comprising at least 80% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO: 54. In some cases, the second antigen-binding domain comprises a VL sequence comprising at least 80% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to SEQ ID NO: 55. In certain aspects, a VH or VL sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity contains substitutions (e.g., conservative substitutions), insertions, or deletions relative to SEQ ID NO: 54 or 55, but a multispecific antibody comprising that sequence retains the ability to bind to CD3. In certain aspects, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 54 or 55. In certain aspects, the substitutions, insertions, or deletions occur in regions outside the CDRs (i.e., in the FRs).

[0480] In some embodiments, the multispecific antigen-binding molecule comprises (A) a first antigen-binding domain that binds to STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and / or CDR-H3 of a VH sequence selected from SEQ ID NO: 7, 17-25, 30-34, 38, and 68; and / or an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and / or CDR-L3 of a VL sequence selected from SEQ ID NO: 8, 26-29, 39, and 69; and (B) a second antigen-binding domain that binds to a T cell receptor. In some instances, at least one, at least two, at least three, at least four, at least five, or all six CDRs are selected from the CDR(s) of the VH sequence selected from SEQ ID NO: 7, 17-25, 30-34, 38, and 68 and the VL sequence selected from SEQ ID NO: 8, 26-29, 39, and 69. In some instances, at least one, at least two, at least three, at least four, at least five, or all six CDRs are selected from the CDR(s) of 40G5c or 38E4v1 .MD1 . In some cases, the six CDRs are defined according to the Kabat numbering. In other cases, the six CDRs are defined according to the Chothia numbering. In additional cases, the six CDRs are defined according to the EU numbering.

[0481] In some embodiments, the multispecific antigen-binding molecule comprises (A) a first antigen-binding domain that binds to STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3; wherein

[0482] CDR-H1 comprises Xaa1Xaa2YMA (SEQ ID NO: 35); wherein

[0483] Xaa1is Asp (D) or Asn (N); and

[0484] Xaa2is His (H), Tyr (Y), or Phe (F);

[0485] CDR-H2 comprises YIXaa3YDGXaa4Xaa5TXaa6YGDSVKG (SEQ ID NO: 36); wherein

[0486] Xaa3is Asp (D) or Ser (S);

[0487] Xaa4is Gly (G), Asp (D), or Leu (L);

[0488] Xaa5is Ser (S), Asp (D), or Asn (N); and

[0489] Xaa6is Ser (S) or Tyr (Y); and

[0490] CDR-H3 comprises RSGXaa7YHVGYAMXaa8Xaa9(SEQ ID NO: 37); wherein

[0491] Xaa7is Phe (F) or Tyr (Y);

[0492] Xaa8is Asn (N) or Asp (D); and Xaa9is Ala (A) or Gly (G);

[0493] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0494] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or

[0495] CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6; and

[0496] (B) a second antigen-binding domain that binds to a T cell receptor. In some cases, the first antigen- binding domain comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3. In some cases, the second antigen-binding domains binds to CD3. In some cases, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or all six CDRs of 40G5c or 38E4v1 .MD1 .

[0497] In some embodiments, the multispecific antigen-binding molecule comprises (A) a first antigen-binding domain that binds to STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3; wherein

[0498] CDR-H1 comprises the amino acid sequence of SEQ ID NO: 10, 1 , or 9; CDR-H2 comprises YIXaa3YDGXaa4Xaa5TXaa6YGDSVKG (SEQ ID NO: 36); wherein

[0499] Xaa3is Asp (D) or Ser (S);

[0500] Xaa4is Gly (G), Asp (D), or Leu (L);

[0501] Xaa5is Ser (S), Asp (D), or Asn (N); and

[0502] Xaa6is Ser (S) or Tyr (Y);

[0503] CDR-H3 comprises RSGXaa7YHVGYAMXaa8Xaa9(SEQ ID NO: 37); wherein

[0504] Xaa7is Phe (F) or Tyr (Y);

[0505] Xaa8is Asn (N) or Asp (D); and

[0506] Xaa9is Ala (A) or Gly (G); CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0507] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6; and

[0508] (B) a second antigen-binding domain that binds to a T cell receptor. In some cases, the first antigen- binding domain comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3. In some cases, the second antigen-binding domains binds to CD3. In some cases, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or all six CDRs of 40G5c or 38E4v1 .MD1 .

[0509] In some embodiments, the multispecific antigen-binding molecule comprises (A) a first antigen-binding domain that binds to STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3; wherein

[0510] CDR-H1 comprises the amino acid sequence of SEQ ID NO: 10, 1 , or 9; CDR-H2 comprises the amino acid sequence of SEQ ID NO: 2, 11 , 12, or 13; CDR-H3 comprises RSGXaa7YHVGYAMXaa8Xaa9(SEQ ID NO: 37); wherein

[0511] Xaa7is Phe (F) or Tyr (Y);

[0512] Xaa8is Asn (N) or Asp (D); and Xaa9is Ala (A) or Gly (G);

[0513] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0514] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6; and

[0515] (B) a second antigen-binding domain that binds to a T cell receptor. In some cases, the first antigen- binding domain comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3. In some cases, the second antigen-binding domains binds to CD3. In some cases, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or all six CDRs of 40G5c or 38E4v1 .MD1 .

[0516] In some embodiments, the multispecific antigen-binding molecule comprises (A) a first antigen-binding domain that binds to STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3; wherein

[0517] CDR-H1 comprises Xaa1Xaa2YMA (SEQ ID NO: 35); wherein

[0518] Xaa1is Asp (D) or Asn (N); and

[0519] Xaa2is His (H), Tyr (Y), or Phe (F);

[0520] CDR-H2 comprises the amino acid sequence of SEQ ID NO: 2, 11 , 12, or 13; CDR-H3 comprises RSGXaa7YHVGYAMXaa8Xaa9(SEQ ID NO: 37); wherein

[0521] Xaa7is Phe (F) or Tyr (Y);

[0522] Xaa8is Asn (N) or Asp (D); and Xaa9is Ala (A) or Gly (G);

[0523] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0524] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6; and

[0525] (B) a second antigen-binding domain that binds to a T cell receptor. In some cases, the first antigen- binding domain comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3. In some cases, the second antigen-binding domains binds to CD3. In some cases, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or all six CDRs of 40G5c or 38E4V1 .MD1 .

[0526] In some embodiments, the multispecific antigen-binding molecule comprises (A) a first antigen-binding domain that binds to STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3; wherein

[0527] CDR-H1 comprises Xaa1Xaa2YMA (SEQ ID NO: 35); wherein

[0528] Xaa1is Asp (D) or Asn (N); and

[0529] Xaa2is His (H), Tyr (Y), or Phe (F);

[0530] CDR-H2 comprises the amino acid sequence of SEQ ID NO: 2, 11 , 12, or 13; CDR-H3 comprises the amino acid sequence of SEQ ID NO: 16, 3, 14, or 15; CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0531] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6; and

[0532] (B) a second antigen-binding domain that binds to a T cell receptor. In some cases, the first antigen- binding domain comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3. In some cases, the second antigen-binding domains binds to CD3. In some cases, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or all six CDRs of 40G5c or 38E4V1 .MD1 .

[0533] In some embodiments, the multispecific antigen-binding molecule comprises (A) a first antigen-binding domain that binds to STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3; wherein

[0534] CDR-H1 comprises Xaa1Xaa2YMA (SEQ ID NO: 35); wherein

[0535] Xaa1is Asp (D) or Asn (N); and Xaa2is His (H), Tyr (Y), or Phe (F);

[0536] CDR-H2 comprises YIXaa3YDGXaa4Xaa5TXaa6YGDSVKG (SEQ ID NO: 36); wherein

[0537] Xaa3is Asp (D) or Ser (S);

[0538] Xaa4is Gly (G), Asp (D), or Leu (L);

[0539] Xaa5is Ser (S), Asp (D), or Asn (N); and

[0540] Xaa6is Ser (S) or Tyr (Y);

[0541] CDR-H3 comprises the amino acid sequence of SEQ ID NO: 16, 3, 14, or 15; CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0542] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6; and

[0543] (B) a second antigen-binding domain that binds to a T cell receptor. In some cases, the first antigen- binding domain comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3. In some cases, the second antigen-binding domains binds to CD3. In some cases, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or all six CDRs of 40G5c or 38E4V1 .MD1 .

[0544] In some embodiments, the multispecific antigen-binding molecule comprises (A) a first antigen-binding domain that binds to STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3; wherein

[0545] CDR-H1 comprises the amino acid sequence of SEQ ID NO: 10, 1 , or 9; CDR-H2 comprises YIXaa3YDGXaa4Xaa5TXaa6YGDSVKG (SEQ ID NO: 36); wherein

[0546] Xaa3is Asp (D) or Ser (S);

[0547] Xaa4is Gly (G), Asp (D), or Leu (L);

[0548] Xaa5is Ser (S), Asp (D), or Asn (N); and Xaa6is Ser (S) or Tyr (Y);

[0549] CDR-H3 comprises the amino acid sequence of SEQ ID NO: 16, 3, 14, or 15; CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0550] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6; and

[0551] (B) a second antigen-binding domain that binds to a T cell receptor. In some cases, the first antigen- binding domain comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3. In some cases, the second antigen-binding domains binds to CD3. In some cases, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or all six CDRs of 40G5c or 38E4V1 .MD1 .

[0552] In some embodiments, the multispecific antigen-binding molecule comprises (A) a first antigen-binding domain that binds to STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3; in which CDR-H1 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 10, 1 , or 9; CDR-H2 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 2, 11 , 12, or 13; CDR- H3 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 16, 3, 14, or 15; CDR-L1 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 6; and (B) a second antigen-binding domain that binds to a T cell receptor. In some cases, the first antigen-binding domain comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3. In some cases, the second antigen-binding domains binds to CD3. In some cases, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or all six CDRs of 40G5c or 38E4V1 .MD1 .

[0553] In some instances, the first antigen-binding domain comprises CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 1 ; CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 2; CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 3; CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6.

[0554] In some instances, the first antigen-binding domain comprises CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 9; CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 11 ; CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 3; CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6.

[0555] In some instances, the first antigen-binding domain comprises CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 9; CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 12; CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 3; CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6. In some instances, the first antigen-binding domain comprises CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 9; CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 12; CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 14; CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6.

[0556] In some instances, the first antigen-binding domain comprises CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 10; CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 13; CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 15; CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6.

[0557] In some instances, the first antigen-binding domain comprises CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 10; CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 2; CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 16; CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6.

[0558] In some embodiments, the multispecific antigen-binding molecule comprises (A) a first antigen-binding domain that binds to STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3; wherein

[0559] CDR-H1 comprises GFTFSXaa10Xaa11(SEQ ID NO: 63); wherein

[0560] Xaa10is Asn (N) or Asp (D); and

[0561] Xaa11is Tyr (Y), Phe (F), or His (H);

[0562] CDR-H2 comprises Xaa12YDGXaa13Xaa14(SEQ ID NO: 64); wherein

[0563] Xaa12is Asp (D) or Ser (S);

[0564] Xaa13is Gly (G), Asp (D), or Leu (L); and Xaa14is Ser (S), Asp (D), or Asn (N);

[0565] CDR-H3 comprises RSGXaa7YHVGYAMXaa8Xaa9(SEQ ID NO: 37); wherein

[0566] Xaa7is Phe (F) or Tyr (Y);

[0567] Xaa8is Asn (N) or Asp (D); and Xaa9is Ala (A) or Gly (G);

[0568] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0569] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6; and

[0570] (B) a second antigen-binding domain that binds to a T cell receptor. In some cases, the first antigen- binding domain comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3. In some cases, the second antigen-binding domains binds to CD3. In some cases, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or all six CDRs of 40G5c or 38E4V1 .MD1 .

[0571] In some embodiments, the multispecific antigen-binding molecule comprises (A) a first antigen-binding domain that binds to STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3; wherein

[0572] CDR-H1 comprises the amino acid sequence of SEQ ID NO: 56, 58, or 59; CDR-H2 comprises Xaa12YDGXaa13Xaa14(SEQ ID NO: 64); wherein

[0573] Xaa12is Asp (D) or Ser (S);

[0574] Xaa13is Gly (G), Asp (D), or Leu (L); and

[0575] Xaa14is Ser (S), Asp (D), or Asn (N);

[0576] CDR-H3 comprises RSGXaa7YHVGYAMXaa8Xaa9(SEQ ID NO: 37); wherein

[0577] Xaa7is Phe (F) or Tyr (Y);

[0578] Xaa8is Asn (N) or Asp (D); and Xaa9is Ala (A) or Gly (G);

[0579] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0580] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6; and

[0581] (B) a second antigen-binding domain that binds to a T cell receptor. In some cases, the first antigen- binding domain comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3. In some cases, the second antigen-binding domains binds to CD3. In some cases, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or all six CDRs of 40G5c or 38E4V1 .MD1 .

[0582] In some embodiments, the multispecific antigen-binding molecule comprises (A) a first antigen-binding domain that binds to STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3; wherein

[0583] CDR-H1 comprises the amino acid sequence of SEQ ID NO: 56, 58, or 59; CDR-H2 comprises the amino acid sequence of SEQ ID NO: 57, 60, 61 , or 62;

[0584] CDR-H3 comprises RSGXaa7YHVGYAMXaa8Xaa9(SEQ ID NO: 37); wherein

[0585] Xaa7is Phe (F) or Tyr (Y);

[0586] Xaa8is Asn (N) or Asp (D); and Xaa9is Ala (A) or Gly (G);

[0587] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0588] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6; and

[0589] (B) a second antigen-binding domain that binds to a T cell receptor. In some cases, the first antigen- binding domain comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3. In some cases, the second antigen-binding domains binds to CD3. In some cases, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or all six CDRs of 40G5c or 38E4V1 .MD1 .

[0590] In some embodiments, the multispecific antigen-binding molecule comprises (A) a first antigen-binding domain that binds to STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3; wherein

[0591] CDR-H1 comprises GFTFSXaa10Xaa11(SEQ ID NO: 63); wherein

[0592] Xaa10is Asn (N) or Asp (D); and

[0593] Xaa11is Tyr (Y), Phe (F), or His (H);

[0594] CDR-H2 comprises the amino acid sequence of SEQ ID NO: 57, 60, 61 , or 62;

[0595] CDR-H3 comprises RSGXaa7YHVGYAMXaa8Xaa9(SEQ ID NO: 37); wherein

[0596] Xaa7is Phe (F) or Tyr (Y);

[0597] Xaa8is Asn (N) or Asp (D); and Xaa9is Ala (A) or Gly (G);

[0598] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0599] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6; and (B) a second antigen-binding domain that binds to a T cell receptor. In some cases, the first antigen- binding domain comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3. In some cases, the second antigen-binding domains binds to CD3. In some cases, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or all six CDRs of 40G5c or 38E4V1 .MD1 .

[0600] In some embodiments, the multispecific antigen-binding molecule comprises (A) a first antigen-binding domain that binds to STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3; wherein

[0601] CDR-H1 comprises GFTFSXaa10Xaa11(SEQ ID NO: 63); wherein

[0602] Xaa10is Asn (N) or Asp (D); and

[0603] Xaa11is Tyr (Y), Phe (F), or His (H);

[0604] CDR-H2 comprises the amino acid sequence of SEQ ID NO: 57, 60, 61 , or 62;

[0605] CDR-H3 comprises the amino acid sequence of SEQ ID NO: 16, 3, 14, or 15;

[0606] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0607] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or

[0608] CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6; and

[0609] (B) a second antigen-binding domain that binds to a T cell receptor. In some cases, the first antigen- binding domain comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3. In some cases, the second antigen-binding domains binds to CD3. In some cases, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or all six CDRs of 40G5c or 38E4V1 .MD1 .

[0610] In some embodiments, the multispecific antigen-binding molecule comprises (A) a first antigen-binding domain that binds to STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3; wherein

[0611] CDR-H1 comprises GFTFSXaa10Xaa11(SEQ ID NO: 63); wherein

[0612] Xaa10is Asn (N) or Asp (D); and

[0613] Xaa11is Tyr (Y), Phe (F), or His (H);

[0614] CDR-H2 comprises Xaa12YDGXaa13Xaa14(SEQ ID NO: 64); wherein

[0615] Xaa12is Asp (D) or Ser (S);

[0616] Xaa13is Gly (G), Asp (D), or Leu (L); and Xaa14is Ser (S), Asp (D), or Asn (N); CDR-H3 comprises the amino acid sequence of SEQ ID NO: 16, 3, 14, or 15; CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0617] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6; and

[0618] (B) a second antigen-binding domain that binds to a T cell receptor. In some cases, the first antigen- binding domain comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3. In some cases, the second antigen-binding domains binds to CD3. In some cases, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or all six CDRs of 40G5c or 38E4V1 .MD1 .

[0619] In some embodiments, the multispecific antigen-binding molecule comprises (A) a first antigen-binding domain that binds to STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3; wherein

[0620] CDR-H1 comprises the amino acid sequence of SEQ ID NO: 56, 58, or 59; CDR-H2 comprises Xaa12YDGXaa13Xaa14(SEQ ID NO: 64); wherein

[0621] Xaa12is Asp (D) or Ser (S);

[0622] Xaa13is Gly (G), Asp (D), or Leu (L); and

[0623] Xaa14is Ser (S), Asp (D), or Asn (N);

[0624] CDR-H3 comprises the amino acid sequence of SEQ ID NO: 16, 3, 14, or 15; CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0625] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6; and

[0626] (B) a second antigen-binding domain that binds to a T cell receptor. In some cases, the first antigen- binding domain comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3. In some cases, the second antigen-binding domains binds to CD3. In some cases, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or all six CDRs of 40G5c or 38E4V1 .MD1 .

[0627] In some embodiments, the multispecific antigen-binding molecule comprises (A) a first antigen-binding domain that binds to STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3; in which CDR-H1 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 56, 58, or 59; CDR-H2 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 57, 60, 61 , or 62; CDR-H3 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 16, 3, 14, or 15; CDR-L1 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 5; and / or CDR-L3 comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 6; and (B) a second antigen-binding domain that binds to a T cell receptor. In some cases, the first antigen-binding domain comprises at least two, at least three, at least four, at least five, or all six CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3. In some cases, the second antigen-binding domains binds to CD3. In some cases, the second antigen- binding domain comprises at least one, at least two, at least three, at least four, at least five, or all six CDRs of 40G5c or 38E4V1 .MD1 .

[0628] In some instances, the first antigen-binding domain comprises CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 56; CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 57; CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 3; CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6.

[0629] In some instances, the first antigen-binding domain comprises CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 58; CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 60; CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 3; CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6.

[0630] In some instances, the first antigen-binding domain comprises CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 58; CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 61 ; CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 3; CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6.

[0631] In some instances, the first antigen-binding domain comprises CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 58; CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 61 ; CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 14; CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6. In some instances, the first antigen-binding domain comprises CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 59; CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 62; CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 15; CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6.

[0632] In some instances, the first antigen-binding domain comprises CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 59; CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 57; CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 16; CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4; CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6.

[0633] The multispecific antigen-binding molecules of the present invention can be humanized antibodies. In some instances, the first antigen-binding domain and / or the second antigen-binding domain each independently comprises a constant region derived from an IgG framework region. In some cases, the IgG framework region is an IgGi, lgG2, or lgG4 framework region. In some cases, the IgG framework region is an IgGi framework region.

[0634] In some embodiments, the multispecific antigen-binding molecule comprises (A) a first antigen-binding domain comprising a heavy chain variable region comprising one or more (e.g., 1 , 2, 3, or all 4) of an FR-H1 sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 110; an FR- H2 having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 111 ; an FR-H3 having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 112; and / or an FR-H4 having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 113.

[0635] In some embodiments, the multispecific antigen-binding molecule comprises (A) a first antigen-binding domain comprising a light chain variable region comprising one or more (e.g., 1 , 2, 3, or all 4) of an FR-L1 having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 114; an FR-L2 having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 115; an FR-L3 co having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 116; and / or an FR-L4 having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 117.

[0636] For example, in some embodiments, the multispecific antigen-binding molecule comprises (A) a first antigen-binding domain comprising an FR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 110; an FR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 111 ; an FR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 112; an FR-H4 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 113; an FR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 114; an FR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 115; an FR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 116; and an FR-L4 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 117.

[0637] In some embodiments, the multispecific antigen-binding molecule comprises (A) a first antigen-binding domain comprising a VH sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 7, 17-25, 30-34, 38, or 68; and (B) a second antigen-binding domain that binds to a T cell receptor. In some instances, the VH sequence of the first antigen-binding domain comprises at least 90% sequence identity to SEQ ID NO: 7, 17-25, 30-34, 38, or 68. In some instances, the VH sequence of the first antigen-binding domain comprises at least 95% sequence identity to SEQ ID NO: 7, 17-25, 30-34, 38, or 68. In some instances, the VH sequence of the first antigen-binding domain comprises at least 98% sequence identity to SEQ ID NO: 7, 17-25, 30-34, 38, or 68. In some instances, the VH sequence of the first antigen-binding domain comprises at least 99% sequence identity to SEQ ID NO: 7, 17-25, 30-34, 38, or 68. In some instances, the VH sequence of the first antigen-binding domain comprises 100% sequence identity to SEQ ID NO: 7, 17-25, 30-34, 38, or 68. In some cases, the second antigen- binding domains binds to CD3. In some cases, the second antigen-binding domain comprises a VH sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 46 or 54. In some cases, the VH sequence of the second antigen-binding domain comprises at least 95% sequence identity to SEQ ID NO: 46 or 54. In some cases, the VH sequence of the second antigen-binding domain comprises at least 99% sequence identity to SEQ ID NO: 46 or 54. In some cases, the VH sequence of the second antigen-binding domain comprises 100% sequence identity to SEQ ID NO: 46 or 54.

[0638] In some embodiments, the multispecific antigen-binding molecule comprises (A) a first antigen-binding domain comprising a VL sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 8, 26-29, 39, or 69; and (B) a second antigen-binding domain that binds to a T cell receptor. In some instances, the VL sequence comprises at least 90% sequence identity to SEQ ID NO: 8, 26-29, 39, or 69. In some instances, the VL sequence comprises at least 95% sequence identity to SEQ ID NO: 8, 26-29, 39, or 69. In some instances, the VL sequence comprises at least 98% sequence identity to SEQ ID NO: 8, 26-29, 39, or 69. In some instances, the VL sequence comprises at least 99% sequence identity to SEQ ID NO: 8, 26-29, 39, or 69. In some instances, the VL sequence comprises 100% sequence identity to SEQ ID NO: 8, 26-29, 39, or 69. In some cases, the second antigen-binding domains binds to CD3. In some cases, the second antigen-binding domain comprises a VL sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 47 or 55. In some cases, the VL sequence of the second antigen-binding domain comprises at least 95% sequence identity to SEQ ID NO: 47 or 55. In some cases, the VL sequence of the second antigen-binding domain comprises at least 99% sequence identity to SEQ ID NO: 47 or 55. In some cases, the VL sequence of the second antigen-binding domain comprises 100% sequence identity to SEQ ID NO: 47 or 55.

[0639] In some embodiments, a multispecific antigen-binding molecule of the present invention comprises a first antigen-binding domain that binds to STEAP1 and comprises at least one, at least two, at least three, at least four, at least five, or all six CDRs as illustrated in Tables 1 or 2. In some instances, the first antigen-binding domain comprises a VH and / or a VL as illustrated in Table 1 . In some instances, the multispecific antigen-binding molecule comprises a second antigen-binding domain that binds to a T cell receptor (e.g., CD3). In some cases, the second antigen-binding domain that binds to CD3 comprises at least one, at least two, at least three, at least four, at least five, or all six CDRs as illustrated in Tables 1 or 2. In some instances, the second antigen-binding domain that binds to CD3 comprises a VH and / or a VL as illustrated in Table 1 .

[0640] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises a first antigen-binding domain that binds to STEAP1 and a second antigen- binding domain that binds to a T cell receptor (e.g., CD3). In some embodiments, the first antigen- binding domain features a VH and a VL region, in which the VH region comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 9, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 11 , or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 3. In some instances, the VH region of the first antigen-binding domain comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 58, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 60, or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 3. In some embodiments, the VH region of the first antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 30 (e.g., at least 95% sequence identity to SEQ ID NO: 30, at least 96% sequence identity to SEQ ID NO: 30, at least 97% sequence identity to SEQ ID NO: 30, at least 98% sequence identity to SEQ ID NO: 30, at least 99% sequence identity to SEQ ID NO: 30, or 100% sequence identity to SEQ ID NO: 30). In some embodiments, the VL region of the first antigen-binding domain comprises one, two, or all three of the following CDRs: (a) CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4, (b) CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5, or (c) CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6. In some embodiments, the VL region of the first antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 27 (e.g., at least 95% sequence identity to SEQ ID NO: 27, at least 96% sequence identity to SEQ ID NO: 27, at least 97% sequence identity to SEQ ID NO: 27, at least 98% sequence identity to SEQ ID NO: 27, at least 99% sequence identity to SEQ ID NO: 27, or 100% sequence identity to SEQ ID NO: 27). In some instances, the second antigen-binding domain features a VH and a VL region, in which the VH region comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 40 or 48, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 41 or 49, or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 42 or 50. In some embodiments, the VH region of the second antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 46 or 54 (e.g., at least 95% sequence identity to SEQ ID NO: 46 or

[0641] 54, at least 96% sequence identity to SEQ ID NO: 46 or 54, at least 97% sequence identity to SEQ ID NO: 46 or 54, at least 98% sequence identity to SEQ ID NO: 46 or 54, at least 99% sequence identity to SEQ ID NO: 46 or 54, or 100% sequence identity to SEQ ID NO: 46 or 54). In some embodiments, the VL region of the second antigen-binding domain comprises one, two, or all three of the following CDRs: (a) CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 43 or 51 , (b) CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO:44 or 52, or (c) CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 45 or 53. In some embodiments, the VL region of the second antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 47 or 55 (e.g., at least 95% sequence identity to SEQ ID NO: 47 or

[0642] 55, at least 96% sequence identity to SEQ ID NO: 47 or 55, at least 97% sequence identity to SEQ ID NO: 47 or 55, at least 98% sequence identity to SEQ ID NO: 47 or 55, at least 99% sequence identity to SEQ ID NO: 47 or 55, or 100% sequence identity to SEQ ID NO: 47 or 55).

[0643] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises a first antigen-binding domain that binds to STEAP1 and a second antigen- binding domain that binds to a T cell receptor (e.g., CD3). In some embodiments, the first antigen- binding domain features a VH and a VL region, in which the VH region comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 9, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 12, or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 3. In some instances, the VH region of the first antigen-binding domain comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 58, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 61 , or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 3. In some embodiments, the VH region of the first antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 31 (e.g., at least 95% sequence identity to SEQ ID NO: 31 , at least 96% sequence identity to SEQ ID NO: 31 , at least 97% sequence identity to SEQ ID NO: 31 , at least 98% sequence identity to SEQ ID NO: 31 , at least 99% sequence identity to SEQ ID NO: 31 , or 100% sequence identity to SEQ ID NO: 31 ). In some embodiments, the VL region of the first antigen-binding domain comprises one, two, or all three of the following CDRs: (a) CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4, (b) CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5, or (c) CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6. In some embodiments, the VL region of the first antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 27 (e.g., at least 95% sequence identity to SEQ ID NO: 27, at least 96% sequence identity to SEQ ID NO: 27, at least 97% sequence identity to SEQ ID NO: 27, at least 98% sequence identity to SEQ ID NO: 27, at least 99% sequence identity to SEQ ID NO: 27, or 100% sequence identity to SEQ ID NO: 27). In some instances, the second antigen-binding domain features a VH and a VL region, in which the VH region comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 40 or 48, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 41 or 49, or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 42 or 50. In some embodiments, the VH region of the second antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 46 or 54 (e.g., at least 95% sequence identity to SEQ ID NO: 46 or

[0644] 54, at least 96% sequence identity to SEQ ID NO: 46 or 54, at least 97% sequence identity to SEQ ID NO: 46 or 54, at least 98% sequence identity to SEQ ID NO: 46 or 54, at least 99% sequence identity to SEQ ID NO: 46 or 54, or 100% sequence identity to SEQ ID NO: 46 or 54). In some embodiments, the VL region of the second antigen-binding domain comprises one, two, or all three of the following CDRs: (a) CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 43 or 51 , (b) CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO:44 or 52, or (c) CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 45 or 53. In some embodiments, the VL region of the second antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 47 or 55 (e.g., at least 95% sequence identity to SEQ ID NO: 47 or

[0645] 55, at least 96% sequence identity to SEQ ID NO: 47 or 55, at least 97% sequence identity to SEQ ID NO: 47 or 55, at least 98% sequence identity to SEQ ID NO: 47 or 55, at least 99% sequence identity to SEQ ID NO: 47 or 55, or 100% sequence identity to SEQ ID NO: 47 or 55).

[0646] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises a first antigen-binding domain that binds to STEAP1 and a second antigen- binding domain that binds to a T cell receptor (e.g., CD3). In some embodiments, the first antigen- binding domain features a VH and a VL region, in which the VH region comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 9, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 12, or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 14. In some instances, the VH region of the first antigen-binding domain comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 58, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 61 , or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 14. In some embodiments, the VH region of the first antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 32 (e.g., at least 95% sequence identity to SEQ ID NO: 32, at least 96% sequence identity to SEQ ID NO: 32, at least 97% sequence identity to SEQ ID NO: 32, at least 98% sequence identity to SEQ ID NO: 32, at least 99% sequence identity to SEQ ID NO: 32, or 100% sequence identity to SEQ ID NO: 32). In some embodiments, the VL region of the first antigen-binding domain comprises one, two, or all three of the following CDRs: (a) CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4, (b) CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5, or (c) CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6. In some embodiments, the VL region of the first antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 27 (e.g., at least 95% sequence identity to SEQ ID NO: 27, at least

[0647] 96% sequence identity to SEQ ID NO: 27, at least 97% sequence identity to SEQ ID NO: 27, at least

[0648] 98% sequence identity to SEQ ID NO: 27, at least 99% sequence identity to SEQ ID NO: 27, or 100% sequence identity to SEQ ID NO: 27). In some instances, the second antigen-binding domain features a VH and a VL region, in which the VH region comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 40 or 48, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 41 or 49, or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 42 or 50. In some embodiments, the VH region of the second antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 46 or 54 (e.g., at least 95% sequence identity to SEQ ID NO: 46 or 54, at least 96% sequence identity to SEQ ID NO: 46 or 54, at least 97% sequence identity to SEQ ID NO: 46 or 54, at least 98% sequence identity to SEQ ID NO: 46 or 54, at least 99% sequence identity to SEQ ID NO: 46 or 54, or 100% sequence identity to SEQ ID NO: 46 or 54). In some embodiments, the VL region of the second antigen-binding domain comprises one, two, or all three of the following CDRs: (a) CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 43 or 51 , (b) CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO:44 or 52, or (c) CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 45 or 53. In some embodiments, the VL region of the second antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 47 or 55 (e.g., at least 95% sequence identity to SEQ ID NO: 47 or 55, at least 96% sequence identity to SEQ ID NO: 47 or 55, at least 97% sequence identity to SEQ ID NO: 47 or 55, at least 98% sequence identity to SEQ ID NO: 47 or 55, at least 99% sequence identity to SEQ ID NO: 47 or 55, or 100% sequence identity to SEQ ID NO: 47 or 55).

[0649] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises a first antigen-binding domain that binds to STEAP1 and a second antigen- binding domain that binds to a T cell receptor (e.g., CD3). In some embodiments, the first antigen- binding domain features a VH and a VL region, in which the VH region comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 10, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 13, or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 15. In some instances, the VH region of the first antigen-binding domain comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 59, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 62, or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 15. In some embodiments, the VH region of the first antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 33 (e.g., at least 95% sequence identity to SEQ ID NO: 33, at least 96% sequence identity to SEQ ID NO: 33, at least 97% sequence identity to SEQ ID NO: 33, at least 98% sequence identity to SEQ ID NO: 33, at least 99% sequence identity to SEQ ID NO: 33, or 100% sequence identity to SEQ ID NO: 33). In some embodiments, the VL region of the first antigen-binding domain comprises one, two, or all three of the following CDRs: (a) CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4, (b) CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5, or (c) CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6. In some embodiments, the VL region of the first antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 27 (e.g., at least 95% sequence identity to SEQ ID NO: 27, at least

[0650] 96% sequence identity to SEQ ID NO: 27, at least 97% sequence identity to SEQ ID NO: 27, at least

[0651] 98% sequence identity to SEQ ID NO: 27, at least 99% sequence identity to SEQ ID NO: 27, or 100% sequence identity to SEQ ID NO: 27). In some instances, the second antigen-binding domain features a VH and a VL region, in which the VH region comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 40 or 48, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 41 or 49, or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 42 or 50. In some embodiments, the VH region of the second antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 46 or 54 (e.g., at least 95% sequence identity to SEQ ID NO: 46 or 54, at least 96% sequence identity to SEQ ID NO: 46 or 54, at least 97% sequence identity to SEQ ID NO: 46 or 54, at least 98% sequence identity to SEQ ID NO: 46 or 54, at least 99% sequence identity to SEQ ID NO: 46 or 54, or 100% sequence identity to SEQ ID NO: 46 or 54). In some embodiments, the VL region of the second antigen-binding domain comprises one, two, or all three of the following CDRs: (a) CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 43 or 51 , (b) CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO:44 or 52, or (c) CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 45 or 53. In some embodiments, the VL region of the second antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 47 or 55 (e.g., at least 95% sequence identity to SEQ ID NO: 47 or 55, at least 96% sequence identity to SEQ ID NO: 47 or 55, at least 97% sequence identity to SEQ ID NO: 47 or 55, at least 98% sequence identity to SEQ ID NO: 47 or 55, at least 99% sequence identity to SEQ ID NO: 47 or 55, or 100% sequence identity to SEQ ID NO: 47 or 55).

[0652] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises a first antigen-binding domain that binds to STEAP1 and a second antigen- binding domain that binds to a T cell receptor (e.g., CD3). In some embodiments, the first antigen- binding domain features a VH and a VL region, in which the VH region comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 10, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 2, or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 16. In some instances, the VH region of the first antigen-binding domain comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 59, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 57, or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 16. In some embodiments, the VH region of the first antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 34 (e.g., at least 95% sequence identity to SEQ ID NO: 34, at least 96% sequence identity to SEQ ID NO: 34, at least 97% sequence identity to SEQ ID NO: 34, at least 98% sequence identity to SEQ ID NO: 34, at least 99% sequence identity to SEQ ID NO: 34, or 100% sequence identity to SEQ ID NO: 34). In some embodiments, the VL region of the first antigen-binding domain comprises one, two, or all three of the following CDRs: (a) CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4, (b) CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5, or (c) CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6. In some embodiments, the VL region of the first antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 27 (e.g., at least 95% sequence identity to SEQ ID NO: 27, at least

[0653] 96% sequence identity to SEQ ID NO: 27, at least 97% sequence identity to SEQ ID NO: 27, at least

[0654] 98% sequence identity to SEQ ID NO: 27, at least 99% sequence identity to SEQ ID NO: 27, or 100% sequence identity to SEQ ID NO: 27). In some instances, the second antigen-binding domain features a VH and a VL region, in which the VH region comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 40 or 48, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 41 or 49, or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 42 or 50. In some embodiments, the VH region of the second antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 46 or 54 (e.g., at least 95% sequence identity to SEQ ID NO: 46 or

[0655] 54, at least 96% sequence identity to SEQ ID NO: 46 or 54, at least 97% sequence identity to SEQ ID NO: 46 or 54, at least 98% sequence identity to SEQ ID NO: 46 or 54, at least 99% sequence identity to SEQ ID NO: 46 or 54, or 100% sequence identity to SEQ ID NO: 46 or 54). In some embodiments, the VL region of the second antigen-binding domain comprises one, two, or all three of the following CDRs: (a) CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 43 or 51 , (b) CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO:44 or 52, or (c) CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 45 or 53. In some embodiments, the VL region of the second antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 47 or 55 (e.g., at least 95% sequence identity to SEQ ID NO: 47 or

[0656] 55, at least 96% sequence identity to SEQ ID NO: 47 or 55, at least 97% sequence identity to SEQ ID NO: 47 or 55, at least 98% sequence identity to SEQ ID NO: 47 or 55, at least 99% sequence identity to SEQ ID NO: 47 or 55, or 100% sequence identity to SEQ ID NO: 47 or 55).

[0657] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises a first antigen-binding domain that binds to STEAP1 and a second antigen- binding domain that binds to a T cell receptor (e.g., CD3). In some embodiments, the first antigen- binding domain features a VH and a VL region, in which the VH region comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 35, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 36, or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 37. In some instances, the VH region of the first antigen-binding domain comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 63, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 64, or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 37. In some embodiments, the VH region of the first antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 38 (e.g., at least 95% sequence identity to SEQ ID NO: 38, at least 96% sequence identity to SEQ ID NO: 38, at least 97% sequence identity to SEQ ID NO: 38, at least 98% sequence identity to SEQ ID NO: 38, at least 99% sequence identity to SEQ ID NO: 38, or 100% sequence identity to SEQ ID NO: 38). In some embodiments, the VL region of the first antigen-binding domain comprises one, two, or all three of the following CDRs: (a) CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 4, (b) CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 5, or (c) CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 6. In some embodiments, the VL region of the first antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 39 (e.g., at least 95% sequence identity to SEQ ID NO: 39, at least

[0658] 96% sequence identity to SEQ ID NO: 39, at least 97% sequence identity to SEQ ID NO: 39, at least

[0659] 98% sequence identity to SEQ ID NO: 39, at least 99% sequence identity to SEQ ID NO: 39, or 100% sequence identity to SEQ ID NO: 39). In some instances, the second antigen-binding domain features a VH and a VL region, in which the VH region comprises one, two, or all three of the following CDRs: (a) CDR-H1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 40 or 48, (b) CDR-H2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 41 or 49, or (c) CDR-H3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 42 or 50. In some embodiments, the VH region of the second antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 46 or 54 (e.g., at least 95% sequence identity to SEQ ID NO: 46 or

[0660] 54, at least 96% sequence identity to SEQ ID NO: 46 or 54, at least 97% sequence identity to SEQ ID NO: 46 or 54, at least 98% sequence identity to SEQ ID NO: 46 or 54, at least 99% sequence identity to SEQ ID NO: 46 or 54, or 100% sequence identity to SEQ ID NO: 46 or 54). In some embodiments, the VL region of the second antigen-binding domain comprises one, two, or all three of the following CDRs: (a) CDR-L1 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 43 or 51 , (b) CDR-L2 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO:44 or 52, or (c) CDR-L3 comprising, consisting essentially of, or consisting of the amino acid sequence of SEQ ID NO: 45 or 53. In some embodiments, the VL region of the second antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 47 or 55 (e.g., at least 95% sequence identity to SEQ ID NO: 47 or

[0661] 55, at least 96% sequence identity to SEQ ID NO: 47 or 55, at least 97% sequence identity to SEQ ID NO: 47 or 55, at least 98% sequence identity to SEQ ID NO: 47 or 55, at least 99% sequence identity to SEQ ID NO: 47 or 55, or 100% sequence identity to SEQ ID NO: 47 or 55).

[0662] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises a first antigen-binding domain that binds to STEAP1 and a second antigen- binding domain that binds to a T cell receptor (e.g., CD3). In some embodiments, the VH region of the first antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 68 (e.g., at least 95% sequence identity to SEQ ID NO: 68, at least 96% sequence identity to SEQ ID NO: 68, at least 97% sequence identity to SEQ ID NO: 68, at least 98% sequence identity to SEQ ID NO: 68, at least 99% sequence identity to SEQ ID NO: 68, or 100% sequence identity to SEQ ID NO: 68). In some embodiments, the VL region of the first antigen- binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 69 (e.g., at least 95% sequence identity to SEQ ID NO: 69, at least 96% sequence identity to SEQ ID NO: 69, at least 97% sequence identity to SEQ ID NO: 69, at least 98% sequence identity to SEQ ID NO: 69, at least 99% sequence identity to SEQ ID NO: 69, or 100% sequence identity to SEQ ID NO: 69). In some embodiments, the VH region of the second antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 46 or 54 (e.g., at least 95% sequence identity to SEQ ID NO: 46 or 54, at least 96% sequence identity to SEQ ID NO: 46 or 54, at least 97% sequence identity to SEQ ID NO: 46 or 54, at least 98% sequence identity to SEQ ID NO: 46 or 54, at least 99% sequence identity to SEQ ID NO: 46 or 54, or 100% sequence identity to SEQ ID NO: 46 or 54). In some embodiments, the VL region of the second antigen-binding domain comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 47 or 55 (e.g., at least 95% sequence identity to SEQ ID NO: 47 or 55, at least 96% sequence identity to SEQ ID NO: 47 or 55, at least 97% sequence identity to SEQ ID NO: 47 or 55, at least 98% sequence identity to SEQ ID NO: 47 or 55, at least 99% sequence identity to SEQ ID NO: 47 or 55, or 100% sequence identity to SEQ ID NO: 47 or 55).

[0663] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises an anti-STEAP1 heavy chain constant region having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 83, and an anti-STEAP1 light chain constant region having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity SEQ ID NO: 82.

[0664] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises an anti-STEAP1 heavy chain constant region having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 85, and an anti-STEAP1 light chain constant region having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity SEQ ID NO: 84.

[0665] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises an anti-CD3 heavy chain constant region having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 83, and an anti-CD3 light chain constant region having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity SEQ ID NO: 82.

[0666] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises an anti-CD3 heavy chain constant region having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 85, and an anti-CD3 light chain constant region having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity SEQ ID NO: 84.

[0667] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises an anti-STEAP1 heavy chain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 71 , and an anti-STEAP1 light chain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity SEQ ID NO: 70.

[0668] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises an anti-STEAP1 heavy chain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 73, and an anti-STEAP1 light chain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity SEQ ID NO: 72.

[0669] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises an anti-STEAP1 heavy chain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 75, and an anti-STEAP1 light chain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity SEQ ID NO: 74.

[0670] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises an anti-STEAP1 heavy chain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 77, and an anti-STEAP1 light chain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity SEQ ID NO: 76.

[0671] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises an anti-STEAP1 heavy chain constant region having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 122, and an anti-STEAP1 light chain constant region having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity SEQ ID NO: 123.

[0672] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises an anti-STEAP1 heavy chain constant region having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 126, and an anti-STEAP1 light chain constant region having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity SEQ ID NO: 127.

[0673] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises an anti-STEAP1 heavy chain constant region having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 130, and an anti-STEAP1 light chain constant region having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity SEQ ID NO: 131.

[0674] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises an anti-STEAP1 heavy chain constant region having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 134, and an anti-STEAP1 light chain constant region having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity SEQ ID NO: 135.

[0675] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises an anti-STEAP1 heavy chain constant region having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 138, and an anti-STEAP1 light chain constant region having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity SEQ ID NO: 139.

[0676] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises an anti-STEAP1 heavy chain constant region having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 142, and an anti-STEAP1 light chain constant region having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity SEQ ID NO: 143.

[0677] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises an anti-CD3 heavy chain having at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 79, and an anti-CD3 light chain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity SEQ ID NO: 78.

[0678] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises an anti-CD3 heavy chain having at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 81 , and an anti-CD3 light chain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity SEQ ID NO: 80.

[0679] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises an anti-CD3 heavy chain having at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 124, and an anti-CD3 light chain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity SEQ ID NO: 125.

[0680] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises an anti-CD3 heavy chain having at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 128, and an anti-CD3 light chain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity SEQ ID NO: 129.

[0681] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises an anti-CD3 heavy chain having at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 132, and an anti-CD3 light chain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity SEQ ID NO: 133.

[0682] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises an anti-CD3 heavy chain having at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 136, and an anti-CD3 light chain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity SEQ ID NO: 137.

[0683] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises an anti-CD3 heavy chain having at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 140, and an anti-CD3 light chain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity SEQ ID NO: 141 .

[0684] In some embodiments, the multispecific antigen-binding molecule of any of the preceding embodiments comprises an anti-CD3 heavy chain having at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 144, and an anti-CD3 light chain having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity SEQ ID NO: 145.

[0685] In some embodiments, the multispecific antigen-binding molecule comprises an anti-STEAP1 heavy chain comprising SEQ ID NO: 122, an anti-STEAP1 light chain comprising SEQ ID NO: 123, an anti-CD3 heavy chain comprising SEQ ID NO: 124, and an anti-CD3 light chain comprising SEQ ID NO: 125.

[0686] In some embodiments, the multispecific antigen-binding molecule comprises an anti-STEAP1 heavy chain comprising SEQ ID NO: 126, an anti-STEAP1 light chain comprising SEQ ID NO: 127, an anti-CD3 heavy chain comprising SEQ ID NO: 128, and an anti-CD3 light chain comprising SEQ ID NO: 129.

[0687] In some embodiments, the multispecific antigen-binding molecule comprises an anti-STEAP1 heavy chain comprising SEQ ID NO: 130, an anti-STEAP1 light chain comprising SEQ ID NO: 131 , an anti-CD3 heavy chain comprising SEQ ID NO: 132, and an anti-CD3 light chain comprising SEQ ID NO: 133.

[0688] In some embodiments, the multispecific antigen-binding molecule comprises an anti-STEAP1 heavy chain comprising SEQ ID NO: 134, an anti-STEAP1 light chain comprising SEQ ID NO: 135, an anti-CD3 heavy chain comprising SEQ ID NO: 136, and an anti-CD3 light chain comprising SEQ ID NO: 137.

[0689] In some embodiments, the multispecific antigen-binding molecule comprises an anti-STEAP1 heavy chain comprising SEQ ID NO: 138, an anti-STEAP1 light chain comprising SEQ ID NO: 139, an anti-CD3 heavy chain comprising SEQ ID NO: 140, and an anti-CD3 light chain comprising SEQ ID NO: 141.

[0690] In some embodiments, the multispecific antigen-binding molecule comprises an anti-STEAP1 heavy chain comprising SEQ ID NO: 142, an anti-STEAP1 light chain comprising SEQ ID NO: 143, an anti-CD3 heavy chain comprising SEQ ID NO: 144, and an anti-CD3 light chain comprising SEQ ID NO: 145.

[0691] In some embodiments, the multispecific antigen-binding molecule further comprises a third antigen-binding domain. The third antigen-binding domain can be an antigen expressed on the surface of a cell. The antigen can be expressed on the surface of a cell obtained from a solid tumor. The antigen can be expressed on the surface of a cell of prostate cancer, Ewing sarcoma, lung cancer, colorectal cancer, breast cancer, bladder cancer, ovarian cancer, or cervical cancer.

[0692] In some embodiments, the antigen is a tumor-associated antigen (TAA). The TAA can be a receptor expressed on the surface of a cell of prostate cancer, Ewing sarcoma, lung cancer, colorectal cancer, breast cancer, bladder cancer, ovarian cancer, or cervical cancer. In some instances, the TAA is a receptor expressed on the surface of a prostate cancer cell. In some cases, the TAA is a receptor expressed on an Ewing sarcoma cell. Exemplary tumor-associated antigens include, but are not limited to, prostate-specific membrane antigen (PSMA), prostate stem cell antigen (PSCA), epithelial cell adhesion molecule (EpCAM), prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), STEAP2, and HBA-71 .

[0693] In some instances, the multispecific antigen-binding molecule further comprises a third antigen-binding domain that binds to a tumor-associated antigen. In some cases, the third antigen- binding domain binds to a TAA of prostate cancer, Ewing sarcoma, lung cancer, colorectal cancer, breast cancer, bladder cancer, ovarian cancer, or cervical cancer. In some cases, the third antigen- binding domain binds to prostate-specific membrane antigen (PSMA), prostate stem cell antigen (PSCA), epithelial cell adhesion molecule (EpCAM), prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), STEAP2, or HBA-71 . In some cases, the third antigen-binding domain binds to PSMA. In some cases, the third antigen-binding domain binds to PSCA. In some cases, the third antigen-binding domain binds to EpCAM. In some cases, the third antigen-binding domain binds to PSA. In some cases, the third antigen-binding domain binds to PAP. In some cases, the third antigen-binding domain binds to STEAP2. In some cases, the third antigen-binding domain binds to HBA-71 .

[0694] In some embodiments, the multispecific antigen-binding molecule binds to human STEAP1 with a KDof less than 100 nM, less than 75 nM, less than 50 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 1 nM, or lower.

[0695] In some embodiments, multispecific antigen-binding molecule binds to human STEAP1 with a KDof about 1 nM to about 100 nM, about 1 nM to about 75 nM, about 1 nM to about 50 nM, about 1 nM to about 40 nM, about 1 nM to about 30 nM, about 1 nM to about 20 nM, about 1 nM to about 10 nM, about 1 nM to about 5 nM, about 5 nM to about 100 nM, about 5 nM to about 75 nM, about 5 nM to about 50 nM, about 5 nM to about 40 nM, about 5 nM to about 30 nM, about 5 nM to about 20 nM, about 5 nM to about 10 nM, about 10 nM to about 100 nM, about 10 nM to about 75 nM, about 10 nM to about 50 nM, about 10 nM to about 40 nM, about 10 nM to about 30 nM, about 10 nM to about 20 nM, about 15 nM to about 100 nM, about 15 nM to about 75 nM, about 15 nM to about 50 nM, about 15 nM to about 40 nM, about 15 nM to about 30 nM, about 15 nM to about 20 nM, about 20 nM to about 100 nM, about 20 nM to about 75 nM, about 20 nM to about 50 nM, about 20 nM to about 40 nM, about 20 nM to about 30 nM, about 25 nM to about 100 nM, about 25 nM to about 75 nM, about 25 nM to about 50 nM, about 25 nM to about 40 nM, about 25 nM to about 30 nM, about 30 nM to about 100 nM, about 30 nM to about 75 nM, about 30 nM to about 50 nM, about 30 nM to about 40 nM, about 35 nM to about 100 nM, about 35 nM to about 75 nM, about 35 nM to about 50 nM, about

[0696] 35 nM to about 40 nM, about 40 nM to about 100 nM, about 40 nM to about 75 nM, about 40 nM to about 50 nM, about 45 nM to about 100 nM, about 45 nM to about 75 nM, about 45 nM to about 50 nM, about 50 nM to about 100 nM, about 50 nM to about 75 nM, about 70 nM to about 100 nM, about 70 nM to about 75 nM, about 80 nM to about 100 nM, or about 90 nM to about 100 nM. In some embodiments, the multispecific antigen-binding molecule binds to human STEAP1 with a KDof 1 nM, about 2 nM, about 3 nM, about 4 nM, about 5 nM, about 6 nM, about 7 nM, about 8 nM, about 9 nM, about 10 nM, about 1 1 nM, about 12 nM, about 13 nM, about 14 nM, about 15 nM, about 16 nM, about 17 nM, about 18 nM, about 19 nM, about 20 nM, about 21 nM, about 22 nM, about 23 nM, about 24 nM, about 25 nM, about 26 nM, about 27 nM, about 28 nM, about 29 nM, about 30 nM, about 31 nM, about 32 nM, about 33 nM, about 34 nM, about 35 nM, about 36 nM, about 37 nM, about 38 nM, about 39 nM, about 40 nM, about 41 nM, about 42 nM, about 43 nM, about 44 nM, about 45 nM, about 46 nM, about 47 nM, about 48 nM, about 49 nM, or about 50 nM. In some embodiments, multispecific antigen-binding molecule binds to human STEAP1 with a KDof about 29 nM. In some embodiments, the KDis determined using a Kinetic Exclusion Assay (KinExA®), e.g., as described in Example 8.

[0697] In some embodiments, the multispecific antigen-binding molecule binds to cyno STEAP1 with a KDof less than 100 nM, less than 75 nM, less than 50 nM, less than 40 nM, less than 30 nM, less than 20 nM, less than 10 nM, less than 1 nM, or lower. In some embodiments, multispecific antigen-binding molecule binds to cyno STEAP1 with a KDof about 1 nM to about 100 nM, about 1 nM to about 75 nM, about 1 nM to about 50 nM, about 1 nM to about 40 nM, about 1 nM to about 30 nM, about 1 nM to about 20 nM, about 1 nM to about 10 nM, about 1 nM to about 5 nM, about 5 nM to about 100 nM, about 5 nM to about 75 nM, about 5 nM to about 50 nM, about 5 nM to about 40 nM, about 5 nM to about 30 nM, about 5 nM to about 20 nM, about 5 nM to about 10 nM, about 10 nM to about 100 nM, about 10 nM to about 75 nM, about 10 nM to about 50 nM, about 10 nM to about 40 nM, about 10 nM to about 30 nM, about 10 nM to about 20 nM, about 15 nM to about 100 nM, about 15 nM to about 75 nM, about 15 nM to about 50 nM, about 15 nM to about 40 nM, about 15 nM to about 30 nM, about 15 nM to about 20 nM, about 20 nM to about 100 nM, about 20 nM to about 75 nM, about 20 nM to about 50 nM, about 20 nM to about 40 nM, about 20 nM to about 30 nM, about 25 nM to about 100 nM, about 25 nM to about 75 nM, about 25 nM to about 50 nM, about 25 nM to about 40 nM, about 25 nM to about 30 nM, about 30 nM to about 100 nM, about 30 nM to about 75 nM, about 30 nM to about 50 nM, about 30 nM to about 40 nM, about 35 nM to about 100 nM, about 35 nM to about 75 nM, about 35 nM to about 50 nM, about 35 nM to about 40 nM, about 40 nM to about 100 nM, about 40 nM to about 75 nM, about 40 nM to about 50 nM, about 45 nM to about 100 nM, about 45 nM to about 75 nM, about 45 nM to about 50 nM, about 50 nM to about 100 nM, about 50 nM to about 75 nM, about 70 nM to about 100 nM, about 70 nM to about 75 nM, about 80 nM to about 100 nM, or about 90 nM to about 100 nM. In some embodiments, the multispecific antigen-binding molecule binds to cyno STEAP1 with a KDof 1 nM, about 2 nM, about 3 nM, about 4 nM, about 5 nM, about 6 nM, about 7 nM, about 8 nM, about 9 nM, about 10 nM, about 1 1 nM, about 12 nM, about 13 nM, about 14 nM, about 15 nM, about 16 nM, about 17 nM, about 18 nM, about 19 nM, about 20 nM, about 21 nM, about 22 nM, about 23 nM, about 24 nM, or about 25 nM. In some embodiments, multispecific antigen-binding molecule binds to cyno STEAP1 with a KDof about 14 nM. In some embodiments, the KDis determined using a Kinetic Exclusion Assay (KinExA®), e.g., as described in Example 8.

[0698] In some embodiments, the multispecific antigen-binding molecule has a Cmax of up to or about 15, 20, 25, or 30 μg / mL. In some instances, the multispecific antigen-binding molecule has a Cmax of about 1 1 , 1 1 .5, 12, 12.1 , 12.6, 13, 13.2, 13.5, 15, 15.3, 18, 20, 23.4, 25, 27.9, 29.1 , or 30 μg / mL.

[0699] In some embodiments, the multispecific antigen-binding molecule has a Cmax of about 10 μg / mL to about 30 μg / mL (e.g., about 10 μg / mL to about 30 μg / mL, about 10 μg / mL to about 28 μg / mL, about 10 μg / mL to about 26 μg / mL, about 10 μg / mL to about 24 μg / mL, about 10 μg / mL to about 22 μg / mL, about 10 μg / mL to about 20 μg / mL, about 10 μg / mL to about 18 μg / mL, about 10 μg / mL to about 16 μg / mL, about 10 μg / mL to about 14 μg / mL, about 10 μg / mL to about 12 μg / mL, about 12 μg / mL to about 30 μg / mL, about 12 μg / mL to about 28 μg / mL, about 12 μg / mL to about 26 μg / mL, about 12 μg / mL to about 24 μg / mL, about 12 μg / mL to about 22 μg / mL, about 12 μg / mL to about 20 μg / mL, about 12 μg / mL to about 18 μg / mL, about 12 μg / mL to about 16 μg / mL, about 12 μg / mL to about 14 μg / mL, about 14 μg / mL to about 30 μg / mL, about 14 μg / mL to about 28 μg / mL, about 14 μg / mL to about 26 μg / mL, about 14 μg / mL to about 24 μg / mL, about 14 μg / mL to about 22 μg / mL, about 14 μg / mL to about 20 μg / mL, about 14 μg / mL to about 18 μg / mL, about 14 μg / mL to about 16 μg / mL, about 16 μg / mL to about 30 μg / mL, about 16 μg / mL to about 28 μg / mL, about 16 μg / mL to about 26 μg / mL, about 16 μg / mL to about 24 μg / mL, about 16 μg / mL to about 22 μg / mL, about 16 μg / mL to about 20 μg / mL, about 16 μg / mL to about 18 μg / mL, about 18 μg / mL to about 30 μg / mL, about 18 μg / mL to about 28 μg / mL, about 18 μg / mL to about 26 μg / mL, about 18 μg / mL to about 24 μg / mL, about 18 μg / mL to about 22 μg / mL, about 18 μg / mL to about 20 μg / mL, about 20 μg / mL to about 30 μg / mL, about 20 μg / mL to about 28 μg / mL, about 20 μg / mL to about 26 μg / mL, about 20 μg / mL to about 24 μg / mL, about 20 μg / mL to about 22 μg / mL, about 22 μg / mL to about 30 μg / mL, about 22 μg / mL to about 28 μg / mL, about 22 μg / mL to about 26 μg / mL, about 22 μg / mL to about 24 μg / mL, about 24 μg / mL to about 30 μg / mL, about 24 μg / mL to about 28 μg / mL, about 22 μg / mL to about 26 μg / mL, about 22 μg / mL to about 24 μg / mL, about 26 μg / mL to about 30 μg / mL, about 26 μg / mL to about 28 μg / mL or about 28 μg / mL to about 30 μg / mL). In some embodiments, the multispecific antigen-binding molecule has a Cmax of about 20 μg / mL to about 28 μg / mL (e.g., about 20 μg / mL, about 21 μg / mL, about 22 μg / mL, about 23 μg / mL, about 24 μg / mL, about 25 μg / mL, about 26 μg / mL, about 27 μg / mL, or about 28 μg / mL). In some embodiments, the multispecific antigen- binding molecule has a Cmax of about 24 μg / mL. In some embodiments, Cmax may be determined as described in Example 9 (in female SCID mice). In some embodiments, Cmax may be determined as described in Example 10 (in cynomolgus monkeys).

[0700] In some embodiments, the multispecific antigen-binding molecule has an EC50of about 0.6, 0.56, 0.5, 0.45, 0.4, 0.35, 0.3, 0.25, 0.2, 0.15, 0.1 , 0.09, 0.05, or lower. In some cases, the multispecific antigen-binding molecule has an EC50of about 0.5 or lower. In some cases, the multispecific antigen-binding molecule has an EC50of about 0.4 or lower. In some cases, the multispecific antigen-binding molecule has an EC50of about 0.3 or lower. In some cases, the multispecific antigen-binding molecule has an EC50of about 0.2 or lower. In some cases, the multispecific antigen-binding molecule has an EC50of about 0.1 or lower.

[0701] In some embodiments, the multispecific antigen-binding molecule has an EC50of about 0.05 to about 0.8 (e.g., about 0.05 to about 0.8, about 0.05 to about 0.75, about 0.05 to about 0.70, about 0.05 to about 0.65, about 0.05 to about 0.6, about 0.05 to about 0.55, about 0.05 to about 0.5, about

[0702] 0.05 to about 0.45, about 0.05 to about 0.4, about 0.05 to about 0.35, about 0.05 to about 0.3, about 0.05 to about 0.25, about 0.05 to about 0.2, about 0.05 to about 0.15, about 0.05 to about 0.1 , about 0.05 to about 0.09, about 0.05 to about 0.08, about 0.05 to about 0.07, about 0.05 to about 0.06, about 0.06 to about 0.8, about 0.06 to about 0.75, about 0.06 to about 0.70, about 0.06 to about 0.65, about 0.06 to about 0.6, about 0.06 to about 0.55, about 0.06 to about 0.5, about 0.06 to about 0.45, about 0.06 to about 0.4, about 0.06 to about 0.35, about 0.06 to about 0.3, about 0.06 to about 0.25, about 0.06 to about 0.2, about 0.06 to about 0.15, about 0.06 to about 0.1 , about 0.06 to about 0.09, about 0.06 to about 0.08, about 0.06 to about 0.07, about 0.07 to about 0.8, about 0.07 to about 0.75, about 0.07 to about 0.70, about 0.07 to about 0.65, about 0.07 to about 0.6, about 0.07 to about 0.55, about 0.07 to about 0.5, about 0.07 to about 0.45, about 0.07 to about 0.4, about 0.07 to about 0.35, about 0.07 to about 0.3, about 0.07 to about 0.25, about 0.07 to about 0.2, about 0.07 to about 0.15, about 0.07 to about 0.1 , about 0.07 to about 0.09, about 0.07 to about 0.08, about 0.08 to about 0.8, about 0.08 to about 0.75, about 0.08 to about 0.70, about 0.08 to about 0.65, about 0.08 to about 0.6, about 0.08 to about 0.55, about 0.08 to about 0.5, about 0.08 to about 0.45, about 0.08 to about 0.4, about 0.08 to about 0.35, about 0.08 to about 0.3, about 0.08 to about 0.25, about 0.08 to about 0.2, about 0.08 to about 0.15, about 0.08 to about 0.1 , about 0.08 to about 0.09, about 0.09 to about 0.8, about 0.09 to about 0.75, about 0.09 to about 0.70, about 0.09 to about 0.65, about 0.09 to about 0.6, about 0.09 to about 0.55, about 0.09 to about 0.5, about 0.09 to about 0.45, about 0.09 to about 0.4, about 0.09 to about 0.35, about 0.09 to about 0.3, about 0.09 to about 0.25, about 0.09 to about 0.2, about 0.09 to about 0.15, about 0.09 to about 0.1 , about 0.1 to about 0.8, about 0.1 to about 0.75, about 0.1 to about 0.70, about 0.1 to about 0.65, about 0.1 to about 0.6, about 0.1 to about 0.55, about 0.1 to about 0.5, about 0.1 to about 0.45, about 0.1 to about 0.4, about 0.1 to about 0.35, about 0.1 to about 0.3, about 0.1 to about 0.25, about 0.1 to about 0.2, about 0.1 to about 0.15, about 0.15 to about 0.8, about 0.15 to about 0.75, about 0.15 to about 0.70, about 0.15 to about 0.65, about 0.15 to about 0.6, about 0.15 to about 0.55, about 0.15 to about 0.5, about 0.15 to about 0.45, about 0.15 to about 0.4, about 0.15 to about 0.35, about 0.15 to about 0.3, about 0.15 to about 0.25, about 0.15 to about 0.2, about 0.2 to about 0.8, about 0.2 to about 0.75, about 0.2 to about 0.70, about 0.2 to about 0.65, about 0.2 to about 0.6, about 0.2 to about 0.55, about 0.2 to about 0.5, about 0.2 to about 0.45, about 0.2 to about 0.4, about 0.2 to about 0.35, about 0.2 to about 0.3, about 0.2 to about 0.25, about 0.25 to about 0.8, about 0.25 to about 0.75, about 0.25 to about 0.70, about 0.25 to about 0.65, about 0.25 to about 0.6, about 0.25 to about 0.55, about 0.25 to about 0.5, about 0.25 to about 0.45, about 0.25 to about 0.4, about 0.25 to about 0.35, about 0.25 to about 0.3, about 0.3 to about 0.8, about 0.3 to about 0.75, about 0.3 to about 0.70, about 0.3 to about 0.65, about 0.3 to about 0.6, about 0.3 to about 0.55, about 0.3 to about 0.5, about 0.3 to about 0.45, about 0.3 to about 0.4, about 0.3 to about 0.35, about 0.35 to about 0.8, about 0.35 to about 0.75, about 0.35 to about 0.70, about 0.35 to about 0.65, about 0.35 to about 0.6, about 0.35 to about 0.55, about 0.35 to about 0.5, about 0.35 to about 0.45, about 0.35 to about 0.4, about 0.4 to about 0.8, about 0.4 to about 0.75, about 0.4 to about 0.70, about 0.4 to about 0.65, about 0.4 to about 0.6, about 0.4 to about 0.55, about 0.4 to about 0.5, about 0.4 to about 0.45, about 0.45 to about 0.8, about 0.45 to about 0.75, about 0.45 to about 0.70, about 0.45 to about 0.65, about 0.45 to about 0.6, about 0.45 to about 0.55, about 0.45 to about 0.5, about 0.5 to about 0.8, about 0.5 to about 0.75, about 0.5 to about 0.70, about 0.5 to about 0.65, about 0.5 to about 0.6, about 0.5 to about 0.55, about 0.55 to about 0.8, about 0.55 to about 0.75, about 0.55 to about 0.70, about 0.55 to about 0.65, about 0.55 to about 0.6, about 0.6 to about 0.8, about 0.6 to about 0.75, about 0.6 to about 0.70, about 0.6 to about 0.65, about 0.65 to about 0.8, about 0.65 to about 0.75, about 0.65 to about 0.70, about 0.7 to about 0.8, about 0.7 to about 0.75, or about 0.75 to about 0.8).

[0703] In some embodiments, the EC50is determined in a cell killing assay at 72 hours with human CD8+ T cells and STEAP1 -expressing LNCaP-X1 .2 cells. In some embodiments, the EC50is about 0.05 to about 0.4 (e.g., about 0.05, about 0.06, about 0.07, about 0.08, about 0.09, about 0.1 , about 0.15, about 0.2, about 0.25, about 0.3, about 0.35, or about 0.4). In some embodiments, the EC50is about 0.08 or about 0.3. In some embodiments, the EC50is about 0.08. In some embodiments, the EC50is about 0.3.

[0704] In some embodiments, the EC50is determined in a cell killing assay at 72 hours with human CD8+ T cells and STEAP1 -expressing LNCaPXI .2KO3-13 cells. In some embodiments, the EC50is about 0.1 to about 0.8 (e.g., about 0.1 , about 0.15, about 0.2, about 0.25, about 0.3, about 0.35, about 0.4, about 0.45, about 0.5, about 0.55, about 0.6, about 0.65, about 0.7, about 0.75, or about 0.8). In some embodiments, the EC50is about 0.1 or about 0.7. In some embodiments, the EC50is about 0.1 . In some embodiments, the EC50is about 0.7.

[0705] In some embodiments, the multispecific antigen-binding molecule binds to STEAP1 monovalently. In other embodiments, the multispecific antigen-binding molecule binds to STEAP1 multivalently (e.g., bivalently).

[0706] Antibodies that bind to a specific STEAP1 epitope

[0707] In certain embodiments, an antibody of the invention comprises a first antigen-binding domain that binds to a STEAP1 protein. In some instances, the first antigen-binding domain binds to a human STEAP1 protein. In other instances, the first antigen-binding domain binds to a primate STEAP1 protein, e.g., a STEAP1 protein from cynomolgus monkey or Pongo abelii.

[0708] In some embodiments, the antibody comprises a first antigen-binding domain that binds to human STEAP1 at one or more residues selected from Ser101 , His102, Gln103, Trp195, Gln198, Gln202, and Lys281 , wherein the residue positions 101 , 102, 103, 195, 198, 202, and 281 correspond to positions 101 , 102, 103, 195, 198, 202, and 281 set forth in SEQ ID NO: 65. In some instances, the first antigen-binding domain binds to at least one residue selected from Seri 01 , His102, Gin 103, Trp195, Gln198, Gln202, and Lys281 of SEQ ID NO: 65.

[0709] In some instances, a residue from the first antigen-binding domain forms a hydrogen bond with at least one residue selected from Seri 01 , His102, Gin 103, Trp195, G In 198, Gln202, and Lys281 . In some cases, at least one residue selected from Leu56, Ser73, Asn74, G ly 101 , Tyr103, and Tyr107 of the VH of the first antigen-binding domain forms a hydrogen bond with at least one residue selected from Seri 01 , His102, Gln103, Trp195, Gln198, Gln202, and Lys281 of STEAP1 , wherein the residue positions 56, 73, 74, 101 , 103, and 107 correspond to positions 56, 73, 74, 101 , 103, and 107 set forth in SEQ ID NO: 18. In some cases, at least one residue selected from Tyr35 or Tyr54 of the VL of the first antigen-binding domain forms a hydrogen bond with at least one residue selected from Gln202 or Gln201 , wherein the residue positions 35 and 54 correspond to positions 35 and 54 set forth in SEQ ID NO: 8. In some cases, residue Asn203 and / or Lys204 of human STEAP1 form van der Waals interactions with one or more VL CDR residues. In some cases, the residues that form the hydrogen bonds are as illustrated in Table 3. Table 3

[0710] In some embodiments, the antibody of the invention is a monospecific antibody described supra under Section A “antigen-binding molecules that binds to STEAP1 In some instances, the antibody comprises a VH region comprising CDR-H1 , CDR-H2, and CDR-H3 of a VH sequence selected from SEQ ID NOs: 7, 17-25, 30-34, 38, and 68; and a VL region comprising CDR-L1 , CDR- L2, and CDR-L3 of a VL sequence selected from SEQ ID NOs: 8, 26-29, 39, and 69. In some cases, the antibody comprises six CDRs in which:

[0711] CDR-H1 comprises Xaa1Xaa2YMA (SEQ ID NO: 35); wherein

[0712] Xaa1is Asp (D) or Asn (N); and

[0713] Xaa2is His (H), Tyr (Y), or Phe (F);

[0714] CDR-H2 comprises YIXaa3YDGXaa4Xaa5TXaa6YGDSVKG (SEQ ID NO: 36); wherein

[0715] Xaa3is Asp (D) or Ser (S);

[0716] Xaa4is Gly (G), Asp (D), or Leu (L);

[0717] Xaa5is Ser (S), Asp (D), or Asn (N); and

[0718] Xaa6is Ser (S) or Tyr (Y);

[0719] CDR-H3 comprises RSGXaa7YHVGYAMXaa8Xaa9(SEQ ID NO: 37); wherein

[0720] Xaa7is Phe (F) or Tyr (Y);

[0721] Xaa8is Asn (N) or Asp (D); and

[0722] Xaa9is Ala (A) or Gly (G);

[0723] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0724] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6.

[0725] In some cases, the antibody comprises six CDRs, in which:

[0726] CDR-H1 comprises GFTFSXaa10Xaa11(SEQ ID NO: 63); wherein

[0727] Xaa10is Asn (N) or Asp (D); and

[0728] Xaa11is Tyr (Y), Phe (F), or His (H); CDR-H2 comprises Xaa12YDGXaa13Xaa14(SEQ ID NO: 64); wherein

[0729] Xaa12is Asp (D) or Ser (S);

[0730] Xaa13is Gly (G), Asp (D), or Leu (L); and

[0731] Xaa14is Ser (S), Asp (D), or Asn (N);

[0732] CDR-H3 comprises RSGXaa7YHVGYAMXaa8Xaa9(SEQ ID NO: 37); wherein

[0733] Xaa7is Phe (F) or Tyr (Y);

[0734] Xaa8is Asn (N) or Asp (D); and

[0735] Xaa9is Ala (A) or Gly (G);

[0736] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0737] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and

[0738] CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6.

[0739] In some embodiments, the antibody of the invention is a multispecific antibody described supra under Section B “Multispecific antigen-binding molecules.” In some instances, the antibody comprises (A) a first antigen-binding domain that binds to STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and / or CDR-H3 of a VH sequence selected from SEQ ID NO: 7, 17-25, 30-34, 38, and 68; and / or an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and / or CDR-L3 of a VL sequence selected from SEQ ID NO: 8, 26-29, 39, and 69; and (B) a second antigen-binding domain that binds to a T cell receptor (e.g., CD3).

[0740] In some instances, the antibody comprises (A) a first antigen-binding domain that binds to STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR- H2, and CDR-H3; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3; wherein

[0741] CDR-H1 comprises Xaa1Xaa2YMA (SEQ ID NO: 35); wherein

[0742] Xaa1is Asp (D) or Asn (N); and

[0743] Xaa2is His (H), Tyr (Y), or Phe (F);

[0744] CDR-H2 comprises YIXaa3YDGXaa4Xaa5TXaa6YGDSVKG (SEQ ID NO: 36); wherein

[0745] Xaa3is Asp (D) or Ser (S);

[0746] Xaa4is Gly (G), Asp (D), or Leu (L);

[0747] Xaa5is Ser (S), Asp (D), or Asn (N); and

[0748] Xaa6is Ser (S) or Tyr (Y); and

[0749] CDR-H3 comprises RSGXaa7YHVGYAMXaa8Xaa9(SEQ ID NO: 37); wherein

[0750] Xaa7is Phe (F) or Tyr (Y); Xaa8is Asn (N) or Asp (D); and

[0751] Xaa9is Ala (A) or Gly (G);

[0752] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0753] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or

[0754] CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6; and

[0755] (B) a second antigen-binding domain that binds to a T cell receptor (e.g., CD3).

[0756] In some embodiments, the antibody comprises (A) a first antigen-binding domain that binds to STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR- H2, and CDR-H3; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3; wherein

[0757] CDR-H1 comprises GFTFSXaa10Xaa11(SEQ ID NO: 63); wherein

[0758] Xaa10is Asn (N) or Asp (D); and

[0759] Xaa11is Tyr (Y), Phe (F), or His (H);

[0760] CDR-H2 comprises Xaa12YDGXaa13Xaa14(SEQ ID NO: 64); wherein

[0761] Xaa12is Asp (D) or Ser (S);

[0762] Xaa13is Gly (G), Asp (D), or Leu (L); and

[0763] Xaa14is Ser (S), Asp (D), or Asn (N);

[0764] CDR-H3 comprises RSGXaa7YHVGYAMXaa8Xaa9(SEQ ID NO: 37); wherein

[0765] Xaa7is Phe (F) or Tyr (Y);

[0766] Xaa8is Asn (N) or Asp (D); and

[0767] Xaa9is Ala (A) or Gly (G);

[0768] CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;

[0769] CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and / or

[0770] CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6; and

[0771] (B) a second antigen-binding domain that binds to a T cell receptor (e.g., CD3).

[0772] Peptide linkers fusing the first and second antigen-binding domains

[0773] In some embodiments, a multispecific antigen-binding molecule (e.g., a bispecific or trispecific antigen-binding molecule) of the invention features a structure wherein the C-terminus of the first antigen-binding domain is fused to the N-terminus of the second antigen-binding domain via a peptide linker. The peptide linker can be 5-20 amino acids in length (e.g., 5-10, 10-15, or 15-20, e.g., 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids in length). In some embodiments, the peptide linker comprises the natural amino acid sequence of the variable heavy chain hinge region (e.g., DKTHT). In some embodiments, the peptide linker comprises a (Gly4Ser)nlinker (or (G4S)nlinker), in which n is from 1 to 10, 2 to 10, 3 to 10, 4 to 10, 5 to 10, 6 to 10, 2 to 6, 2 to 6, 3 to 6, or 4 to 6. In some instances, n is 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, the peptide linker comprises a G4SG2 linker. In some embodiments, the peptide linker comprises the G4SG2 linker and the hinge region (e.g., DKTHT). In some embodiments, the peptide linker comprises a plurality of glycines, alanines, or a combination thereof.

[0774] Fc domains

[0775] Antigen-binding molecules (e.g., monospecific and / or multispecific antigen-binding molecules such as bispecific or trispecific antigen-binding molecules) of the invention may feature an Fc domain. The Fc domain may be an IgG Fc domain (e.g., an IgGi, lgG2, or lgG4 Fc domain). For example, the Fc domain can be a human Fc domain. In some embodiments, the Fc domain comprises one or more amino acid substitution(s) that reduces binding to an Fc receptor and / or effector function. For example, in some embodiments, the one or more amino acid substitutions that reduces binding to an Fc receptor and / or effector function is at one or more position selected from the group of L234, L235, and P329 (e.g., wherein the first Fc subunit and the second Fc subunit each comprises the amino acid substitutions of L234A, L235A and P329G). The Fc receptor may be, for example, an Fey receptor. Thus, the antigen-binding molecules (e.g., monospecific and / or multispecific antigen- binding molecules such as bispecific or trispecific antigen-binding molecules) of the invention can be configured to reduce antibody-dependent cell-mediated cytotoxicity (ADCC).

[0776] In some instances, the Fc domain comprises a modification configured to promote the association of the first Fc subunit with the second Fc subunit. “Knob-in-hole” engineering of bispecific antibodies may be utilized to generate a first arm containing a knob and a second arm containing the hole into which the knob of the first arm may bind. The knob of the multispecific antigen-binding molecules of the invention may be an anti-STEAP1 arm in one embodiment. Alternatively, the knob of the multispecific antigen-binding molecules of the invention may be an anti-CD3 arm. The hole of the multispecific antigen-binding molecules of the invention may be an anti-STEAP1 arm in one embodiment. Alternatively, the hole of the multispecific antigen-binding molecules of the invention may be an anti-CD3 arm. Multispecific antigen-binding molecules such as bispecific antibodies may also be engineered using immunoglobulin crossover (also known as Fab domain exchange or CrossMab format) technology (see e.g., W02009 / 080253; Schaefer et al., Proc. Natl. Acad. Sci. USA, 108:11187-11192 (2011 )). Multispecific antibodies may also be made by engineering electrostatic steering effects for making antibody Fc-heterodimeric molecules (WO 2009 / 089004A1 ); cross-linking two or more antibodies or fragments (see, e.g., US Patent No. 4,676,980, and Brennan et al., Science, 229: 81 (1985)); or by using leucine zippers to produce bi-specific antibodies (see, e.g., Kostelny et al., J. Immunol., 148(5):1547-1553 (1992)).

[0777] An amino acid residue in the CH3 domain of the second Fc subunit may be replaced with an amino acid residue having a larger side chain volume, thereby generating a protuberance (e.g., a knob) within the CH3 domain of the second Fc subunit which is positionable in a cavity (e.g., a hole) within the CH3 domain of the first Fc subunit, and an amino acid residue in the CH3 domain of the first Fc subunit may be replaced with an amino acid residue having a smaller side chain volume, thereby generating a cavity (e.g., a hole) within the CH3 domain of the first Fc subunit within which the protuberance (e.g., a knob) within the CH3 domain of the second Fc subunit may be positionable. In some embodiments, the CH3 domain of the second Fc subunit comprises the amino acid substitution of T366, and the CH3 domain of the first Fc subunit comprises amino acid substitutions at one, two, or all three of T366, L368, and / or Y407 (all EU numbering). In some embodiments, the CH3 domain of the second Fc subunit comprises the amino acid substitution of T366W, and the CH3 domain of the first Fc subunit comprises one, two, or all three amino acid substitutions of T366S, L368A, and / or Y407V (all EU numbering).

[0778] In some embodiments, the multispecific antigen-binding molecule described herein comprises an anti-STEAP1 arm comprising N297G (EU numbering) and T366W (EU numbering) substitutions in the heavy chain, and an anti-CD3 arm comprising N297G (EU numbering), T366S (EU numbering), L368A (EU numbering), and Y407V (EU numbering) substitutions in the heavy chain. In some embodiments, the multispecific antigen-binding molecule described herein comprises an anti-STEAP1 arm comprising N297G (EU numbering) and T366W (EU numbering) substitutions in the heavy chain, and an anti-CD3 arm comprising N297G (EU numbering), T366S (EU numbering), L368A (EU numbering), and Y407V (EU numbering) substitutions in the heavy chain.

[0779] In some embodiments, the multispecific antigen-binding molecule described herein comprises a) a first heavy chain / light chain pair binding to a first antigen which comprises a first heavy chain polypeptide (H1 ) and a first light chain polypeptide (L1 ), and b) a second heavy chain / light chain pair binding to a second antigen which comprises a second heavy chain polypeptide (H2) and a second light chain polypeptide (L2), wherein each H1 and H2 comprises a heavy chain variable domain (VH) and a heavy chain constant domain (CH1 ), and each L1 and L2 comprises a light chain variable domain (VL) and a light chain constant domain (VL), wherein: (i) an amino acid at S183 (EU numbering) in the CH1 domain of H1 is replaced with a positively charged residue, an amino acid at Q39 (Kabat numbering) in the VH domain of H1 is replaced with a negatively charged residue, an amino acid at V133 (EU numbering) in the CL domain of L1 is replaced with a negatively charged residue, and an amino acid at Q38 (Kabat numbering) in the VL domain of L1 is replaced with a positively charged residue; and an amino acid at Q39 (Kabat numbering) in the VH domain of H2 is replaced with a positively charged residue and an amino acid at Q38 (Kabat numbering) in the VL domain of L2 is replaced with a negatively charged residue; or (ii) an amino acid at S183 (EU numbering) in the CH1 domain of H1 is replaced with a negatively charged residue, an amino acid at Q39 (Kabat numbering) in the VH domain of H1 is replaced with a positively charged residue, an amino acid at V133 (EU numbering) in the CL domain of L1 is replaced with a positively charged residue, and an amino acid at Q38 (Kabat numbering) in the VL domain of L1 is replaced with a negatively charged residue; and an amino acid at Q39 (Kabat numbering) in the VH domain of H2 is replaced with a negatively charged residue and an amino acid at Q38 (Kabat numbering) in the VL domain of L2 is replaced with a positively charged residue. In some embodiments, the positively charged residue is selected from R and K and the negatively charged residue is selected from D and E. In some embodiments, the positively charged residue is R. In other embodiments, the positively charged residue is K. In some embodiments, the negatively charged residue is D. In other embodiments, the negatively charged residue is E. In some embodiments, the first antigen is STEAP1 and the second antigen is CD3. In other embodiments, the first antigen is CD3 and the second antigen is STEAP1 .

[0780] For example, in some embodiments, the multispecific antigen-binding molecule described herein comprises an anti-STEAP1 arm comprising a first heavy chain polypeptide (H1 ) and a first light chain polypeptide (L1 ), and an anti-CD3 arm comprising a second heavy chain polypeptide (H2) and a second light chain polypeptide (L2), wherein each H1 and H2 comprises a heavy chain variable domain (VH) and a heavy chain constant domain (CH1 ), and each L1 and L2 comprises a light chain variable domain (VL) and a light chain constant domain (VL), wherein: (i) an amino acid at S183 (EU numbering) in the CH1 domain of H1 is replaced with an R or K residue, an amino acid at Q39 (Kabat numbering) in the VH domain of H1 is replaced with a D or E residue, an amino acid at V133 (EU numbering) in the CL domain of L1 is replaced with a D or E residue, and an amino acid at Q38 (Kabat numbering) in the VL domain of L1 is replaced with an R or K residue; and an amino acid at Q39 (Kabat numbering) in the VH domain of H2 is replaced with an R or K residue and an amino acid at Q38 (Kabat numbering) in the VL domain of L2 is replaced with a D or E residue; or (ii) an amino acid at S183 (EU numbering) in the CH1 domain of H1 is replaced with a D or E residue, an amino acid at Q39 (Kabat numbering) in the VH domain of H1 is replaced with an R or K residue, an amino acid at V133 (EU numbering) in the CL domain of L1 is replaced with an R or K residue, and an amino acid at Q38 (Kabat numbering) in the VL domain of L1 is replaced with a D or E residue; and an amino acid at Q39 (Kabat numbering) in the VH domain of H2 is replaced with a D or E residue and an amino acid at Q38 (Kabat numbering) in the VL domain of L2 is replaced with an R or K residue.

[0781] In some embodiments, the multispecific antigen-binding molecule described herein comprises an anti-STEAP1 arm comprising a first heavy chain polypeptide (H1 ) and a first light chain polypeptide (L1 ), and an anti-CD3 arm comprising a second heavy chain polypeptide (H2) and a second light chain polypeptide (L2), wherein each H1 and H2 comprises a heavy chain variable domain (VH) and a heavy chain constant domain (CH1 ), and each L1 and L2 comprises a light chain variable domain (VL) and a light chain constant domain (VL), wherein: (i) an amino acid at S183 (EU numbering) in the CH1 domain of H1 is replaced with a K residue, an amino acid at Q39 (Kabat numbering) in the VH domain of H1 is replaced with an E residue, an amino acid at V133 (EU numbering) in the CL domain of L1 is replaced with an E residue, and an amino acid at Q38 (Kabat numbering) in the VL domain of L1 is replaced with a K residue; and an amino acid at Q39 (Kabat numbering) in the VH domain of H2 is replaced with a K residue and an amino acid at Q38 (Kabat numbering) in the VL domain of L2 is replaced with an E residue; or (ii) an amino acid at S183 (EU numbering) in the CH1 domain of H1 is replaced with an E residue, an amino acid at Q39 (Kabat numbering) in the VH domain of H1 is replaced with a K residue, an amino acid at V133 (EU numbering) in the CL domain of L1 is replaced with a K residue, and an amino acid at Q38 (Kabat numbering) in the VL domain of L1 is replaced with an E residue; and an amino acid at Q39 (Kabat numbering) in the VH domain of H2 is replaced with an E residue and an amino acid at Q38 (Kabat numbering) in the VL domain of L2 is replaced with a K residue.

[0782] For example, in other embodiments, the multispecific antigen-binding molecule described herein comprises an anti-CD3 arm comprising a first heavy chain polypeptide (H1 ) and a first light chain polypeptide (L1 ), and an anti-STEAP1 arm comprising a second heavy chain polypeptide (H2) and a second light chain polypeptide (L2), wherein each H1 and H2 comprises a heavy chain variable domain (VH) and a heavy chain constant domain (CH1 ), and each L1 and L2 comprises a light chain variable domain (VL) and a light chain constant domain (VL), wherein: (i) an amino acid at S183 (EU numbering) in the CH1 domain of H1 is replaced with an R or K residue, an amino acid at Q39 (Kabat numbering) in the VH domain of H1 is replaced with a D or E residue, an amino acid at V133 (EU numbering) in the CL domain of L1 is replaced with a D or E residue, and an amino acid at Q38 (Kabat numbering) in the VL domain of L1 is replaced with an R or K residue; and an amino acid at Q39 (Kabat numbering) in the VH domain of H2 is replaced with an R or K residue and an amino acid at Q38 (Kabat numbering) in the VL domain of L2 is replaced with a D or E residue; or (ii) an amino acid at S183 (EU numbering) in the CH1 domain of H1 is replaced with a D or E residue, an amino acid at Q39 (Kabat numbering) in the VH domain of H1 is replaced with an R or K residue, an amino acid at V133 (EU numbering) in the CL domain of L1 is replaced with an R or K residue, and an amino acid at Q38 (Kabat numbering) in the VL domain of L1 is replaced with a D or E residue; and an amino acid at Q39 (Kabat numbering) in the VH domain of H2 is replaced with a D or E residue and an amino acid at Q38 (Kabat numbering) in the VL domain of L2 is replaced with an R or K residue.

[0783] In some embodiments, the multispecific antigen-binding molecule described herein comprises an anti-CD3 arm comprising a first heavy chain polypeptide (H1 ) and a first light chain polypeptide (L1 ), and an anti-STEAP1 arm comprising a second heavy chain polypeptide (H2) and a second light chain polypeptide (L2), wherein each H1 and H2 comprises a heavy chain variable domain (VH) and a heavy chain constant domain (CH1 ), and each L1 and L2 comprises a light chain variable domain (VL) and a light chain constant domain (VL), wherein: (i) an amino acid at S183 (EU numbering) in the CH1 domain of H1 is replaced with a K residue, an amino acid at Q39 (Kabat numbering) in the VH domain of H1 is replaced with an E residue, an amino acid at V133 (EU numbering) in the CL domain of L1 is replaced with an E residue, and an amino acid at Q38 (Kabat numbering) in the VL domain of L1 is replaced with a K residue; and an amino acid at Q39 (Kabat numbering) in the VH domain of H2 is replaced with a K residue and an amino acid at Q38 (Kabat numbering) in the VL domain of L2 is replaced with an E residue; or (ii) an amino acid at S183 (EU numbering) in the CH1 domain of H1 is replaced with an E residue, an amino acid at Q39 (Kabat numbering) in the VH domain of H1 is replaced with a K residue, an amino acid at V133 (EU numbering) in the CL domain of L1 is replaced with a K residue, and an amino acid at Q38 (Kabat numbering) in the VL domain of L1 is replaced with an E residue; and an amino acid at Q39 (Kabat numbering) in the VH domain of H2 is replaced with an E residue and an amino acid at Q38 (Kabat numbering) in the VL domain of L2 is replaced with a K residue. In some embodiments, the multispecific antigen-binding molecule described herein comprises an anti-STEAP1 arm comprising Q39K (Kabat numbering) and S183E (EU numbering) substitutions in the heavy chain and Q38E (Kabat numbering) and V133K (EU numbering) substitutions in the light chain; and an anti-CD3 arm comprising a Q39E (Kabat numbering) substitution in the heavy chain and a Q38K (Kabat numbering) substitution in the light chain.

[0784] In some embodiments, the multispecific antigen-binding molecule described herein comprises an anti-CD3 arm comprising Q39K (Kabat numbering) and S183E (EU numbering) substitutions in the heavy chain and Q38E (Kabat numbering) and V133K (EU numbering) substitutions in the light chain; and an anti-STEAP1 arm comprising a Q39E (Kabat numbering) substitution in the heavy chain and a Q38K (Kabat numbering) substitution in the light chain.

[0785] In some embodiments, the multispecific antigen-binding molecule described herein comprises an anti-STEAP1 arm comprising Q39E (Kabat numbering) and S183K (EU numbering) substitutions in the heavy chain and Q38K (Kabat numbering) and V133E (EU numbering) substitutions in the light chain; and an anti-CD3 arm comprising a Q39K (Kabat numbering) substitution in the heavy chain and a Q38E (Kabat numbering) substitution in the light chain.

[0786] In some embodiments, the multispecific antigen-binding molecule described herein comprises an anti-CD3 arm comprising Q39E (Kabat numbering) and S183K (EU numbering) substitutions in the heavy chain and Q38K (Kabat numbering) and V133E (EU numbering) substitutions in the light chain; and an anti-STEAP1 arm comprising a Q39K (Kabat numbering) substitution in the heavy chain and a Q38E (Kabat numbering) substitution in the light chain.

[0787] In some embodiments, the multispecific antigen-binding molecule described herein comprises a) a first heavy chain / light chain pair binding to a first antigen which comprises a first heavy chain polypeptide (H1 ) and a first light chain polypeptide (L1 ), and b) a second heavy chain / light chain pair binding to a second antigen which comprises a second heavy chain polypeptide (H2) and a second light chain polypeptide (L2), wherein each H1 and H2 comprises a heavy chain variable domain (VH) and a heavy chain constant domain (CH1 ), and each L1 and L2 comprises a light chain variable domain (VL) and a light chain constant domain (VL), wherein: (i) an amino acid at S183 (EU numbering) in the CH1 domain of H1 is replaced with a positively charged residue, an amino acid at Q39 (Kabat numbering) in the VH domain of H1 is replaced with a negatively charged residue, an amino acid at V133 (EU numbering) in the CL domain of L1 is replaced with a negatively charged residue, an amino acid at Q38 (Kabat numbering) in the VL domain of L1 is replaced with a positively charged residue, an amino acid at S183 (EU numbering) in the CH1 domain of H2 is replaced with a negatively charged residue, an amino acid at Q39 (Kabat numbering) in the VH domain of H2 is replaced with a positively charged residue, an amino acid at Q38 (Kabat numbering) in the VL domain of L2 is replaced with a negatively charged residue, and an amino acid at V133 (EU numbering) in the CL domain of L2 is replaced with a positively charged residue; or (ii) an amino acid at S183 (EU numbering) in the CH1 domain of H1 is replaced with a negatively charged residue, an amino acid at Q39 (Kabat numbering) in the VH domain of H1 is replaced with a positively charged residue, an amino acid at V133 (EU numbering) in the CL domain of L1 is replaced with a positively charged residue, an amino acid at Q38 (Kabat numbering) in the VL domain of L1 ...

Claims

WHAT IS CLAIMED IS:1 . A multispecific antigen-binding molecule comprising: (A) a first antigen-binding domain that binds to STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR- H1 , CDR-H2, and CDR-H3 of a VH sequence selected from SEQ ID NOs: 7, 17-25, 30-34, 38 and 68; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3 of a VL sequence selected from SEQ ID NOs: 8, 26-29, 39 and 69; and (B) a second antigen-binding domain that binds to a T cell receptor.

2. A multispecific antigen-binding molecule comprising:(A) a first antigen-binding domain that binds to STEAP1 and comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3; whereinCDR-H1 comprises Xaa1Xaa2YMA (SEQ ID NO: 35); whereinXaa1is Asp (D) or Asn (N); andXaa2is His (H), Tyr (Y), or Phe (F);CDR-H2 comprises YIXaa3YDGXaa4Xaa5TXaa6YGDSVKG (SEQ ID NO: 36); whereinXaa3is Asp (D) or Ser (S);Xaa4is Gly (G), Asp (D), or Leu (L);Xaa5is Ser (S), Asp (D), or Asn (N); andXaa6is Ser (S) or Tyr (Y); andCDR-H3 comprises RSGXaa7YHVGYAMXaa8Xaa9(SEQ ID NO: 37); whereinXaa7is Phe (F) or Tyr (Y);Xaa8is Asn (N) or Asp (D); andXaa9is Ala (A) or Gly (G);CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6; and(B) a second antigen-binding domain that binds to a T cell receptor.

3. The multispecific antigen-binding molecule of claim 1 or 2, wherein the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 10, 1 , or 9.

4. The multispecific antigen-binding molecule of any one of claims 1 -3, wherein the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 2, 11 , 12, or 13.

5. The multispecific antigen-binding molecule of any one of claims 1 -4, wherein the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 16, 3, 14, or 15.

6. The multispecific antigen-binding molecule of any one of claims 1 -5, wherein the first antigen- binding domain comprises:CDR-H1 comprising the amino acid sequence of SEQ ID NO: 10;CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2;CDR-H3 comprising the amino acid sequence of SEQ ID NO: 16;CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; andCDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

7. The multispecific antigen-binding molecule of any one of claims 1 -5, wherein the first antigen- binding domain comprises:CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ;CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2;CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; andCDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

8. The multispecific antigen-binding molecule of any one of claims 1 -5, wherein the first antigen- binding domain comprises:CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9;CDR-H2 comprising the amino acid sequence of SEQ ID NO: 11 ;CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; andCDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

9. The multispecific antigen-binding molecule of any one of claims 1 -5, wherein the first antigen- binding domain comprises:CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9;CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12;CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; andCDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

10. The multispecific antigen-binding molecule of any one of claims 1 -5, wherein the first antigen- binding domain comprises:CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9;CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12;CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14;CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.11 . The multispecific antigen-binding molecule of any one of claims 1 -5, wherein the first antigen- binding domain comprises:CDR-H1 comprising the amino acid sequence of SEQ ID NO: 10;CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13;CDR-H3 comprising the amino acid sequence of SEQ ID NO: 15;CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; andCDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

12. The multispecific antigen-binding molecule of any one of claims 1 -11 , wherein the multispecific antigen-binding molecule is a humanized antibody.

13. The multispecific antigen-binding molecule of any one of claims 1 -12, wherein the first antigen-binding domain and the second antigen-binding domain each independently comprises an IgG framework region, optionally an IgGi or lgG4 framework region.

14. The multispecific antigen-binding molecule of any one of claims 1 -13, wherein the first antigen-binding domain comprises an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 7, 17-25, 30-34, 38, or 68.

15. The multispecific antigen-binding molecule of any one of claims 1 -14, wherein the first antigen-binding domain comprises an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 8, 26-29, 39, or 69.

16. The multispecific antigen-binding molecule of any one of claims 1 -15, wherein the first antigen-binding domain comprises an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 68, andan anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 69.

17. The multispecific antigen-binding molecule of any one of claims 1 -15, wherein the first antigen-binding domain comprises an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 34, and an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 27.

18. The multispecific antigen-binding molecule of any one of claims 1 -15, wherein the first antigen-binding domain comprises an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 30, and an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 27.

19. The multispecific antigen-binding molecule of any one of claims 1 -15, wherein the first antigen-binding domain comprises an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 31 , and an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 27.

20. The multispecific antigen-binding molecule of any one of claims 1 -15, wherein the first antigen-binding domain comprises an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 32, and an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 27.21 . The multispecific antigen-binding molecule of any one of claims 1 -15, wherein the first antigen-binding domain comprises an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 33, and an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 27.

22. The multispecific antigen-binding molecule of any one of claims 1 -21 , wherein the T cell receptor is cluster of differentiation 3 (CD3).

23. The multispecific antigen-binding molecule of claim 22, wherein the second antigen-binding domain that binds to CD3 comprises an anti-CD3 heavy chain variable region (VH) comprising CDR- H1 , CDR-H2, and CDR-H3, and an anti-CD3 light chain variable region (VL) comprising CDR-L1 ,CDR-L2, and CDR-L3, wherein the CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3 comprise the sequences of SEQ ID NOs: 48-53, respectively.

24. The multispecific antigen-binding molecule of claim 23, wherein the second antigen-binding domain that binds to CD3 comprises an anti-CD3 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 54, and a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 55.

25. The multispecific antigen-binding molecule of claim 22, wherein the second antigen-binding domain that binds to CD3 comprises an anti-CD3 heavy chain variable region (VH) comprising CDR- H1 , CDR-H2, and CDR-H3, and an anti-CD3 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3, wherein the CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3 comprise the sequences of SEQ ID NOs: 40-45, respectively.

26. The multispecific antigen-binding molecule of claim 25, wherein the second antigen-binding domain that binds to CD3 comprises an anti-CD3 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 46, and an anti-CD3 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 47.

27. The multispecific antigen-binding molecule of any one of claims 1 -26, wherein the multispecific antigen binding molecule comprises one or more heavy chain constant domains, wherein the one or more heavy chain constant domains are selected from a first CH1 (CH11) domain, a first CH2 (CH21) domain, a first CH3 (CH31) domain, a second CH1 (CH12) domain, a second CH2 (CH22) domain, and a second CH3 (CH32) domain.

28. The multispecific antigen-binding molecule of claim 27, wherein at least one of the one or more heavy chain constant domains is paired with another heavy chain constant domain.

29. The multispecific antigen-binding molecule of claim 28, wherein the CH31and CH32domains each comprise a protuberance or cavity, and wherein the protuberance or cavity in the CH31domain is positionable in the cavity or protuberance, respectively, in the CH32domain.

30. The multispecific antigen-binding molecule of claim 29, wherein the CH31and CH32domains meet at an interface between said protuberance and cavity.31 . The multispecific antigen-binding molecule of any one of claims 27-30, wherein the CH21and CH22domains each comprise a protuberance or cavity, and wherein the protuberance or cavity in the CH21domain is positionable in the cavity or protuberance, respectively, in the CH22domain.

32. The multispecific antigen-binding molecule of claim 31 , wherein the CH21and CH22 domains meet at an interface between said protuberance and cavity.

33. The multispecific antigen-binding molecule of any one of claims 22 and 27-32, wherein the first antigen-binding domain comprises an anti-STEAP1 heavy chain constant region sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 83 and an anti- STEAP1 light chain constant region sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 82; and wherein the second antigen-binding domain comprises an anti-CD3 heavy chain constant region sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 85 and an anti-CD3 light chain constant region sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 84.

34. The multispecific antigen-binding molecule of any one of claims 22 and 27-32, wherein the first antigen-binding domain comprises an anti-STEAP1 heavy chain constant region sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 85 and an anti- STEAP1 light chain constant region sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 84; and wherein the second antigen-binding domain comprises an anti-CD3 heavy chain constant region sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 83 and an anti-CD3 light chain constant region sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 82.

35. The multispecific antigen-binding molecule of any one of claims 22 and 27-32, wherein the multispecific antigen-binding molecule comprises an anti-STEAP1 heavy chain comprising SEQ ID NO: 73, an anti-STEAP1 light chain comprising SEQ ID NO: 72, an anti-CD3 heavy chain comprising SEQ ID NO: 81 , and an anti-CD3 light chain comprising SEQ ID NO: 80.

36. The multispecific antigen-binding molecule of any one of claims 22 and 27-32, wherein the multispecific antigen-binding molecule comprises an anti-STEAP1 heavy chain comprising SEQ ID NO: 73, an anti-STEAP1 light chain comprising SEQ ID NO: 72, an anti-CD3 heavy chain comprising SEQ ID NO: 79, and an anti-CD3 light chain comprising SEQ ID NO: 78.

37. The multispecific antigen-binding molecule of any one of claims 1 -36, wherein the antigen- binding molecule is a single-chain Fv (scFv), trispecific (Fabs), bispecific (Fab2), diabody ((VL-VH)2or (VH-VL)2), triabody (trivalent), tetrabody (tetravalent), minibody ((SCFV-CH)2), bispecific single-chain Fv (Bis-scFv), lgGdeltaCH2, scFv-Fc, or (scFv)2-Fc.

38. The multispecific antigen-binding molecule of any one of claims 1 -37, wherein the multispecific antigen-binding molecule is a multispecific antibody, preferably a bispecific or trispecific antibody.

39. The multispecific antigen-binding molecule of any one of claims 1 -38, wherein the multispecific antigen-binding molecule further comprises a third antigen-binding domain that binds to a tumor-associated antigen.

40. The multispecific antigen-binding molecule of claim 39, wherein the tumor-associated antigen is a receptor expressed on a prostate cancer cell or Ewing sarcoma.41 . The multispecific antigen-binding molecule of claim 39 or 40, wherein the tumor-associated antigen is prostate-specific membrane antigen (PSMA), STEAP2, prostate stem cell antigen (PSCA), epithelial cell adhesion molecule (EpCAM), prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), or HBA-71 .

42. The multispecific antigen-binding molecule of any one of claims 1 -41 , wherein the multispecific antigen-binding molecule binds to human STEAP1 , cynomolgus monkey STEAP1 , or a combination thereof, preferably wherein the multispecific antigen-binding molecule binds to the human STEAP1 of SEQ ID NO: 65.

43. The multispecific antigen-binding molecule of any one of claims 1 -42, wherein the first antigen-binding domain binds to at least one residue selected from Seri 01 , His102, Gin 103, and Lys281 of STEAP1 , wherein the residue positions 101 , 102, 103, and 281 correspond to positions 101 , 102, 103, and 281 set forth in SEQ ID NO: 65.

44. The multispecific antigen-binding molecule of any one of claims 1 -43, wherein the first antigen-binding domain binds to Seri 01 , His102, G In 103, and Lys281 of STEAP1 .

45. The multispecific antigen-binding molecule of any one of claims 1 -44, wherein the multispecific antigen-binding molecule has a Cmax of about 11 , 11.5, 12, 12.6, 13, 13.5, 15, 18, 20, 23.4, 25, 27.9, 29.1 , or 30 μg / mL.

46. The multispecific antigen-binding molecule of any one of claims 1 -44, wherein the multispecific antigen-binding molecule has a Cmax of about 11 μg / mL to about 30 μg / mL.

47. The multispecific antigen-binding molecule of claim 46, wherein the multispecific antigen- binding molecule has a Cmax of about 20 μg / mL to about 28 μg / mL.

48. The multispecific antigen-binding molecule of claim 47, wherein the multispecific antigen- binding molecule has a Cmax of about 24 μg / mL.

49. The multispecific antigen-binding molecule of any one of claims 1 -48, wherein the multispecific antigen-binding molecule has an EC50of about 0.6, 0.56, 0.5, 0.45, 0.4, 0.35, 0.3, 0.25, 0.2, 0.15, 0.1 , 0.09, 0.05, or lower.

50. The multispecific antigen-binding molecule of any one of claims 1 -48, wherein the multispecific antigen-binding molecule has an EC50of about 0.05 to about 0.8.51 . The multispecific antigen-binding molecule of claim 50, wherein the EC50is determined in a cell killing assay at 72 hours with human CD8+ T cells and STEAP1 -expressing LNCaP-X1 .2 cells, and the EC50is about 0.05 to about 0.4.

52. The multispecific antigen-binding molecule of claim 51 , wherein the EC50is about 0.08 or about 0.3.

53. The multispecific antigen-binding molecule of claim 50, wherein the EC50is determined in a cell killing assay at 72 hours with human CD8+ T cells and STEAP1 -expressing LNCaPXI .2KO3-13 cells, and the EC50is about 0.1 to about 0.8.

54. The multispecific antigen-binding molecule of claim 53, wherein the EC50is about 0.1 or about 0.7.

55. An antigen-binding molecule that binds to STEAP1 , comprising an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3 of a VH sequence selected from SEQ ID NO: 7, 17-25, 30-34, 38, and 68; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3 of a VL sequence selected from SEQ ID NOs: 8, 26-29, 39, and 69.

56. An antigen-binding molecule that binds to STEAP1 , comprising: an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3; and an anti-STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3; whereinCDR-H1 comprises Xaa1Xaa2YMA (SEQ ID NO: 35); whereinXaa1is Asp (D) or Asn (N); andXaa2is His (H), Tyr (Y), or Phe (F);CDR-H2 comprises YIXaa3YDGXaa4Xaa5TXaa6YGDSVKG (SEQ ID NO: 36); whereinXaa3is Asp (D) or Ser (S);Xaa4is Gly (G), Asp (D), or Leu (L);Xaa5is Ser (S), Asp (D), or Asn (N); andXaa6is Ser (S) or Tyr (Y);CDR-H3 comprises RSGXaa7YHVGYAMXaa8Xaa9(SEQ ID NO: 37); whereinXaa7is Phe (F) or Tyr (Y);Xaa8is Asn (N) or Asp (D); and Xaa9is Ala (A) or Gly (G);CDR-L1 comprises the amino acid sequence of SEQ ID NO: 4;CDR-L2 comprises the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprises the amino acid sequence of SEQ ID NO: 6.

57. The antigen-binding molecule of claim 55 or 56, wherein the CDR-H1 comprises the amino acid sequence of SEQ ID NO: 10, 1 , or 9.

58. The antigen-binding molecule of any one of claims 55-57, wherein the CDR-H2 comprises the amino acid sequence of SEQ ID NO: 2, 1 1 , 12, or 13.

59. The antigen-binding molecule of any one of claims 55-58, wherein the CDR-H3 comprises the amino acid sequence of SEQ ID NO: 16, 3, 14, or 15.

60. The antigen-binding molecule of any one of claims 55-59, wherein the antigen-binding molecule comprises:CDR-H1 comprising the amino acid sequence of SEQ ID NO: 10;CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2;CDR-H3 comprising the amino acid sequence of SEQ ID NO: 16;CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.61 . The antigen-binding molecule of any one of claims 55-59, wherein the antigen-binding molecule comprises:CDR-H1 comprising the amino acid sequence of SEQ ID NO: 1 ;CDR-H2 comprising the amino acid sequence of SEQ ID NO: 2;CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

62. The antigen-binding molecule of any one of claims 55-59, wherein the antigen-binding molecule comprises:CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9;CDR-H2 comprising the amino acid sequence of SEQ ID NO: 1 1 ;CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

63. The antigen-binding molecule of any one of claims 55-59, wherein the antigen-binding molecule comprises:CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9;CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12;CDR-H3 comprising the amino acid sequence of SEQ ID NO: 3;CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; andCDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

64. The antigen-binding molecule of any one of claims 55-59, wherein the antigen-binding molecule comprises:CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9;CDR-H2 comprising the amino acid sequence of SEQ ID NO: 12;CDR-H3 comprising the amino acid sequence of SEQ ID NO: 14;CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; and CDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

65. The antigen-binding molecule of any one of claims 55-59, wherein the antigen-binding molecule comprises:CDR-H1 comprising the amino acid sequence of SEQ ID NO: 10;CDR-H2 comprising the amino acid sequence of SEQ ID NO: 13;CDR-H3 comprising the amino acid sequence of SEQ ID NO: 15;CDR-L1 comprising the amino acid sequence of SEQ ID NO: 4;CDR-L2 comprising the amino acid sequence of SEQ ID NO: 5; andCDR-L3 comprising the amino acid sequence of SEQ ID NO: 6.

66. The antigen-binding molecule of any one of claims 55-65, wherein the antigen-binding molecule is a humanized antibody.

67. The antigen-binding molecule of any one of claims 55-66, wherein the antigen-binding molecule comprises an IgG framework region, optionally an IgG 1 framework region.

68. The antigen-binding molecule of any one of claims 55-67, comprising an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 7, 17-25, 30-34, 38, or 68.

69. The antigen-binding molecule of any one of claims 55-68, comprising an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 8, 26-29, 39, or 69.

70. The antigen-binding molecule of any one of claims 55-69, comprising an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 68, and an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 69.71 . The antigen-binding molecule of any one of claims 55-69, comprising an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 34, and an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 27.

72. The antigen-binding molecule of any one of claims 55-69, comprising an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 30, and an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 27.

73. The antigen-binding molecule of any one of claims 55-69, comprising an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 31 , and an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 27.

74. The antigen-binding molecule of any one of claims 55-69, comprising an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 32, and an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 27.

75. The antigen-binding molecule of any one of claims 55-69, comprising an anti-STEAP1 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 33, and an anti-STEAP1 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 27.

76. The antigen-binding molecule of any one of claims 55-75, wherein the antigen-binding molecule comprises an anti-STEAP1 heavy chain constant region sequence having at least 80%,85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 83 and an anti-STEAP1 light chain constant region sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 82; or wherein the antigen-binding molecule comprises an anti-STEAP1 heavy chain constant region sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 85 and an anti-STEAP1 light chain constant region sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 84.

77. The antigen-binding molecule of claim 76, wherein the antigen-binding molecule comprises an anti-STEAP1 heavy chain comprising SEQ ID NO: 73 and an anti-STEAP1 light chain comprising SEQ ID NO: 72.

78. The antigen-binding molecule of any one of claims 55-77, wherein the antigen-binding molecule is a full-length antibody or a fragment thereof.

79. The antigen-binding molecule of any one of claims 55-78, wherein the antigen-binding molecule is a Fab, Fab’, F(ab’)2, Fv, Fd, single-chain Fv (scFv), trispecific (Fabs), bispecific (Fab2), diabody ((VL-VH)2or (VH-VL)2), triabody (trivalent), tetrabody (tetravalent), minibody ((SCFV-CH)2), bispecific single-chain Fv (Bis-scFv), lgGdeltaCH2, scFv-Fc, or (scFv)2-Fc.

80. The antigen-binding molecule of any one of claims 55-79, wherein the antigen-binding molecule further comprises an antigen-binding domain that binds to a T cell receptor.81 . The antigen-binding molecule of any one of claims 55-80, wherein the antigen-binding molecule is a multispecific antibody, preferably wherein the antigen-binding molecule is a bispecific antibody or a trispecific antibody.

82. The antigen-binding molecule of claim 80 or 81 , wherein the T cell receptor is cluster of differentiation 3 (CD3).

83. The antigen-binding molecule of claim 82, wherein the antigen-binding domain that binds to CD3 comprises an anti-CD3 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3, and an anti-CD3 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3, wherein CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3 comprise the amino acid sequences of SEQ ID NO: 48-53, respectively.

84. The antigen-binding molecule of claim 83, wherein the antigen-binding domain that binds to CD3 comprises an anti-CD3 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 54, and an anti-CD3 light chainvariable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 55.

85. The antigen-binding molecule of claim 82, wherein the antigen-binding domain that binds to CD3 comprises an anti-CD3 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3, and an anti-CD3 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3, wherein CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3 comprise the amino acid sequences of SEQ ID NO: 40-45, respectively.

86. The antigen-binding molecule of claim 83, wherein the antigen-binding domain that binds to CD3 comprises an anti-CD3 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 46, and an anti-CD3 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 47.

87. The antigen-binding molecule of claim 82, wherein the antigen-binding molecule comprises an anti-CD3 heavy chain comprising SEQ ID NO: 79 and an anti-CD3 light chain comprising SEQ ID NO: 78.

88. The antigen-binding molecule of claim 82, wherein the antigen-binding molecule comprises an anti-CD3 heavy chain comprising SEQ ID NO: 81 and an anti-CD3 light chain comprising SEQ ID NO: 80.

89. The antigen-binding molecule of any one of claims 55-88, wherein the antigen-binding molecule further comprises an additional antigen-binding domain that binds to a tumor-associated antigen.

90. The antigen-binding molecule of claim 89, wherein the tumor-associated antigen is a receptor expressed on a prostate cancer cell or Ewing sarcoma.91 . The antigen-binding molecule of claim 89 or 90, wherein the tumor-associated antigen is prostate-specific membrane antigen (PSMA), STEAP2, prostate stem cell antigen (PSCA), epithelial cell adhesion molecule (EpCAM), prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), or HBA-71 .

92. The antigen-binding molecule of any one of claims 55-91 , wherein the antigen-binding molecule binds to human STEAP1 , cynomolgus monkey STEAP1 , or a combination thereof, preferably wherein the antigen-binding molecule binds to the human STEAP1 of SEQ ID NO: 65.

93. The antigen-binding molecule of any one of claims 55-92, wherein the antigen-binding molecule binds to at least one residue selected from Seri 01 , His102, Gin 103, and Lys281 of STEAP1 , wherein the residue positions 101 , 102, 103, and 281 correspond to positions 101 , 102, 103, and 281 set forth in SEQ ID NO: 65.

94. The antigen-binding molecule of any one of claims 55-93, wherein the antigen-binding molecule binds to Seri 01 , His102, Gin 103, and Lys281 of SEQ ID NO: 65.

95. An antibody comprising a first antigen-binding domain that binds to human STEAP1 at one or more residues selected from Seri 01 , His102, G In 103, and Lys281 , wherein the residue positions 101 , 102, 103, and 281 correspond to positions 101 , 102, 103, and 281 set forth in SEQ ID NO: 65.

96. The antibody of claim 95, wherein the first antigen-binding domain binds to Seri 01 , His102, Gln103, and Lys281 of SEQ ID NO: 65.

97. The antibody of claim 95 or 96, wherein the heavy chain variable region of the first antigen- binding domain forms a hydrogen bond with at least one residue selected from Seri 01 , His102, Gln103, and Lys281.

98. The antibody of any one of claims 95-97, wherein Leu56, Ser73, and Asn74 of the heavy chain variable region of the first antigen-binding domain forms a hydrogen bond with Seri 01 , His102, G In 103, and Lys281 of STEAP1 , wherein the residue positions of the heavy chain variable region correspond to positions 56, 73, and 74 set forth in SEQ ID NO: 18.

99. The antibody of any one of claims 95-98, wherein the first antigen-binding domain comprises an anti-STEAP1 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3 of a VH sequence selected from SEQ ID NO: 7, 17-25, 30-34, 38, and 68; and three CDRs of an anti- STEAP1 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3 of a VL sequence selected from SEQ ID NO: 8, 26-29, 39, and 69.

100. The antibody of any one of claims 95-99, wherein the first antigen-binding domain comprises an anti-STEAP1 heavy chain variable region comprising a VH sequence comprising at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 7, 17-25, 30-34, 38, or 68.101 . The antibody of any one of claims 95-100, wherein the first antigen-binding domain comprises an anti-STEAP1 light chain variable region comprising a VL sequence comprising at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 8, 26-29, 39, or 69.

102. The antibody of any one of claims 95-101 , wherein the antibody further comprises a second antigen-binding domain that binds to a T cell receptor.

103. The antibody of claim 102, wherein the T cell receptor is cluster of differentiation 3 (CD3).

104. The antibody of claim 103, wherein the second antigen-binding domain that binds to CD3 comprises an anti-CD3 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3, and an anti-CD3 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3, wherein the CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3 comprise the amino acid sequences of SEQ ID NOs: 48-53, respectively.

105. The antibody of claim 104, wherein the second antigen-binding domain that binds to CD3 comprises an anti-CD3 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 54 and an anti-CD3 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 55.

106. The antibody of claim 103, wherein the second antigen-binding domain that binds to CD3 comprises an anti-CD3 heavy chain variable region (VH) comprising CDR-H1 , CDR-H2, and CDR-H3, and an anti-CD3 light chain variable region (VL) comprising CDR-L1 , CDR-L2, and CDR-L3, wherein the CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3 comprise the amino acid sequences of SEQ ID NOs: 40-45, respectively.

107. The antibody of claim 106, wherein the second antigen-binding domain that binds to CD3 comprises an anti-CD3 heavy chain variable region comprising a VH sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 46 and an anti-CD3 light chain variable region comprising a VL sequence having at least 80%, 85%, 90%, 95%, or 100% sequence identity to SEQ ID NO: 47.

108. The antibody of any one of claims 95-107, wherein the multispecific antigen-binding molecule further comprises a third antigen-binding domain that binds to a tumor-associated antigen.

109. The antibody of claim 108, wherein the tumor-associated antigen is a receptor expressed on a prostate cancer cell.

110. The antibody of claim 108 or 109, wherein the tumor-associated antigen is prostate-specific membrane antigen (PSMA), STEAP2, prostate stem cell antigen (PSCA), epithelial cell adhesion molecule (EpCAM), prostate-specific antigen (PSA), or prostatic acid phosphatase (PAP).

111. One or more isolated nucleic acids individually or together encoding the multispecific antigen- binding molecule of any one of claims 1 -54, the antigen-binding molecule of any one of claims 55-94, or the antibody of any one of claims 95-110.

112. One or more vectors individually or together comprising the isolated nucleic acid(s) of claim 111.

113. One or more host cells individually or together comprising the isolated nucleic acid(s) of claim 111 , or the vector(s) of claim 112.

114. The host cell(s) of claim 113, wherein the host cell is a mammalian cell.

115. The host cell(s) of claim 114, wherein the mammalian cell is a Chinese hamster ovary(CHO) cell.

116. The host cell(s) of claim 113, wherein the host cell is an insect cell.

117. The host cell(s) of claim 113, wherein the host cell is a prokaryotic cell.

118. A method of producing the multispecific antigen-binding molecule of any one of claims 1 -54, the antigen-binding molecule of any one of claims 55-94, or the antibody of any one of claims 95-110 comprising culturing the host cell(s) of any one of claims 113-117 in a culture medium.

119. The method of claim 118, further comprising harvesting the multispecific antigen-binding molecule of any one of claims 1 -54, the antigen-binding molecule of any one of claims 55-94, or the antibody of any one of claims 95-110 from the host cell(s) or the culture medium.

120. A pharmaceutical composition comprising the multispecific antigen-binding molecule of any one of claims 1 -54, the antigen-binding molecule of any one of claims 55-94, or the antibody of any one of claims 95-110.121 . The pharmaceutical composition of claim 120, further comprising a pharmaceutically acceptable carrier, excipient, or diluent.

122. The pharmaceutical composition of claim 120 or 121 for use as a medicament.

123. The pharmaceutical composition of claim 120 or 121 for use in treating or delaying progression of a STEAP1 -expressing cancer.

124. The pharmaceutical composition of claim 120 or 121 for use in treating or delaying progression of prostate cancer or Ewing sarcoma.

125. The multispecific antigen-binding molecule of any one of claims 1 -54, the antigen-binding molecule of any one of claims 55-94, or the antibody of any one of claims 95-110 for use in treating or delaying progression of a STEAP1 -expressing cancer in a subject in need thereof.

126. The multispecific antigen-binding molecule of any one of claims 1 -54, the antigen-binding molecule of any one of claims 55-94, or the antibody of any one of claims 95-110 for use in inhibiting or reducing the proliferation of a STEAP1 -expressing cancer cell.

127. The multispecific antigen-binding molecule for use, the antigen-binding molecule for use, or the antibody for use of claim 125 or 126, wherein the STEAP1 -expressing cancer is a solid tumor.

128. The multispecific antigen-binding molecule for use, the antigen-binding molecule for use, or the antibody for use of any one of claims 125-127, wherein the STEAP1 -expressing cancer is prostate cancer or Ewing sarcoma.

129. The multispecific antigen-binding molecule for use, the antigen-binding molecule for use, or the antibody for use of any one of claims 125-128, which is to be used in combination with an additional therapeutic agent or an additional therapeutic regimen.

130. The multispecific antigen-binding molecule for use, the antigen-binding molecule for use, or the antibody for use of claim 129, wherein the additional therapeutic agent comprises a chemotherapeutic agent, an immunotherapeutic agent, a targeted therapy, radiation therapy, or a combination thereof.131 . The multispecific antigen-binding molecule for use, the antigen-binding molecule for use, or the antibody for use of claim 129 or 130, wherein the additional therapeutic agent comprises a first- line, second-line, or third-line therapy.

132. The multispecific antigen-binding molecule for use, the antigen-binding molecule for use, or the antibody for use of claim 129, wherein the additional therapeutic regimen comprises surgery.

133. The multispecific antigen-binding molecule for use, the antigen-binding molecule for use, or the antibody for use of any one of claims 129-131 , wherein the multispecific antigen binding molecule, the antigen binding molecule, or the antibody and the additional therapeutic agent are to be administered simultaneously.

134. The multispecific antigen-binding molecule for use, the antigen-binding molecule for use, or the antibody for use of any one of claims 129-131 , wherein the multispecific antigen binding molecule, the antigen binding molecule, or the antibody and the additional therapeutic agent are to be administered sequentially.

135. The multispecific antigen-binding molecule for use, the antigen-binding molecule for use, or the antibody for use of any one of claims 129-131 , wherein the multispecific antigen binding molecule, the antigen binding molecule, or the antibody is to be administered first prior to administering the additional therapeutic agent.

136. The multispecific antigen-binding molecule for use, the antigen-binding molecule for use, or the antibody for use of any one of claims 129-131 , wherein the multispecific antigen binding molecule, the antigen binding molecule, or the antibody is to be administered after administering the additional therapeutic agent.

137. The multispecific antigen-binding molecule for use, the antigen-binding molecule for use, or the antibody for use of any one of claims 125-136, wherein the multispecific antigen binding molecule, the antigen binding molecule, or the antibody is to be administered systemically.

138. The multispecific antigen-binding molecule for use, the antigen-binding molecule for use, or the antibody for use of any one of claims 125-136, wherein the multispecific antigen binding molecule, the antigen binding molecule, or the antibody is to be administered locally.

139. The multispecific antigen-binding molecule for use, the antigen-binding molecule for use, or the antibody for use of any one of claims 125-136, wherein the multispecific antigen binding molecule, the antigen binding molecule, or the antibody is to be administered by parenteral administration.

140. The multispecific antigen-binding molecule for use, the antigen-binding molecule for use, or the antibody for use of any one of claims 125-136, wherein the multispecific antigen binding molecule, the antigen binding molecule, or the antibody is to be administered intravenously or subcutaneously.141 . The multispecific antigen-binding molecule for use, the antigen-binding molecule for use, or the antibody for use of any one of claims 125-136, wherein the subject is a human.

142. Use of the multispecific antigen-binding molecule of any one of claims 1 -54, the antigen- binding molecule of any one of claims 55-94, or the antibody of any one of claims 95-1 10 in the manufacture of a medicament for treating or delaying progression of a STEAP1 -expressing cancer in a subject in need thereof, optionally for treating or delaying progression of prostate cancer or Ewing sarcoma.

143. Use of the multispecific antigen-binding molecule of any one of claims 1 -54, the antigen- binding molecule of any one of claims 55-94, or the antibody of any one of claims 95-110 in the manufacture of a medicament 16, optionally a prostate cancer cell or Ewing sarcoma cell.

144. A method for treating or delaying progression of a STEAP1 -expressing cancer in a subject in need thereof, comprising administering to the subject an effective amount of the multispecific antigen- binding molecule of any one of claims 1 -54, the antigen-binding molecule of any one of claims 55-94, or the antibody of any one of claims 95-110.

145. The method of claim 144, wherein the STEAP1 -expressing cancer is a solid tumor.

146. The method of claim 144 or 145, wherein the STEAP1 -expressing cancer is prostate cancer or Ewing sarcoma.

147. The method of any one of claims 144-146, further comprising administering to the subject an additional therapeutic agent or an additional therapeutic regimen.

148. The method of claim 147, wherein the additional therapeutic agent comprises a chemotherapeutic agent, an immunotherapeutic agent, a targeted therapy, radiation therapy, or a combination thereof.

149. The method of claim 148, wherein the additional therapeutic agent comprises a first-line, second-line, or third-line therapy.

150. The method of claim 148, wherein the additional therapeutic regimen comprises surgery.151 . The method of any one of claims 144-150, wherein the multispecific antigen-binding molecule, the antigen-binding molecule, or the antibody and the additional therapeutic agent are administered simultaneously.

152. The method of any one of claims 144-150, wherein the multispecific antigen-binding molecule, the antigen-binding molecule, or the antibody and the additional therapeutic agent are administered sequentially.

153. The method of claim 152, wherein the multispecific antigen-binding molecule, the antigen- binding molecule, or the antibody is administered first prior to administering the additional therapeutic agent.

154. The method of claim 152, wherein the multispecific antigen-binding molecule, the antigen- binding molecule, or the antibody is administered after administering the additional therapeutic agent.

155. The method of any one of claims 144-154, wherein the multispecific antigen-binding molecule, the antigen-binding molecule, or the antibody is administered systemically.

156. The method of any one of claims 144-154, wherein the multispecific antigen-binding molecule, the antigen-binding molecule, or the antibody is administered locally.

157. The method of any one of claims 144-156, wherein the multispecific antigen-binding molecule, the antigen-binding molecule, or the antibody is administered by parenteral administration.

158. The method of any one of claims 144-157, wherein the multispecific antigen-binding molecule, the antigen-binding molecule, or the antibody is administered intravenously or subcutaneously.

159. The method of any one of claims 144-158, wherein the subject is a human.

160. A method of inhibiting or reducing the proliferation of a STEAP1 -expressing cell, comprising contacting the cell with the multispecific antigen-binding molecule of any one of claims 1 -54, the antigen-binding molecule of any one of claims 55-94, or the antibody of any one of claims 95-110 for a time sufficient to inhibit proliferation of the cell.161 . The method of claim 160, wherein the cell is a prostate cancer cell or Ewing sarcoma cell.

162. The method of claim 160 or 161 , wherein the method is an in vivo method.

163. The method of claim 160 or 161 , wherein the method is an in vitro or an ex vivo method.

164. A kit comprising the multispecific antigen-binding molecule of any one of claims 1 -54, the antigen-binding molecule of any one of claims 55-94, or the antibody of any one of claims 95-110, the isolated nucleic acid(s) of claim 111 , the vector(s) of claim 112, the host cell(s) of any one of claims 113-117, or the pharmaceutical composition of any one of claims 120-124, optionally comprising a set of instructions.